

117TH CONGRESS
2D SESSION

H. R. 7667

AN ACT

To amend the Federal Food, Drug, and Cosmetic Act to revise and extend the user-fee programs for prescription drugs, medical devices, generic drugs, and biosimilar biological products, and for other purposes.

1 *Be it enacted by the Senate and House of Representa-*
2 *tives of the United States of America in Congress assembled,*

1 **SECTION 1. SHORT TITLE.**

2 This Act may be cited as the “Food and Drug
3 Amendments of 2022”.

4 **SEC. 2. TABLE OF CONTENTS.**

5 The table of contents of this Act is as follows:

Sec. 1. Short title.
Sec. 2. Table of contents.

TITLE I—FEES RELATING TO DRUGS

Sec. 101. Short title; finding.
Sec. 102. Definitions.
Sec. 103. Authority to assess and use drug fees.
Sec. 104. Reauthorization; reporting requirements.
Sec. 105. Sunset dates.
Sec. 106. Effective date.
Sec. 107. Savings clause.

TITLE II—FEES RELATING TO DEVICES

Sec. 201. Short title; finding.
Sec. 202. Definitions.
Sec. 203. Authority to assess and use device fees.
Sec. 204. Reauthorization; reporting requirements.
Sec. 205. Conformity assessment pilot program.
Sec. 206. Reauthorization of third-party review program.
Sec. 207. Sunset dates.
Sec. 208. Effective date.
Sec. 209. Savings clause.

TITLE III—FEES RELATING TO GENERIC DRUGS

Sec. 301. Short title; finding.
Sec. 302. Authority to assess and use human generic drug fees.
Sec. 303. Reauthorization; reporting requirements.
Sec. 304. Sunset dates.
Sec. 305. Effective date.
Sec. 306. Savings clause.

**TITLE IV—FEES RELATING TO BIOSIMILAR BIOLOGICAL
PRODUCTS**

Sec. 401. Short title; finding.
Sec. 402. Definitions.
Sec. 403. Authority to assess and use biosimilar fees.
Sec. 404. Reauthorization; reporting requirements.
Sec. 405. Sunset dates.
Sec. 406. Effective date.
Sec. 407. Savings clause.

TITLE V—IMPROVING DIVERSITY IN CLINICAL STUDIES

- Sec. 501. Diversity action plans for clinical studies.
- Sec. 502. Evaluation of the need for FDA authority to mandate postapproval studies or postmarket surveillance due to insufficient demographic subgroup data.
- Sec. 503. Public workshops to enhance clinical study diversity.
- Sec. 504. Annual summary report on progress to increase diversity in clinical studies.
- Sec. 505. Public meeting on clinical study flexibilities initiated in response to COVID–19 pandemic.
- Sec. 506. Decentralized clinical studies.

TITLE VI—GENERIC DRUG COMPETITION

- Sec. 601. Increasing transparency in generic drug applications.
- Sec. 602. Enhancing access to affordable medicines.

TITLE VII—RESEARCH, DEVELOPMENT, AND SUPPLY CHAIN IMPROVEMENTS

Subtitle A—In General

- Sec. 701. Animal testing alternatives.
- Sec. 702. Emerging technology program.
- Sec. 703. Improving the treatment of rare diseases and conditions.
- Sec. 704. Antifungal research and development.
- Sec. 705. Advancing qualified infectious disease product innovation.
- Sec. 706. National Centers of Excellence in Advanced and Continuous Pharmaceutical Manufacturing.
- Sec. 707. Advanced manufacturing technologies designation pilot program.
- Sec. 708. Public workshop on cell therapies.
- Sec. 709. Reauthorization of best pharmaceuticals for children.
- Sec. 710. Reauthorization for humanitarian device exemption and demonstration grants for improving pediatric availability.
- Sec. 711. Reauthorization of provision related to exclusivity of certain drugs containing single enantiomers.
- Sec. 712. Reauthorization of the critical path public-private partnership program.
- Sec. 713. Reauthorization of orphan drug grants.
- Sec. 714. Research into pediatric uses of drugs; additional authorities of Food and Drug Administration regarding molecularly targeted cancer drugs.

Subtitle B—Inspections

- Sec. 721. Factory inspection.
- Sec. 722. Uses of certain evidence.
- Sec. 723. Improving FDA inspections.
- Sec. 724. GAO report on inspections of foreign establishments manufacturing drugs.
- Sec. 725. Unannounced foreign facility inspections pilot program.
- Sec. 726. Reauthorization of inspection program.
- Sec. 727. Enhancing intra-agency coordination and public health assessment with regard to compliance activities.
- Sec. 728. Reporting of mutual recognition agreements for inspections and review activities.
- Sec. 729. Enhancing transparency of drug facility inspection timelines.

TITLE VIII—TRANSPARENCY, PROGRAM INTEGRITY, AND
REGULATORY IMPROVEMENTS

- Sec. 801. Prompt reports of marketing status by holders of approved applications for biological products.
- Sec. 802. Encouraging blood donation.
- Sec. 803. Regulation of certain products as drugs.
- Sec. 804. Postapproval studies and program integrity for accelerated approval drugs.
- Sec. 805. Facilitating the use of real world evidence.
- Sec. 806. Dual Submission for Certain Devices.
- Sec. 807. Medical Devices Advisory Committee meetings.
- Sec. 808. Ensuring cybersecurity of medical devices.
- Sec. 809. Public docket on proposed changes to third-party vendors.
- Sec. 810. Facilitating exchange of product information prior to approval.
- Sec. 811. Bans of devices for one or more intended uses.
- Sec. 812. Clarifying application of exclusive approval, certification, or licensure for drugs designated for rare diseases or conditions.
- Sec. 813. GAO report on third-party review.
- Sec. 814. Reporting on pending generic drug applications and priority review applications.
- Sec. 815. FDA Workforce Improvements.

TITLE IX—MISCELLANEOUS

- Sec. 901. Determination of budgetary effects.
- Sec. 902. Medicaid Improvement Fund.

**TITLE I—FEES RELATING TO
DRUGS**

SEC. 101. SHORT TITLE; FINDING.

(a) SHORT TITLE.—This title may be cited as the “Prescription Drug User Fee Amendments of 2022”.

(b) FINDING.—The Congress finds that the fees authorized by the amendments made by this title will be dedicated toward expediting the drug development process and the process for the review of human drug applications, including postmarket drug safety activities, as set forth in the goals identified for purposes of part 2 of subchapter C of chapter VII of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 379g et seq.), in the letters from the Sec-

1 retary of Health and Human Services to the Chairman
2 of the Committee on Health, Education, Labor, and Pen-
3 sions of the Senate and the Chairman of the Committee
4 on Energy and Commerce of the House of Representa-
5 tives, as set forth in the Congressional Record.

6 **SEC. 102. DEFINITIONS.**

7 (a) HUMAN DRUG APPLICATION.—Section 735(1) of
8 the Federal Food, Drug, and Cosmetic Act (21 U.S.C.
9 379g(1)) is amended by striking “an allergenic extract
10 product, or” and inserting “does not include an applica-
11 tion with respect to an allergenic extract product licensed
12 before October 1, 2022, does not include an application
13 with respect to a standardized allergenic extract product
14 submitted pursuant to a notification to the applicant from
15 the Secretary regarding the existence of a potency test
16 that measures the allergenic activity of an allergenic ex-
17 tract product licensed by the applicant before October 1,
18 2022, does not include an application with respect to”.

19 (b) PRESCRIPTION DRUG PRODUCT.—Section 735(3)
20 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C.
21 379g(3)) is amended—

22 (1) by redesignating subparagraphs (A), (B),
23 and (C) as clauses (i), (ii), and (iii), respectively;

24 (2) by striking “(3) The term” and inserting
25 “(3)(A) The term”;

1 (3) by striking “Such term does not include
2 whole blood” and inserting the following:

3 “(B) Such term does not include whole blood”;

4 (4) by striking “an allergenic extract product,”
5 and inserting “an allergenic extract product licensed
6 before October 1, 2022, a standardized allergenic ex-
7 tract product submitted pursuant to a notification to
8 the applicant from the Secretary regarding the exist-
9 ence of a potency test that measures the allergenic
10 activity of an allergenic extract product licensed by
11 the applicant before October 1, 2022,” ; and

12 (5) by adding at the end the following:

13 “(C)(i) If a written request to place a
14 product in the discontinued section of either of
15 the lists referenced in subparagraph (A)(iii) is
16 submitted to the Secretary on behalf of an ap-
17 plicant, and the request identifies the date the
18 product is withdrawn from sale, then for pur-
19 poses of assessing the prescription drug pro-
20 gram fee under section 736(a)(2), the Secretary
21 shall consider such product to have been in-
22 cluded in the discontinued section on the later
23 of—

24 “(I) the date such request was re-
25 ceived; or

1 “(II) if the product will be withdrawn
 2 from sale on a future date, such future
 3 date when the product is withdrawn from
 4 sale.

5 “(ii) For purposes of this subparagraph, a
 6 product shall be considered withdrawn from
 7 sale once the applicant has ceased its own dis-
 8 tribution of the product, whether or not the ap-
 9 plicant has ordered recall of all previously dis-
 10 tributed lots of the product, except that a rou-
 11 tine, temporary interruption in supply shall not
 12 render a product withdrawn from sale.”.

13 (c) SKIN-TEST DIAGNOSTIC PRODUCT.—Section 735
 14 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C.
 15 379g) is amended by adding at the end the following:

16 “(12) The term ‘skin-test diagnostic product’—

17 “(A) means a product—

18 “(i) for prick, scratch, intradermal, or
 19 subcutaneous administration;

20 “(ii) expected to produce a limited,
 21 local reaction at the site of administration
 22 (if positive), rather than a systemic effect;

23 “(iii) not intended to be a preventive
 24 or therapeutic intervention; and

“(iv) intended to detect an immediate-
or delayed-type skin hypersensitivity reac-
tion to aid in the diagnosis of—

“(I) an allergy to an anti-
microbial agent;

“(II) an allergy that is not to an
antimicrobial agent, if the diagnostic
product was authorized for marketing
prior to October 1, 2022; or

“(III) infection with fungal or
mycobacterial pathogens; and

“(B) includes positive and negative con-
trols required to interpret the results of a prod-
uct described in subparagraph (A).”.

SEC. 103. AUTHORITY TO ASSESS AND USE DRUG FEES.

(a) TYPES OF FEES.—

(1) HUMAN DRUG APPLICATION FEE.—Section
736(a) of the Federal Food, Drug, and Cosmetic Act
(21 U.S.C. 379h(a)) is amended—

(A) in the matter preceding paragraph (1),
by striking “fiscal year 2018” and inserting
“fiscal year 2023”;

(B) in paragraph (1)(A), by striking
“(c)(5)” each place it appears and inserting
“(c)(6)”;

1 (C) in paragraph (1)(C), by inserting
 2 “prior to approval” after “or was withdrawn”;
 3 and

4 (D) in paragraph (1), by adding at the end
 5 the following:

6 “(H) EXCEPTION FOR SKIN-TEST DIAG-
 7 NOSTIC PRODUCTS.—A human drug application
 8 for a skin-test diagnostic product shall not be
 9 subject to a fee under subparagraph (A).”.

10 (2) PRESCRIPTION DRUG PROGRAM FEE.—Sec-
 11 tion 736(a)(2) of the Federal Food, Drug, and Cos-
 12 metic Act (21 U.S.C. 379h(a)(2)) is amended—

13 (A) in subparagraph (A)—

14 (i) by striking “Except as provided in
 15 subparagraphs (B) and (C)” and inserting
 16 the following:

17 “(i) FEE.—Except as provided in sub-
 18 paragraphs (B) and (C)”;

19 (ii) by striking “subsection (c)(5)”
 20 and inserting “subsection (c)(6)”; and

21 (iii) by adding at the end the fol-
 22 lowing:

23 “(ii) SPECIAL RULE.—If a drug prod-
 24 uct that is identified in a human drug ap-
 25 plication approved as of October 1 of a fis-

1 cal year is not a prescription drug product
2 as of that date because the drug product
3 is in the discontinued section of a list ref-
4 erenced in section 735(3)(A)(iii), and on
5 any subsequent day during such fiscal year
6 the drug product is a prescription drug
7 product, then except as provided in sub-
8 paragraphs (B) and (C), each person who
9 is named as the applicant in a human drug
10 application with respect to such product,
11 and who, after September 1, 1992, had
12 pending before the Secretary a human
13 drug application or supplement, shall pay
14 the annual prescription drug program fee
15 established for a fiscal year under sub-
16 section (c)(6) for such prescription drug
17 product. Such fee shall be due on the last
18 business day of such fiscal year and shall
19 be paid only once for each such product for
20 a fiscal year in which the fee is payable.”;
21 and

22 (B) by amending subparagraph (B) to read
23 as follows:

24 “(B) EXCEPTION FOR CERTAIN PRESCRIP-
25 TION DRUG PRODUCTS.—A prescription drug

1 program fee shall not be assessed for a pre-
2 scription drug product under subparagraph (A)
3 if such product is—

4 “(i) a large volume parenteral product
5 (a sterile aqueous drug product packaged
6 in a single-dose container with a volume
7 greater than or equal to 100 mL, not in-
8 cluding powders for reconstitution or phar-
9 macy bulk packages) identified on the list
10 compiled under section 505(j)(7);

11 “(ii) pharmaceutically equivalent (as
12 defined in section 314.3 of title 21, Code
13 of Federal Regulations (or any successor
14 regulation)) to another product on the list
15 of products compiled under section
16 505(j)(7) (not including the discontinued
17 section of such list); or

18 “(iii) a skin-test diagnostic product.”.

19 (b) FEE REVENUE AMOUNTS.—

20 (1) IN GENERAL.—Paragraph (1) of section
21 736(b) of the Federal Food, Drug, and Cosmetic Act
22 (21 U.S.C. 379h(b)) is amended to read as follows:

23 “(1) IN GENERAL.—For each of the fiscal years
24 2023 through 2027, fees under subsection (a) shall,
25 except as provided in subsections (c), (d), (f), and

(g), be established to generate a total revenue amount under such subsection that is equal to the sum of—

“(A) the annual base revenue for the fiscal year (as determined under paragraph (3));

“(B) the dollar amount equal to the inflation adjustment for the fiscal year (as determined under subsection (c)(1));

“(C) the dollar amount equal to the strategic hiring and retention adjustment for the fiscal year (as determined under subsection (c)(2));

“(D) the dollar amount equal to the capacity planning adjustment for the fiscal year (as determined under subsection (c)(3));

“(E) the dollar amount equal to the operating reserve adjustment for the fiscal year, if applicable (as determined under subsection (c)(4));

“(F) the dollar amount equal to the additional direct cost adjustment for the fiscal year (as determined under subsection (c)(5)); and

“(G) additional dollar amounts for each fiscal year as follows:

“(i) \$65,773,693 for fiscal year 2023.

1 “(ii) \$25,097,671 for fiscal year 2024.

2 “(iii) \$14,154,169 for fiscal year
3 2025.

4 “(iv) \$4,864,860 for fiscal year 2026.

5 “(v) \$1,314,620 for fiscal year
6 2027.”.

7 (2) ANNUAL BASE REVENUE.—Paragraph (3)
8 of section 736(b) of the Federal Food, Drug, and
9 Cosmetic Act (21 U.S.C. 379h(b)) is amended to
10 read as follows:

11 “(3) ANNUAL BASE REVENUE.—For purposes
12 of paragraph (1), the dollar amount of the annual
13 base revenue for a fiscal year shall be—

14 “(A) for fiscal year 2023, \$1,151,522,958;
15 and

16 “(B) for fiscal years 2024 through 2027,
17 the dollar amount of the total revenue amount
18 established under paragraph (1) for the pre-
19 vious fiscal year, not including any adjustments
20 made under subsection (c)(4) or (c)(5).”.

21 (c) ADJUSTMENTS; ANNUAL FEE SETTING.—

22 (1) INFLATION ADJUSTMENT.—Section
23 736(c)(1)(B)(ii) of the Federal Food, Drug, and
24 Cosmetic Act (21 U.S.C. 379h(c)(1)(B)(ii)) is
25 amended by striking “Washington-Baltimore, DC–

1 MD–VA–WV” and inserting “Washington–Arlington–
2 Alexandria, DC–VA–MD–WV”.

3 (2) STRATEGIC HIRING AND RETENTION AD-
4 JUSTMENT.—Section 736(c) of the Federal Food,
5 Drug, and Cosmetic Act (21 U.S.C. 379h(c)) is
6 amended—

7 (A) by redesignating paragraphs (2)
8 through (6) as paragraphs (3) through (7), re-
9 spectively; and

10 (B) by inserting after paragraph (1) the
11 following:

12 “(2) STRATEGIC HIRING AND RETENTION AD-
13 JUSTMENT.—For each fiscal year, after the annual
14 base revenue established in subsection (b)(1)(A) is
15 adjusted for inflation in accordance with paragraph
16 (1), the Secretary shall further increase the fee rev-
17 enue and fees by the following amounts:

18 “(A) For fiscal year 2023, \$9,000,000.

19 “(B) For each of fiscal years 2024 through
20 2027, \$4,000,000.”.

21 (3) CAPACITY PLANNING ADJUSTMENT.—Para-
22 graph (3), as redesignated, of section 736(c) of the
23 Federal Food, Drug, and Cosmetic Act (21 U.S.C.
24 379h(c)) is amended to read as follows:

25 “(3) CAPACITY PLANNING ADJUSTMENT.—

1 “(A) IN GENERAL.—For each fiscal year,
2 after the annual base revenue established in
3 subsection (b)(1)(A) is adjusted in accordance
4 with paragraphs (1) and (2), such revenue shall
5 be adjusted further for such fiscal year, in ac-
6 cordance with this paragraph, to reflect changes
7 in the resource capacity needs of the Secretary
8 for the process for the review of human drug
9 applications.

10 “(B) METHODOLOGY.—For purposes of
11 this paragraph, the Secretary shall employ the
12 capacity planning methodology utilized by the
13 Secretary in setting fees for fiscal year 2021, as
14 described in the notice titled ‘Prescription Drug
15 User Fee Rates for Fiscal Year 2021’ published
16 in the Federal Register on August 3, 2020 (85
17 Fed. Reg. 46651). The workload categories
18 used in applying such methodology in fore-
19 casting shall include only the activities de-
20 scribed in that notice and, as feasible, addi-
21 tional activities that are also directly related to
22 the direct review of applications and supple-
23 ments, including additional formal meeting
24 types, the direct review of postmarketing com-
25 mitments and requirements, the direct review of

1 risk evaluation and mitigation strategies, and
2 the direct review of annual reports for approved
3 prescription drug products. Subject to the ex-
4 ceptions in the preceding sentence, the Sec-
5 retary shall not include as workload categories
6 in applying such methodology in forecasting any
7 non-core review activities, including those activi-
8 ties that the Secretary referenced for potential
9 future use in such notice but did not utilize in
10 setting fees for fiscal year 2021.

11 “(C) LIMITATION.—Under no cir-
12 cumstances shall an adjustment under this
13 paragraph result in fee revenue for a fiscal year
14 that is less than the sum of the amounts under
15 subsections (b)(1)(A) (the annual base revenue
16 for the fiscal year), (b)(1)(B) (the dollar
17 amount of the inflation adjustment for the fis-
18 cal year), and (b)(1)(C) (the dollar amount of
19 the strategic hiring and retention adjustment
20 for the fiscal year).

21 “(D) PUBLICATION IN FEDERAL REG-
22 ISTER.—The Secretary shall publish in the Fed-
23 eral Register notice under paragraph (6) of the
24 fee revenue and fees resulting from the adjust-

1 ment and the methodologies under this para-
2 graph.”.

3 (4) OPERATING RESERVE ADJUSTMENT.—Para-
4 graph (4), as redesignated, of section 736(c) of the
5 Federal Food, Drug, and Cosmetic Act (21 U.S.C.
6 379h(c)) is amended—

7 (A) by amending subparagraph (A) to read
8 as follows:

9 “(A) INCREASE.—For fiscal year 2023 and
10 subsequent fiscal years, the Secretary shall, in
11 addition to adjustments under paragraphs (1),
12 (2), and (3), further increase the fee revenue
13 and fees if such an adjustment is necessary to
14 provide for operating reserves of carryover user
15 fees for the process for the review of human
16 drug applications for each fiscal year in at least
17 the following amounts:

18 “(i) For fiscal year 2023, at least 8
19 weeks of operating reserves.

20 “(ii) For fiscal year 2024, at least 9
21 weeks of operating reserves.

22 “(iii) For fiscal year 2025 and subse-
23 quent fiscal years, at least 10 weeks of op-
24 erating reserves.”; and

1 (B) in subparagraph (C), by striking
2 “paragraph (5)” and inserting “paragraph
3 (6)”.

4 (5) ADDITIONAL DIRECT COST ADJUSTMENT.—
5 Paragraph (5), as redesignated, of section 736(c) of
6 the Federal Food, Drug, and Cosmetic Act (21
7 U.S.C. 379h(c)) is amended to read as follows:

8 “(5) ADDITIONAL DIRECT COST ADJUST-
9 MENT.—

10 “(A) INCREASE.—The Secretary shall, in
11 addition to adjustments under paragraphs (1),
12 (2), (3), and (4), further increase the fee rev-
13 enue and fees—

14 “(i) for fiscal year 2023, by
15 \$44,386,150; and

16 “(ii) for each of fiscal years 2024
17 through 2027, by the amount set forth in
18 clauses (i) through (iv) of subparagraph
19 (B), as applicable, multiplied by the Con-
20 sumer Price Index for urban consumers
21 (Washington-Arlington-Alexandria, DC-
22 VA-MD-WV; Not Seasonally Adjusted; All
23 Items; Annual Index) for the most recent
24 year of available data, divided by such
25 Index for 2021.

1 “(B) APPLICABLE AMOUNTS.—The
2 amounts referred to in subparagraph (A)(ii) are
3 the following:

4 “(i) For fiscal year 2024,
5 \$60,967,993.

6 “(ii) For fiscal year 2025,
7 \$35,799,314.

8 “(iii) For fiscal year 2026, \$35,799,
9 314.

10 “(iv) For fiscal year 2027,
11 \$35,799,314.”.

12 (6) ANNUAL FEE SETTING.—Paragraph (6), as
13 redesignated, of section 736(c) of the Federal Food,
14 Drug, and Cosmetic Act (21 U.S.C. 379h(c)) is
15 amended by striking “September 30, 2017” and in-
16 serting “September 30, 2022”.

17 (d) CREDITING AND AVAILABILITY OF FEES.—Sec-
18 tion 736(g)(3) of the Federal Food, Drug, and Cosmetic
19 Act (21 U.S.C. 379h(g)(3)) is amended by striking “fiscal
20 years 2018 through 2022” and inserting “fiscal years
21 2023 through 2027”.

22 (e) WRITTEN REQUESTS FOR WAIVERS, REDUC-
23 TIONS, EXEMPTIONS, AND RETURNS; DISPUTES CON-
24 CERNING FEES.—Section 736(i) of the Federal Food,

1 Drug, and Cosmetic Act (21 U.S.C. 379h(i)) is amended
2 to read as follows:

3 “(i) WRITTEN REQUESTS FOR WAIVERS, REDUC-
4 TIONS, EXEMPTIONS, AND RETURNS; DISPUTES CON-
5 CERNING FEES.—To qualify for consideration for a waiver
6 or reduction under subsection (d), an exemption under
7 subsection (k), or the return of any fee paid under this
8 section, including if the fee is claimed to have been paid
9 in error, a person shall—

10 “(1) not later than 180 days after such fee is
11 due, submit to the Secretary a written request justi-
12 fying such waiver, reduction, exemption, or return;
13 and

14 “(2) include in the request any legal authorities
15 under which the request is made.”.

16 (f) ORPHAN DRUGS.—Section 736(k) of the Federal
17 Food, Drug, and Cosmetic Act (21 U.S.C. 379h(k)) is
18 amended—

19 (1) in paragraph (1)(B), by striking “during
20 the previous year” and inserting “as determined
21 under paragraph (2)”; and

22 (2) by amending paragraph (2) to read as fol-
23 lows:

24 “(2) EVIDENCE OF QUALIFICATION.—An ex-
25 emption under paragraph (1) applies with respect to

1 a drug only if the applicant involved submits a cer-
 2 tification that the applicant’s gross annual revenues
 3 did not exceed \$50,000,000 for the last calendar
 4 year ending prior to the fiscal year for which the ex-
 5 emption is requested. Such certification shall be sup-
 6 ported by—

7 “(A) tax returns submitted to the United
 8 States Internal Revenue Service; or

9 “(B) as necessary, other appropriate finan-
 10 cial information.”.

11 **SEC. 104. REAUTHORIZATION; REPORTING REQUIREMENTS.**

12 Section 736B of the Federal Food, Drug, and Cos-
 13 metic Act (21 U.S.C. 379h–2) is amended—

14 (1) in subsection (a)(1), by striking “Beginning
 15 with fiscal year 2018, not” and inserting “Not”;

16 (2) by striking “Prescription Drug User Fee
 17 Amendments of 2017” each place it appears and in-
 18 serting “Prescription Drug User Fee Amendments
 19 of 2022”;

20 (3) in subsection (a)(3)(A), by striking “Not
 21 later than 30 calendar days after the end of the sec-
 22 ond quarter of fiscal year 2018, and not later than
 23 30 calendar days after the end of each quarter of
 24 each fiscal year thereafter” and inserting “Not later
 25 than 30 calendar days after the end of each quarter

1 of each fiscal year for which fees are collected under
2 this part”;

3 (4) in subsection (a)(3)(B), by adding at the
4 end the following:

5 “(v) For fiscal years 2023 and 2024,
6 of the meeting requests from sponsors for
7 which the Secretary has determined that a
8 face-to-face meeting is appropriate, the
9 number of face-to-face meetings requested
10 by sponsors to be conducted in person (in
11 such manner as the Secretary shall pre-
12 scribe on the internet website of the Food
13 and Drug Administration), and the num-
14 ber of such in-person meetings granted by
15 the Secretary.”;

16 (5) in subsection (a)(4), by striking “Beginning
17 with fiscal year 2020, the” and inserting “The”;

18 (6) in subsection (b), by striking “Beginning
19 with fiscal year 2018, not” and inserting “Not”;

20 (7) in subsection (c), by striking “Beginning
21 with fiscal year 2018, for” and inserting “For”; and

22 (8) in subsection (f)—

23 (A) in paragraph (1), in the matter pre-
24 ceding subparagraph (A), by striking “fiscal

1 year 2022” and inserting “fiscal year 2027”;
2 and

3 (B) in paragraph (5), by striking “January
4 15, 2022” and inserting “January 15, 2027”.

5 **SEC. 105. SUNSET DATES.**

6 (a) AUTHORIZATION.—Sections 735 and 736 of the
7 Federal Food, Drug, and Cosmetic Act (21 U.S.C. 379g;
8 379h) shall cease to be effective October 1, 2027.

9 (b) REPORTING REQUIREMENTS.—Section 736B of
10 the Federal Food, Drug, and Cosmetic Act (21 U.S.C.
11 379h–2) shall cease to be effective January 31, 2028.

12 (c) PREVIOUS SUNSET PROVISION.—Effective Octo-
13 ber 1, 2022, subsections (a) and (b) of section 104 of the
14 FDA Reauthorization Act of 2017 (Public Law 115–52)
15 are repealed.

16 **SEC. 106. EFFECTIVE DATE.**

17 The amendments made by this title shall take effect
18 on October 1, 2022, or the date of the enactment of this
19 Act, whichever is later, except that fees under part 2 of
20 subchapter C of chapter VII of the Federal Food, Drug,
21 and Cosmetic Act (21 U.S.C. 379g et seq.) shall be as-
22 sessed for all human drug applications received on or after
23 October 1, 2022, regardless of the date of the enactment
24 of this Act.

1 **SEC. 107. SAVINGS CLAUSE.**

2 Notwithstanding the amendments made by this title,
3 part 2 of subchapter C of chapter VII of the Federal Food,
4 Drug, and Cosmetic Act (21 U.S.C. 379g et seq.), as in
5 effect on the day before the date of the enactment of this
6 title, shall continue to be in effect with respect to human
7 drug applications and supplements (as defined in such
8 part as of such day) that on or after October 1, 2017,
9 but before October 1, 2022, were accepted by the Food
10 and Drug Administration for filing with respect to assess-
11 ing and collecting any fee required by such part for a fiscal
12 year prior to fiscal year 2023.

13 **TITLE II—FEES RELATING TO**
14 **DEVICES**

15 **SEC. 201. SHORT TITLE; FINDING.**

16 (a) **SHORT TITLE.**—This title may be cited as the
17 “Medical Device User Fee Amendments of 2022”.

18 (b) **FINDING.**—The Congress finds that the fees au-
19 thorized under the amendments made by this title will be
20 dedicated toward expediting the process for the review of
21 device applications and for assuring the safety and effec-
22 tiveness of devices, as set forth in the goals identified for
23 purposes of part 3 of subchapter C of chapter VII of the
24 Federal Food, Drug, and Cosmetic Act (21 U.S.C. 379i
25 et seq.), in the letters from the Secretary of Health and
26 Human Services to the Chairman of the Committee on

1 Health, Education, Labor, and Pensions of the Senate and
2 the Chairman of the Committee on Energy and Commerce
3 of the House of Representatives, as set forth in the Con-
4 gressional Record.

5 **SEC. 202. DEFINITIONS.**

6 Section 737 of the Federal Food, Drug, and Cosmetic
7 Act (21 U.S.C. 379i) is amended—

8 (1) in paragraph (9)—

9 (A) in the matter preceding subparagraph
10 (A), by striking “and premarket notification
11 submissions” and inserting “premarket notifica-
12 tion submissions, and de novo classification re-
13 quests”;

14 (B) in subparagraph (D), by striking “and
15 submissions” and inserting “submissions, and
16 requests”;

17 (C) in subparagraph (F), by striking “and
18 premarket notification submissions” and insert-
19 ing “premarket notification submissions, and de
20 novo classification requests”;

21 (D) in each of subparagraphs (G) and (H),
22 by striking “or submissions” and inserting
23 “submissions, or requests”; and

24 (E) in subparagraph (K), by striking “or
25 premarket notification submissions” and insert-

1 ing “premarket notification submissions, or de
 2 novo classification requests”; and
 3 (2) in paragraph (11), by striking “2016” and
 4 inserting “2021”.

5 **SEC. 203. AUTHORITY TO ASSESS AND USE DEVICE FEES.**

6 (a) TYPES OF FEES.—Section 738(a) of the Federal
 7 Food, Drug, and Cosmetic Act (21 U.S.C. 379j(a)) is
 8 amended—

9 (1) in paragraph (1), by striking “fiscal year
 10 2018” and inserting “fiscal year 2023”; and

11 (2) in paragraph (2)—

12 (A) in subparagraph (A)—

13 (i) in the matter preceding clause (i),
 14 by striking “October 1, 2017” and insert-
 15 ing “October 1, 2022”;

16 (ii) in clause (iii), by striking “75 per-
 17 cent” and inserting “80 percent”; and

18 (iii) in clause (viii), by striking “3.4
 19 percent” and inserting “4.5 percent”;

20 (B) in subparagraph (B)(iii), by striking
 21 “or premarket notification submission” and in-
 22 serting “premarket notification submission, or
 23 de novo classification request”; and

24 (C) in subparagraph (C), by striking “or
 25 periodic reporting concerning a class III device”

1 and inserting “periodic reporting concerning a
 2 class III device, or de novo classification re-
 3 quest”.

4 (b) FEE AMOUNTS.—Section 738(b) of the Federal
 5 Food, Drug, and Cosmetic Act (21 U.S.C. 379j(b)) is
 6 amended—

7 (1) in paragraph (1), by striking “2018
 8 through 2022” and inserting “2023 through 2027”;
 9 (2) by amending paragraph (2) to read as fol-
 10 lows:

11 “(2) BASE FEE AMOUNTS SPECIFIED.—For
 12 purposes of paragraph (1), the base fee amounts
 13 specified in this paragraph are as follows:

“Fee Type	Fiscal Year 2023	Fiscal Year 2024	Fiscal Year 2025	Fiscal Year 2026	Fiscal Year 2027
Premarket Application	\$425,000	\$435,000	\$445,000	\$455,000	\$470,000
Establishment Registration	\$6,250	\$6,875	\$7,100	\$7,575	\$8,465”; and

14 (3) by amending paragraph (3) to read as fol-
 15 lows:

16 “(3) TOTAL REVENUE AMOUNTS SPECIFIED.—
 17 For purposes of paragraph (1), the total revenue
 18 amounts specified in this paragraph are as follows:

19 “(A) \$312,606,000 for fiscal year 2023.

20 “(B) \$335,750,000 for fiscal year 2024.

21 “(C) \$350,746,400 for fiscal year 2025.

22 “(D) \$366,486,300 for fiscal year 2026.

23 “(E) \$418,343,000 for fiscal year 2027.”.

1 (c) ANNUAL FEE SETTING; ADJUSTMENTS.—Section
2 738(c) of the Federal Food, Drug, and Cosmetic Act (21
3 U.S.C. 379j(c)) is amended—

4 (1) in paragraph (1), by striking “2017” and
5 inserting “2022”;

6 (2) in paragraph (2)—

7 (A) in subparagraph (A), by striking
8 “2018” and inserting “2023”;

9 (B) in subparagraph (B)—

10 (i) in the matter preceding clause (i),
11 by striking “fiscal year 2018” and insert-
12 ing “fiscal year 2023”; and

13 (ii) in clause (ii), by striking “fiscal
14 year 2016” and inserting “fiscal year
15 2022”;

16 (C) in subparagraph (C), by striking
17 “Washington-Baltimore, DC–MD–VA–WV”
18 and inserting “Washington-Arlington-Alexan-
19 dria, DC–VA–MD–WV”; and

20 (D) in subparagraph (D), in the matter
21 preceding clause (i), by striking “fiscal years
22 2018 through 2022” and inserting “fiscal years
23 2023 through 2027”;

24 (3) in paragraph (3), by striking “2018
25 through 2022” and inserting “2023 through 2027”;

1 (4) by redesignating paragraphs (4) and (5) as
2 paragraphs (7) and (8), respectively; and

3 (5) by inserting after paragraph (3) the fol-
4 lowing:

5 “(4) PERFORMANCE IMPROVEMENT ADJUST-
6 MENT.—

7 “(A) IN GENERAL.—For each of fiscal
8 years 2025 through 2027, after the adjust-
9 ments under paragraphs (2) and (3), the base
10 establishment registration fee amounts for such
11 fiscal year shall be increased to reflect changes
12 in the resource needs of the Secretary due to
13 improved review performance goals for the proc-
14 ess for the review of device applications identi-
15 fied in the letters described in section 201(b) of
16 the Medical Device User Fee Amendments of
17 2022, as the Secretary determines necessary to
18 achieve an increase in total fee collections for
19 such fiscal year equal to the following amounts:

20 “(i) For fiscal year 2025, the product
21 of—

22 “(I) the amount determined
23 under subparagraph (B)(i)(I); and

1 “(II) the applicable inflation ad-
 2 justment under paragraph (2)(B) for
 3 such fiscal year.

4 “(ii) For fiscal year 2026, the product
 5 of—

6 “(I) the sum of the amounts de-
 7 termined under subparagraphs
 8 (B)(i)(II), (B)(ii)(I), and (B)(iii)(I);
 9 and

10 “(II) the applicable inflation ad-
 11 justment under paragraph (2)(B) for
 12 such fiscal year.

13 “(iii) For fiscal year 2027, the prod-
 14 uct of—

15 “(I) the sum of the amounts de-
 16 termined under subparagraphs
 17 (B)(i)(III), (B)(ii)(II), and
 18 (B)(iii)(II); and

19 “(II) the applicable inflation ad-
 20 justment under paragraph (2)(B) for
 21 such fiscal year.

22 “(B) AMOUNTS.—

23 “(i) PRE-SUBMISSION AMOUNT.—For
 24 purposes of subparagraph (A), with respect
 25 to the pre-submission written feedback

1 goal, the amounts determined under this
2 subparagraph are as follows:

3 “(I) For fiscal year 2025,
4 \$15,396,600 if such goal for fiscal
5 year 2023 is met.

6 “(II) For fiscal year 2026:

7 “(aa) \$15,396,600 if such
8 goal for fiscal year 2023 is met
9 and such goal for fiscal year
10 2024 is not met.

11 “(bb) \$36,792,200 if such
12 goal for fiscal year 2024 is met.

13 “(III) For fiscal year 2027:

14 “(aa) \$15,396,600 if such
15 goal for fiscal year 2023 is met
16 and such goal for each of fiscal
17 years 2024 and 2025 is not met.

18 “(bb) \$36,792,200 if such
19 goal for fiscal year 2024 is met
20 and such goal for fiscal year
21 2025 is not met.

22 “(cc) \$40,572,600 if such
23 goal for fiscal year 2025 is met.

24 “(ii) DE NOVO CLASSIFICATION
25 AMOUNT.—For purposes of subparagraph

1 (A), with respect to the de novo decision
2 goal, the amounts determined under this
3 subparagraph are as follows:

4 “(I) For fiscal year 2026,
5 \$6,323,500 if such goal for fiscal year
6 2023 is met.

7 “(II) For fiscal year 2027:

8 “(aa) \$6,323,500 if such
9 goal for fiscal year 2023 is met
10 and such goal for fiscal year
11 2024 is not met.

12 “(bb) \$11,765,400 if such
13 goal for fiscal year 2024 is met.

14 “(iii) PREMARKET NOTIFICATION AND
15 PREMARKET APPROVAL AMOUNT.—For
16 purposes of subparagraph (A), with respect
17 to the 510(k) decision goal, 510(k) shared
18 outcome total time to decision goal, PMA
19 decision goal, and PMA shared outcome
20 total time to decision goal, the amounts de-
21 termined under this subparagraph are as
22 follows:

23 “(I) For fiscal year 2026,
24 \$1,020,000 if the four goals for fiscal
25 year 2023 are met.

1 “(II) For fiscal year 2027:

2 “(aa) \$1,020,000 if the four
3 goals for fiscal year 2023 are met
4 and one or more of the four goals
5 for fiscal year 2024 are not met.

6 “(bb) \$3,906,000 if the four
7 goals for fiscal year 2024 are
8 met.

9 “(C) PERFORMANCE CALCULATION.—For
10 purposes of this paragraph, performance of the
11 goals listed in subparagraph (D) shall be deter-
12 mined as specified in the letters described in
13 section 201(b) of the Medical Device User Fee
14 Amendments of 2022 and based on data avail-
15 able as of the following dates:

16 “(i) The performance of the pre-sub-
17 mission written feedback goal shall be
18 based on data available as of—

19 “(I) for fiscal year 2023, March
20 31, 2024;

21 “(II) for fiscal year 2024, March
22 31, 2025; and

23 “(III) for fiscal year 2025,
24 March 31, 2026.

1 “(ii) The performance of the de novo
2 decision goal, 510(k) decision goal, 510(k)
3 shared outcome total time to decision goal,
4 PMA decision goal, and PMA shared out-
5 come total time to decision goal shall be
6 based on data available as of—

7 “(I) for fiscal year 2023, March
8 31, 2025; and

9 “(II) for fiscal year 2024, March
10 31, 2026.

11 “(D) GOALS DEFINED.—For purposes of
12 this paragraph, the terms ‘pre-submission writ-
13 ten feedback goal’, ‘de novo decision goal’,
14 ‘510(k) decision goal’, ‘510(k) shared outcome
15 total time to decision goal’, ‘PMA decision
16 goal’, and ‘PMA shared outcome total time to
17 decision goal’ refer to the goals identified by the
18 same names in the letters described in section
19 201(b) of the Medical Device User Fee Amend-
20 ments of 2022.

21 “(5) HIRING ADJUSTMENT.—

22 “(A) IN GENERAL.—For each of fiscal
23 years 2025 through 2027, after the adjust-
24 ments under paragraphs (2), (3), and (4), if ap-
25 plicable, if the number of hires to support the

1 process for the review of device applications
2 falls below the thresholds specified in subpara-
3 graph (B) for the applicable fiscal years, the
4 base establishment registration fee amounts
5 shall be decreased as the Secretary determines
6 necessary to achieve a reduction in total fee col-
7 lections equal to the hiring adjustment amount
8 under subparagraph (C).

9 “(B) THRESHOLDS.—The thresholds speci-
10 fied in this subparagraph are as follows:

11 “(i) For fiscal year 2025, the thresh-
12 old is 123 hires for fiscal year 2023.

13 “(ii) For fiscal year 2026, the thresh-
14 old is 38 hires for fiscal year 2024.

15 “(iii) For fiscal year 2027, the thresh-
16 old is—

17 “(I) 22 hires for fiscal year 2025
18 if the base establishment registration
19 fees are not increased by the amount
20 determined under paragraph
21 (4)(A)(i); or

22 “(II) 75 hires for fiscal year
23 2025 if such fees are so increased.

24 “(C) HIRING ADJUSTMENT AMOUNT.—The
25 hiring adjustment amount for fiscal year 2025

1 and each subsequent fiscal year is the product
2 of—

3 “(i) the number of hires by which the
4 hiring goal specified in subparagraph (D)
5 for the fiscal year before the prior fiscal
6 year was not met;

7 “(ii) \$72,877; and

8 “(iii) the applicable inflation adjust-
9 ment under paragraph (2)(B) for the fiscal
10 year for which the hiring goal was not met.

11 “(D) HIRING GOALS.—The hiring goals for
12 each of fiscal years 2023 through 2025 are as
13 follows:

14 “(i) For fiscal year 2023, 144 hires.

15 “(ii) For fiscal year 2024, 42 hires.

16 “(iii) For fiscal year 2025:

17 “(I) 24 hires if the base estab-
18 lishment registration fees are not in-
19 creased by the amount determined
20 under paragraph (4)(A)(i).

21 “(II) 83 hires if the base estab-
22 lishment registration fees are in-
23 creased by the amount determined
24 under paragraph (4)(A)(i).

1 “(E) NUMBER OF HIRES.—For purposes
2 of this paragraph, the number of hires shall be
3 determined by the Secretary as set forth in the
4 letters described in section 201(b) of the Med-
5 ical Device User Fee Amendments of 2022.

6 “(6) OPERATING RESERVE ADJUSTMENT.—

7 “(A) IN GENERAL.—For each of fiscal
8 years 2023 through 2027, after the adjust-
9 ments under paragraphs (2), (3), (4), and (5),
10 if applicable, if the Secretary has operating re-
11 serves of carryover user fees for the process for
12 the review of device applications in excess of the
13 designated amount in subparagraph (B), the
14 Secretary shall decrease the base establishment
15 registration fee amounts to provide for not
16 more than such designated amount of operating
17 reserves.

18 “(B) DESIGNATED AMOUNT.—Subject to
19 subparagraph (C), for each fiscal year, the des-
20 ignated amount in this subparagraph is equal
21 to the sum of—

22 “(i) 13 weeks of operating reserves of
23 carryover user fees; and

24 “(ii) 1 month of operating reserves
25 maintained pursuant to paragraph (8).

1 “(C) EXCLUDED AMOUNT.—For the period
 2 of fiscal years 2023 through 2026, a total
 3 amount equal to \$118,000,000 shall not be con-
 4 sidered part of the designated amount under
 5 subparagraph (B) and shall not be subject to
 6 the decrease under subparagraph (A).”.

7 (d) SMALL BUSINESSES.—Section 738 of the Federal
 8 Food, Drug, and Cosmetic Act (21 U.S.C. 379j) is amend-
 9 ed in each of subsections (d)(2)(B)(iii) and (e)(2)(B)(iii)
 10 by inserting “, if extant,” after “national taxing author-
 11 ity”.

12 (e) CONDITIONS.—Section 738(g) of the Federal
 13 Food, Drug, and Cosmetic Act (21 U.S.C. 379j(g)) is
 14 amended—

15 (1) in paragraph (1)(A), by striking
 16 “\$320,825,000” and inserting “\$398,566,000”; and

17 (2) in paragraph (2), by inserting “de novo
 18 classification requests,” after “class III device,”.

19 (f) CREDITING AND AVAILABILITY OF FEES.—Sec-
 20 tion 738(h)(3) of the Federal Food, Drug, and Cosmetic
 21 Act (21 U.S.C. 379j(h)(3)) is amended to read as follows:

22 “(3) AUTHORIZATION OF APPROPRIATIONS.—

23 “(A) IN GENERAL.—For each of fiscal
 24 years 2023 through 2027, there is authorized to
 25 be appropriated for fees under this section an

1 amount equal to the revenue amount deter-
2 mined under subparagraph (B), less the
3 amount of reductions determined under sub-
4 paragraph (C).

5 “(B) REVENUE AMOUNT.—For purposes of
6 this paragraph, the revenue amount for each
7 fiscal year is the sum of—

8 “(i) the total revenue amount under
9 subsection (b)(3) for the fiscal year, as ad-
10 justed under paragraphs (2) and (3) of
11 subsection (c); and

12 “(ii) the performance improvement
13 adjustment amount for the fiscal year
14 under subsection (c)(4), if applicable.

15 “(C) REDUCTIONS.—For purposes of this
16 paragraph, the amount of reductions for each
17 fiscal year is the sum of—

18 “(i) the hiring adjustment amount for
19 the fiscal year under subsection (c)(5), if
20 applicable; and

21 “(ii) the operating reserve adjustment
22 amount for the fiscal year under sub-
23 section (c)(6), if applicable.”.

1 **SEC. 204. REAUTHORIZATION; REPORTING REQUIREMENTS.**

2 (a) PERFORMANCE REPORTS.—Section 738A(a) of
3 the Federal Food, Drug, and Cosmetic Act (21 U.S.C.
4 379j–1(a)) is amended—

5 (1) by striking “fiscal year 2018” each place it
6 appears and inserting “fiscal year 2023”;

7 (2) by striking “Medical Device User Fee
8 Amendments of 2017” each place it appears and in-
9 serting “Medical Device User Fee Amendments of
10 2022”;

11 (3) in paragraph (1)—

12 (A) in subparagraph (A), by redesignating
13 the second clause (iv) (relating to analysis) as
14 clause (v); and

15 (B) in subparagraph (A)(iv), by striking
16 “fiscal year 2020” and inserting “fiscal year
17 2023”; and

18 (4) in paragraph (4), by striking “2018
19 through 2022” and inserting “2023 through 2027”.

20 (b) REAUTHORIZATION.—Section 738A(b) of the
21 Federal Food, Drug, and Cosmetic Act (21 U.S.C. 379j–
22 1(b)) is amended—

23 (1) in paragraph (1), by striking “2022” and
24 inserting “2027”; and

25 (2) in paragraph (5), by striking “2022” and
26 inserting “2027”.

1 **SEC. 205. CONFORMITY ASSESSMENT PILOT PROGRAM.**

2 Section 514(d) of the Federal Food, Drug, and Cos-
3 metic Act (21 U.S.C. 360d(d)) is amended to read as fol-
4 lows:

5 “(d) ACCREDITATION SCHEME FOR CONFORMITY AS-
6 SESSMENT.—

7 “(1) IN GENERAL.—The Secretary shall estab-
8 lish a program under which—

9 “(A) testing laboratories meeting criteria
10 specified in guidance by the Secretary may be
11 accredited by accreditation bodies meeting cri-
12 teria specified in guidance by the Secretary, to
13 conduct testing to support the assessment of
14 the conformity of a device to certain standards
15 recognized under this section; and

16 “(B) subject to paragraph (2), results
17 from tests conducted to support the assessment
18 of conformity of devices as described in sub-
19 paragraph (A) conducted by testing laboratories
20 accredited pursuant to this subsection shall be
21 accepted by the Secretary for purposes of dem-
22 onstrating such conformity unless the Secretary
23 finds that certain results of such tests should
24 not be so accepted.

25 “(2) SECRETARIAL REVIEW OF ACCREDITED
26 LABORATORY RESULTS.—The Secretary may—

1 “(A) review the results of tests conducted
2 by testing laboratories accredited pursuant to
3 this subsection, including by conducting peri-
4 odic audits of such results or of the processes
5 of accredited bodies or testing laboratories;

6 “(B) following such review, take additional
7 measures under this Act, as the Secretary de-
8 termines appropriate, such as—

9 “(i) suspension or withdrawal of ac-
10 creditation of a testing laboratory or rec-
11 ognition of an accreditation body under
12 paragraph (1)(A); or

13 “(ii) requesting additional information
14 with respect to a device; and

15 “(C) if the Secretary becomes aware of in-
16 formation materially bearing on the safety or
17 effectiveness of a device for which an assess-
18 ment of conformity was supported by testing
19 conducted by a testing laboratory accredited
20 under this subsection, take such additional
21 measures under this Act, as the Secretary de-
22 termines appropriate, such as—

23 “(i) suspension or withdrawal of ac-
24 creditation of a testing laboratory or rec-

1 ognition of an accreditation body under
2 paragraph (1)(A); or

3 “(ii) requesting additional information
4 with regard to such device.

5 “(3) IMPLEMENTATION AND REPORTING.—

6 “(A) PILOT PROGRAM TRANSITION.—After
7 September 30, 2023, the pilot program pre-
8 viously initiated under this subsection, as in ef-
9 fect prior to the date of enactment of the Med-
10 ical Device User Fee Amendments of 2022,
11 shall be considered to be completed, and the
12 Secretary may continue operating a program
13 consistent with this subsection.

14 “(B) REPORT.—The Secretary shall make
15 available on the internet website of the Food
16 and Drug Administration an annual report on
17 the progress of the pilot program under this
18 subsection.”.

19 **SEC. 206. REAUTHORIZATION OF THIRD-PARTY REVIEW**
20 **PROGRAM.**

21 Section 523(c) of the Federal Food, Drug, and Cos-
22 metic Act (21 U.S.C. 360m(c)) is amended by striking
23 “2022” and inserting “2027”.

1 **SEC. 207. SUNSET DATES.**

2 (a) AUTHORIZATION.—Sections 737 and 738 of the
3 Federal Food, Drug, and Cosmetic Act (21 U.S.C. 379i;
4 379j) shall cease to be effective October 1, 2027.

5 (b) REPORTING REQUIREMENTS.—Section 738A (21
6 U.S.C. 379j– 1) of the Federal Food, Drug, and Cosmetic
7 Act (regarding reauthorization and reporting require-
8 ments) shall cease to be effective January 31, 2028.

9 (c) PREVIOUS SUNSET PROVISIONS.—Effective Octo-
10 ber 1, 2022, subsections (a) and (b) of section 210 of the
11 FDA Reauthorization Act of 2017 (Public Law 115–52)
12 are repealed.

13 **SEC. 208. EFFECTIVE DATE.**

14 The amendments made by this title shall take effect
15 on October 1, 2022, or the date of the enactment of this
16 Act, whichever is later, except that fees under part 3 of
17 subchapter C of chapter VII of the Federal Food, Drug,
18 and Cosmetic Act (21 U.S.C. 379i et seq.) shall be as-
19 sessed for all submissions listed in section 738(a)(2)(A)
20 of such Act received on or after October 1, 2022, regard-
21 less of the date of the enactment of this Act.

22 **SEC. 209. SAVINGS CLAUSE.**

23 Notwithstanding the amendments made by this title,
24 part 3 of subchapter C of chapter VII of the Federal Food,
25 Drug, and Cosmetic Act (21 U.S.C. 379i et seq.), as in
26 effect on the day before the date of the enactment of this

1 title, shall continue to be in effect with respect to the sub-
2 missions listed in section 738(a)(2)(A) of such Act (as de-
3 fined in such part as of such day) that on or after October
4 1, 2017, but before October 1, 2022, were received by the
5 Food and Drug Administration with respect to assessing
6 and collecting any fee required by such part for a fiscal
7 year prior to fiscal year 2023.

8 **TITLE III—FEES RELATING TO** 9 **GENERIC DRUGS**

10 **SEC. 301. SHORT TITLE; FINDING.**

11 (a) SHORT TITLE.—This title may be cited as the
12 “Generic Drug User Fee Amendments of 2022”.

13 (b) FINDING.—The Congress finds that the fees au-
14 thorized by the amendments made by this title will be
15 dedicated to human generic drug activities, as set forth
16 in the goals identified for purposes of part 7 of subchapter
17 C of chapter VII of the Federal Food, Drug, and Cosmetic
18 Act (21 U.S.C. 379j–41 et seq.), in the letters from the
19 Secretary of Health and Human Services to the Chairman
20 of the Committee on Health, Education, Labor, and Pen-
21 sions of the Senate and the Chairman of the Committee
22 on Energy and Commerce of the House of Representa-
23 tives, as set forth in the Congressional Record.

1 **SEC. 302. AUTHORITY TO ASSESS AND USE HUMAN GE-**
2 **NERIC DRUG FEES.**

3 (a) TYPES OF FEES.—Section 744B(a) of the Fed-
4 eral Food, Drug, and Cosmetic Act (21 U.S.C. 379j–
5 42(a)) is amended—

6 (1) in the matter preceding paragraph (1), by
7 striking “fiscal year 2018” and inserting “fiscal year
8 2023”;

9 (2) in paragraph (2)(C), by striking “2018
10 through 2022” and inserting “2023 through 2027”;

11 (3) in paragraph (3)(B), by striking “2018
12 through 2022” and inserting “2023 through 2027”;

13 (4) in paragraph (4)(D), by striking “2018
14 through 2022” and inserting “2023 through 2027”;
15 and

16 (5) in paragraph (5)(D), by striking “2018
17 through 2022” and inserting “2023 through 2027”.

18 (b) FEE REVENUE AMOUNTS.—Section 744B(b) of
19 the Federal Food, Drug, and Cosmetic Act (21 U.S.C.
20 379j–42(b)) is amended—

21 (1) in paragraph (1)—

22 (A) in subparagraph (A)—

23 (i) in the heading, by striking “2018”
24 and inserting “2023”;

25 (ii) by striking “2018” and inserting
26 “2023”; and

1 (iii) by striking “\$493,600,000” and
2 inserting “\$582,500,000”; and

3 (B) by amending subparagraph (B) to read
4 as follows:

5 “(B) FISCAL YEARS 2024 THROUGH 2027.—

6 “(i) IN GENERAL.—For each of the
7 fiscal years 2024 through 2027, fees under
8 paragraphs (2) through (5) of subsection
9 (a) shall be established to generate a total
10 estimated revenue amount under such sub-
11 section that is equal to the base revenue
12 amount for the fiscal year under clause
13 (ii), as adjusted pursuant to subsection (c).

14 “(ii) BASE REVENUE AMOUNT.—The
15 base revenue amount for a fiscal year re-
16 ferred to in clause (i) is equal to the total
17 revenue amount established under this
18 paragraph for the previous fiscal year, not
19 including any adjustments made for such
20 previous fiscal year under subsection
21 (c)(3).”; and

22 (2) in paragraph (2)—

23 (A) in subparagraph (C), by striking “one-
24 third the amount” and inserting “twenty-four
25 percent”;

1 (B) in subparagraph (D), by striking
 2 “Seven percent” and inserting “Six percent”;
 3 and

4 (C) in subparagraph (E)(i), by striking
 5 “Thirty-five percent” and inserting “Thirty-six
 6 percent”.

7 (c) ADJUSTMENTS.—Section 744B(c) of the Federal
 8 Food, Drug, and Cosmetic Act (21 U.S.C. 379j–42(c)) is
 9 amended—

10 (1) in paragraph (1)—

11 (A) in the matter preceding subparagraph
 12 (A)—

13 (i) by striking “2019” and inserting
 14 “2024”; and

15 (ii) by striking “to equal the product
 16 of the total revenues established in such
 17 notice for the prior fiscal year multiplied”
 18 and inserting “to equal the base revenue
 19 amount for the fiscal year (as specified in
 20 subsection (b)(1)(B)) multiplied”; and

21 (B) in subparagraph (C), by striking
 22 “Washington-Baltimore, DC–MD–VA–WV”
 23 and inserting “Washington-Arlington-Alexan-
 24 dria, DC–VA–MD–WV”; and

(2) by striking paragraph (2) and inserting the following:

“(2) CAPACITY PLANNING ADJUSTMENT.—

“(A) IN GENERAL.—Beginning with fiscal year 2024, the Secretary shall, in addition to the adjustment under paragraph (1), further increase the fee revenue and fees under this section for a fiscal year, in accordance with this paragraph, to reflect changes in the resource capacity needs of the Secretary for human generic drug activities.

“(B) CAPACITY PLANNING METHODOLOGY.—The Secretary shall establish a capacity planning methodology for purposes of this paragraph, which shall—

“(i) be derived from the methodology and recommendations made in the report titled ‘Independent Evaluation of the GDUFA Resource Capacity Planning Adjustment Methodology: Evaluation and Recommendations’ announced in the Federal Register on August 3, 2020;

“(ii) incorporate approaches and attributes determined appropriate by the Secretary, including approaches and at-

1 tributes made in such report, except that
2 in incorporating such approaches and at-
3 tributes the workload categories used in
4 forecasting resources shall only be the
5 workload categories specified in section
6 VIII.B.2.e. of the letters described in sec-
7 tion 301(b) of the Generic Drug User Fee
8 Amendments of 2022; and

9 “(iii) be effective beginning with fiscal
10 year 2024.

11 “(C) LIMITATIONS.—

12 “(i) IN GENERAL.—Under no cir-
13 cumstances shall an adjustment under this
14 paragraph result in fee revenue for a fiscal
15 year that is less than the sum of the
16 amounts under subsection (b)(1)(B)(ii)
17 (the base revenue amount for the fiscal
18 year) and paragraph (1) (the dollar
19 amount of the inflation adjustment for the
20 fiscal year).

21 “(ii) PERCENTAGE LIMITATION.—An
22 adjustment under this paragraph shall not
23 exceed three percent of the sum described
24 in clause (i) for the fiscal year, except that
25 such limitation shall be four percent if—

1 “(I) for purposes of a fiscal year
2 2024 adjustment, the Secretary deter-
3 mines that during the period from
4 April 1, 2021, through March 31,
5 2023—

6 “(aa) the total number of
7 abbreviated new drug applica-
8 tions submitted was greater than
9 or equal to 2,000; or

10 “(bb) thirty-five percent or
11 more of abbreviated new drug ap-
12 plications submitted related to
13 complex products (as that term is
14 defined in section XI of the let-
15 ters described in section 301(b)
16 of the Generic Drug User Fee
17 Amendments of 2022);

18 “(II) for purposes of a fiscal year
19 2025 adjustment, the Secretary deter-
20 mines that during the period from
21 April 1, 2022, through March 31,
22 2024—

23 “(aa) the total number of
24 abbreviated new drug applica-

1 tions submitted was greater than
2 or equal to 2,300; or

3 “(bb) thirty-five percent or
4 more of abbreviated new drug ap-
5 plications submitted related to
6 complex products (as so defined);

7 “(III) for purposes of a fiscal
8 year 2026 adjustment, the Secretary
9 determines that during the period
10 from April 1, 2023, through March
11 31, 2025—

12 “(aa) the total number of
13 abbreviated new drug applica-
14 tions submitted was greater than
15 or equal to 2,300; or

16 “(bb) thirty-five percent or
17 more of abbreviated new drug ap-
18 plications submitted related to
19 complex products (as so defined);
20 and

21 “(IV) for purposes of a fiscal
22 year 2027 adjustment, the Secretary
23 determines that during the period
24 from April 1, 2024, through March
25 31, 2026—

1 “(aa) the total number of
2 abbreviated new drug applica-
3 tions submitted was greater than
4 or equal to 2,300; or

5 “(bb) thirty-five percent or
6 more of abbreviated new drug ap-
7 plications submitted related to
8 complex products (as so defined).

9 “(D) PUBLICATION IN FEDERAL REG-
10 ISTER.—The Secretary shall publish in the Fed-
11 eral Register notice referred to in subsection (a)
12 the fee revenue and fees resulting from the ad-
13 justment and the methodology under this para-
14 graph.

15 “(3) OPERATING RESERVE ADJUSTMENT.—

16 “(A) IN GENERAL.—For fiscal year 2024
17 and each subsequent fiscal year, the Secretary
18 may, in addition to adjustments under para-
19 graphs (1) and (2), further increase the fee rev-
20 enue and fees under this section for such fiscal
21 year if such an adjustment is necessary to pro-
22 vide operating reserves of carryover user fees
23 for human generic drug activities for not more
24 than the number of weeks specified in subpara-
25 graph (B) with respect to that fiscal year.

1 “(B) NUMBER OF WEEKS.—The number of
2 weeks specified in this subparagraph is—

3 “(i) 8 weeks for fiscal year 2024;

4 “(ii) 9 weeks for fiscal year 2025; and

5 “(iii) 10 weeks for each of fiscal year
6 2026 and 2027.

7 “(C) DECREASE.—If the Secretary has
8 carryover balances for human generic drug ac-
9 tivities in excess of 12 weeks of the operating
10 reserves referred to in subparagraph (A), the
11 Secretary shall decrease the fee revenue and
12 fees referred to in such subparagraph to provide
13 for not more than 12 weeks of such operating
14 reserves.

15 “(D) RATIONALE FOR ADJUSTMENT.—If
16 an adjustment under this paragraph is made,
17 the rationale for the amount of the increase or
18 decrease (as applicable) in fee revenue and fees
19 shall be contained in the annual Federal Reg-
20 ister notice under subsection (a) publishing the
21 fee revenue and fees for the fiscal year in-
22 volved.”.

23 (d) ANNUAL FEE SETTING.—Section 744B(d)(1) of
24 the Federal Food, Drug, and Cosmetic Act (21 U.S.C.
25 379j–42(d)(1)) is amended—

1 (1) in the paragraph heading, by striking “2018
2 THROUGH 2022” and inserting “2023 THROUGH
3 2027”; and

4 (2) by striking “more than 60 days before the
5 first day of each of fiscal years 2018 through 2022”
6 and inserting “later than 60 days before the first
7 day of each of fiscal years 2023 through 2027”.

8 (e) CREDITING AND AVAILABILITY OF FEES.—Sec-
9 tion 744B(i)(3) of the Federal Food, Drug, and Cosmetic
10 Act (21 U.S.C. 379j–42(i)(3)) is amended by striking “fis-
11 cal years 2018 through 2022” and inserting “fiscal years
12 2023 through 2027”.

13 (f) EFFECT OF FAILURE TO PAY FEES.—The head-
14 ing of paragraph (3) of section 744B(g) of the Federal
15 Food, Drug, and Cosmetic Act (21 U.S.C. 379j–42(g)) is
16 amended by striking “AND PRIOR APPROVAL SUPPLEMENT
17 FEE”.

18 **SEC. 303. REAUTHORIZATION; REPORTING REQUIREMENTS.**

19 Section 744C of the Federal Food, Drug, and Cos-
20 metic Act (21 U.S.C. 379j–43) is amended—

21 (1) in subsection (a)(1), by striking “Beginning
22 with fiscal year 2018, not” and inserting “Not”;

23 (2) by striking “Generic Drug User Fee
24 Amendments of 2017” each place it appears and in-

1 serting “Generic Drug User Fee Amendments of
2 2022”;

3 (3) in subsection (a)(2), by striking “Not later
4 than 30 calendar days after the end of the second
5 quarter of fiscal year 2018, and not later than 30
6 calendar days after the end of each quarter of each
7 fiscal year thereafter” and inserting “Not later than
8 30 calendar days after the end of each quarter of
9 each fiscal year for which fees are collected under
10 this part”;

11 (4) in subsection (a)(3), by striking “Beginning
12 with fiscal year 2020, the” and inserting “The”;

13 (5) in subsection (b), by striking “Beginning
14 with fiscal year 2018, not” and inserting “Not”;

15 (6) in subsection (c), by striking “Beginning
16 with fiscal year 2018, for” and inserting “For”; and

17 (7) in subsection (f)—

18 (A) in paragraph (1), in the matter pre-
19 ceding subparagraph (A), by striking “fiscal
20 year 2022” and inserting “fiscal year 2027”;
21 and

22 (B) in paragraph (5), by striking “January
23 15, 2022” and inserting “January 15, 2027”.

1 **SEC. 304. SUNSET DATES.**

2 (a) AUTHORIZATION.—Sections 744A and 744B of
3 the Federal Food, Drug, and Cosmetic Act (21 U.S.C.
4 379j–41; 379j–42) shall cease to be effective October 1,
5 2027.

6 (b) REPORTING REQUIREMENTS.—Section 744C of
7 the Federal Food, Drug, and Cosmetic Act (21 U.S.C.
8 379j–43) shall cease to be effective January 31, 2028.

9 (c) PREVIOUS SUNSET PROVISION.—Effective Octo-
10 ber 1, 2022, subsections (a) and (b) of section 305 of the
11 FDA Reauthorization Act of 2017 (Public Law 115–52)
12 are repealed.

13 **SEC. 305. EFFECTIVE DATE.**

14 The amendments made by this title shall take effect
15 on October 1, 2022, or the date of the enactment of this
16 Act, whichever is later, except that fees under part 7 of
17 subchapter C of chapter VII of the Federal Food, Drug,
18 and Cosmetic Act (21 U.S.C. 379j–41 et seq.) shall be
19 assessed for all abbreviated new drug applications received
20 on or after October 1, 2022, regardless of the date of the
21 enactment of this Act.

22 **SEC. 306. SAVINGS CLAUSE.**

23 Notwithstanding the amendments made by this title,
24 part 7 of subchapter C of chapter VII of the Federal Food,
25 Drug, and Cosmetic Act (21 U.S.C. 379j–41 et seq.), as
26 in effect on the day before the date of the enactment of

1 this title, shall continue to be in effect with respect to ab-
 2 breviated new drug applications (as defined in such part
 3 as of such day) that were received by the Food and Drug
 4 Administration within the meaning of section 505(j)(5)(A)
 5 of such Act (21 U.S.C. 355(j)(5)(A)), prior approval sup-
 6 plements that were submitted, and drug master files for
 7 Type II active pharmaceutical ingredients that were first
 8 referenced on or after October 1, 2017, but before October
 9 1, 2022, with respect to assessing and collecting any fee
 10 required by such part for a fiscal year prior to fiscal year
 11 2023.

12 **TITLE IV—FEES RELATING TO** 13 **BIOSIMILAR BIOLOGICAL** 14 **PRODUCTS**

15 **SEC. 401. SHORT TITLE; FINDING.**

16 (a) **SHORT TITLE.**—This title may be cited as the
 17 “Biosimilar User Fee Amendments of 2022”.

18 (b) **FINDING.**—The Congress finds that the fees au-
 19 thorized by the amendments made by this title will be
 20 dedicated to expediting the process for the review of bio-
 21 similar biological product applications, including
 22 postmarket safety activities, as set forth in the goals iden-
 23 tified for purposes of part 8 of subchapter C of chapter
 24 VII of the Federal Food, Drug, and Cosmetic Act (21
 25 U.S.C. 379j–51 et seq.), in the letters from the Secretary

1 of Health and Human Services to the Chairman of the
2 Committee on Health, Education, Labor, and Pensions of
3 the Senate and the Chairman of the Committee on Energy
4 and Commerce of the House of Representatives, as set
5 forth in the Congressional Record.

6 **SEC. 402. DEFINITIONS.**

7 (a) ADJUSTMENT FACTOR.—Section 744G(1) of the
8 Federal Food, Drug, and Cosmetic Act (21 U.S.C. 379j–
9 51(1)) is amended to read as follows:

10 “(1) The term ‘adjustment factor’ applicable to
11 a fiscal year is the Consumer Price Index for urban
12 consumers (Washington-Arlington-Alexandria, DC–
13 VA–MD–WV; Not Seasonally Adjusted; All items;
14 Annual Index) for September of the preceding fiscal
15 year divided by such Index for September 2011.”.

16 (b) BIOSIMILAR BIOLOGICAL PRODUCT APPLICA-
17 TION.—Section 744G(4)(B)(iii) of the Federal Food,
18 Drug, and Cosmetic Act (21 U.S.C. 379j–51(4)(B)(iii))
19 is amended—

20 (1) by striking subclause (II) (relating to an al-
21 lergenic extract product); and

22 (2) by redesignating subclauses (III) and (IV)
23 as subclauses (II) and (III), respectively.

1 **SEC. 403. AUTHORITY TO ASSESS AND USE BIOSIMILAR**
2 **FEES.**

3 (a) TYPES OF FEES.—

4 (1) IN GENERAL.—The matter preceding para-
5 graph (1) in section 744H(a) of the Federal Food,
6 Drug, and Cosmetic Act (21 U.S.C. 379j–52(a)) is
7 amended by striking “fiscal year 2018” and insert-
8 ing “fiscal year 2023”.

9 (2) INITIAL BIOSIMILAR BIOLOGICAL PRODUCT
10 DEVELOPMENT FEE.—Clauses (iv)(I) and (v)(II) of
11 section 744H(a)(1)(A) of the Federal Food, Drug,
12 and Cosmetic Act (21 U.S.C. 379j–52(a)(1)(A)) are
13 each amended by striking “5 days” and inserting “7
14 days”.

15 (3) ANNUAL BIOSIMILAR BIOLOGICAL PRODUCT
16 DEVELOPMENT FEE.—Section 744H(a)(1)(B) of the
17 Federal Food, Drug, and Cosmetic Act (21 U.S.C.
18 379j–52(a)(1)(B)) is amended—

19 (A) in clause (i), by inserting before the
20 period at the end the following: “, except where
21 such product (including, where applicable, own-
22 ership of the relevant investigational new drug
23 application) is transferred to a licensee, as-
24 signee, or successor of such person, and written
25 notice of such transfer is provided to the Sec-
26 retary, in which case such licensee, assignee, or

successor shall pay the annual biosimilar biological product development fee”;

(B) in clause (iii)—

(i) in subclause (I), by striking “or” at the end;

(ii) in subclause (II), by striking the period at the end and inserting “; or”; and

(iii) by adding at the end the following:

“(III) been administratively re-

moved from the biosimilar biological

product development program for the

product under subparagraph (E)(v).”; and

and

(C) in clause (iv), by striking “is accepted for filing on or after October 1 of such fiscal year” and inserting “is subsequently accepted for filing”.

(4) REACTIVATION FEE.—Section 744H(a)(1)(D) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 379j–52(a)(1)(D)) is amended to read as follows:

“(D) REACTIVATION FEE.—

“(i) IN GENERAL.—A person that has discontinued participation in the biosimilar

1 biological product development program for
2 a product under subparagraph (C), or who
3 has been administratively removed from
4 the biosimilar biological product develop-
5 ment program for a product under sub-
6 paragraph (E)(v), shall, if the person seeks
7 to resume participation in such program,
8 pay all annual biosimilar biological product
9 development fees previously assessed for
10 such product and still owed and a fee (re-
11 ferred to in this section as ‘reactivation
12 fee’) by the earlier of the following:

13 “(I) Not later than 7 days after
14 the Secretary grants a request by
15 such person for a biosimilar biological
16 product development meeting for the
17 product (after the date on which such
18 participation was discontinued or the
19 date of administrative removal, as ap-
20 plicable).

21 “(II) Upon the date of submis-
22 sion (after the date on which such
23 participation was discontinued or the
24 date of administrative removal, as ap-
25 plicable) by such person of an inves-

1 tigation new drug application de-
2 scribing an investigation that the Sec-
3 retary determines is intended to sup-
4 port a biosimilar biological product
5 application for that product.

6 “(ii) APPLICATION OF ANNUAL
7 FEE.—A person that pays a reactivation
8 fee for a product shall pay for such prod-
9 uct, beginning in the next fiscal year, the
10 annual biosimilar biological product devel-
11 opment fee under subparagraph (B), ex-
12 cept where such product (including, where
13 applicable, ownership of the relevant inves-
14 tigational new drug application) is trans-
15 ferred to a licensee, assignee, or successor
16 of such person, and written notice of such
17 transfer is provided to the Secretary, in
18 which case such licensee, assignee, or suc-
19 cessor shall pay the annual biosimilar bio-
20 logical product development fee.”.

21 (5) EFFECT OF FAILURE TO PAY FEES.—Sec-
22 tion 744H(a)(1)(E) of the Federal Food, Drug, and
23 Cosmetic Act (21 U.S.C. 379j–52(a)(1)(E)) is
24 amended by adding at the end the following:

1 “(v) ADMINISTRATIVE REMOVAL FROM
2 THE BIOSIMILAR BIOLOGICAL PRODUCT
3 DEVELOPMENT PROGRAM.—If a person has
4 failed to pay an annual biosimilar biological
5 product development fee for a product
6 as required under subparagraph (B) for a
7 period of two consecutive fiscal years, the
8 Secretary may administratively remove
9 such person from the biosimilar biological
10 product development program for the prod-
11 uct. At least 30 days prior to administra-
12 tively removing a person from the bio-
13 similar biological product development pro-
14 gram for a product under this clause, the
15 Secretary shall provide written notice to
16 such person of the intended administrative
17 removal.”.

18 (6) BIOSIMILAR BIOLOGICAL PRODUCT APPLICA-
19 TION FEE.—Section 744H(a)(2)(D) of the Federal
20 Food, Drug, and Cosmetic Act (21 U.S.C. 379j–
21 52(a)(2)(D)) is amended by inserting after “or was
22 withdrawn” the following: “prior to approval”.

23 (7) BIOSIMILAR BIOLOGICAL PRODUCT PRO-
24 GRAM FEE.—Section 744H(a)(3) of the Federal

1 Food, Drug, and Cosmetic Act (21 U.S.C. 379j–
2 52(a)(3)) is amended—

3 (A) in subparagraph (A)—

4 (i) in clause (i), by striking “and” at
5 the end;

6 (ii) by redesignating clause (ii) as
7 clause (iii); and

8 (iii) by inserting after clause (i) the
9 following:

10 “(ii) may be dispensed only under pre-
11 scription pursuant to section 503(b); and”;
12 and

13 (B) by adding at the end the following:

14 “(E) MOVEMENT TO DISCONTINUED
15 LIST.—

16 “(i) DATE OF INCLUSION.—If a writ-
17 ten request to place a product on the list
18 referenced in subparagraph (A) of discon-
19 tinued biosimilar biological products is sub-
20 mitted to the Secretary on behalf of an ap-
21 plicant, and the request identifies the date
22 the product is withdrawn from sale, then
23 for purposes of assessing the biosimilar bi-
24 ological product program fee, the Secretary

1 shall consider such product to have been
2 included on such list on the later of—

3 “(I) the date such request was
4 received; or

5 “(II) if the product will be with-
6 drawn from sale on a future date,
7 such future date when the product is
8 withdrawn from sale.

9 “(ii) TREATMENT AS WITHDRAWN
10 FROM SALE.—For purposes of clause (i), a
11 product shall be considered withdrawn
12 from sale once the applicant has ceased its
13 own distribution of the product, whether or
14 not the applicant has ordered recall of all
15 previously distributed lots of the product,
16 except that a routine, temporary interrup-
17 tion in supply shall not render a product
18 withdrawn from sale.

19 “(iii) SPECIAL RULE.—If a biosimilar
20 biological product that is identified in a
21 biosimilar biological product application
22 approved as of October 1 of a fiscal year
23 appears, as of October 1 of such fiscal
24 year, on the list referenced in subpara-
25 graph (A) of discontinued biosimilar bio-

1 logical products, and on any subsequent
2 day during such fiscal year the biosimilar
3 biological product does not appear on such
4 list, then except as provided in subpara-
5 graph (D), each person who is named as
6 the applicant in a biosimilar biological
7 product application with respect to such
8 product shall pay the annual biosimilar bi-
9 ological product program fee established
10 for a fiscal year under subsection (c)(5) for
11 such biosimilar biological product. Not-
12 withstanding subparagraph (B), such fee
13 shall be due on the last business day of
14 such fiscal year and shall be paid only once
15 for each such product for each fiscal
16 year.”.

17 (8) BIOSIMILAR BIOLOGICAL PRODUCT FEE.—
18 Section 744H(a) of the Federal Food, Drug, and
19 Cosmetic Act (21 U.S.C. 379j–52(a)) is amended by
20 striking paragraph (4).

21 (c) FEE REVENUE AMOUNTS.—Subsection (b) of sec-
22 tion 744H of the Federal Food, Drug, and Cosmetic Act
23 (21 U.S.C. 379j–52) is amended—

24 (1) by striking paragraph (1);

1 (2) by redesignating paragraphs (2) through
2 (4) as paragraphs (1) through (3), respectively;

3 (3) by amending paragraph (1) (as so redesign-
4 nated) to read as follows:

5 “(1) IN GENERAL.—For each of the fiscal years
6 2023 through 2027, fees under subsection (a) shall,
7 except as provided in subsection (c), be established
8 to generate a total revenue amount equal to the sum
9 of—

10 “(A) the annual base revenue for the fiscal
11 year (as determined under paragraph (3));

12 “(B) the dollar amount equal to the infla-
13 tion adjustment for the fiscal year (as deter-
14 mined under subsection (c)(1));

15 “(C) the dollar amount equal to the stra-
16 tegic hiring and retention adjustment (as deter-
17 mined under subsection (c)(2));

18 “(D) the dollar amount equal to the capac-
19 ity planning adjustment for the fiscal year (as
20 determined under subsection (c)(3));

21 “(E) the dollar amount equal to the oper-
22 ating reserve adjustment for the fiscal year, if
23 applicable (as determined under subsection
24 (c)(4));

1 “(F) for fiscal year 2023 an additional
2 amount of \$4,428,886; and

3 “(G) for fiscal year 2024 an additional
4 amount of \$320,569.”;

5 (4) in paragraph (2) (as so redesignated)—

6 (A) in the paragraph heading, by striking
7 “; LIMITATIONS ON FEE AMOUNTS”;

8 (B) by striking subparagraph (B); and

9 (C) by redesignating subparagraphs (C)
10 and (D) as subparagraphs (B) and (C), respec-
11 tively; and

12 (5) by amending paragraph (3) (as so redesign-
13 ated) to read as follows:

14 “(3) ANNUAL BASE REVENUE.—For purposes
15 of paragraph (1), the dollar amount of the annual
16 base revenue for a fiscal year shall be—

17 “(A) for fiscal year 2023, \$43,376,922;
18 and

19 “(B) for fiscal years 2024 through 2027,
20 the dollar amount of the total revenue amount
21 established under paragraph (1) for the pre-
22 vious fiscal year, excluding any adjustments to
23 such revenue amount under subsection (c)(4).”.

1 (d) ADJUSTMENTS; ANNUAL FEE SETTING.—Section
 2 744H(c) of the Federal Food, Drug, and Cosmetic Act
 3 (21 U.S.C. 379j–52(c)) is amended—

4 (1) in paragraph (1)—

5 (A) in subparagraph (A)—

6 (i) in the matter preceding clause (i),
 7 by striking “subsection (b)(2)(B)” and in-
 8 serting “subsection (b)(1)(B)”; and

9 (ii) in clause (i), by striking “sub-
 10 section (b)” and inserting “subsection
 11 (b)(1)(A)”; and

12 (B) in subparagraph (B)(ii), by striking
 13 “Washington-Baltimore, DC–MD–VA–WV”
 14 and inserting “Washington-Arlington-Alexan-
 15 dria, DC–VA–MD–WV”;

16 (2) by striking paragraphs (2) through (4) and
 17 inserting the following:

18 “(2) STRATEGIC HIRING AND RETENTION AD-
 19 JUSTMENT.—For each fiscal year, after the annual
 20 base revenue under subsection (b)(1)(A) is adjusted
 21 for inflation in accordance with paragraph (1), the
 22 Secretary shall further increase the fee revenue and
 23 fees by \$150,000.

24 “(3) CAPACITY PLANNING ADJUSTMENT.—

1 “(A) IN GENERAL.—For each fiscal year,
2 the Secretary shall, in addition to the adjust-
3 ments under paragraphs (1) and (2), further
4 adjust the fee revenue and fees under this sec-
5 tion for a fiscal year to reflect changes in the
6 resource capacity needs of the Secretary for the
7 process for the review of biosimilar biological
8 product applications.

9 “(B) METHODOLOGY.—For purposes of
10 this paragraph, the Secretary shall employ the
11 capacity planning methodology utilized by the
12 Secretary in setting fees for fiscal year 2021, as
13 described in the notice titled ‘Biosimilar User
14 Fee Rates for Fiscal Year 2021’ published in
15 the Federal Register on August 4, 2020 (85
16 Fed. Reg. 47220). The workload categories
17 used in applying such methodology in fore-
18 casting shall include only the activities de-
19 scribed in that notice and, as feasible, addi-
20 tional activities that are also directly related to
21 the direct review of biosimilar biological product
22 applications and supplements, including addi-
23 tional formal meeting types, the direct review of
24 postmarketing commitments and requirements,
25 the direct review of risk evaluation and mitiga-

tion strategies, and the direct review of annual reports for approved biosimilar biological products. Subject to the exceptions in the preceding sentence, the Secretary shall not include as workload categories in applying such methodology in forecasting any non-core review activities, including those activities that the Secretary referenced for potential future use in such notice but did not utilize in setting fees for fiscal year 2021.

“(C) LIMITATIONS.—Under no circumstances shall an adjustment under this paragraph result in fee revenue for a fiscal year that is less than the sum of the amounts under subsections (b)(1)(A) (the annual base revenue for the fiscal year), (b)(1)(B) (the dollar amount of the inflation adjustment for the fiscal year), and (b)(1)(C) (the dollar amount of the strategic hiring and retention adjustment).

“(D) PUBLICATION IN FEDERAL REGISTER.—The Secretary shall publish in the Federal Register notice under paragraph (5) the fee revenue and fees resulting from the adjustment and the methodologies under this paragraph.

“(4) OPERATING RESERVE ADJUSTMENT.—

1 “(A) INCREASE.—For fiscal year 2023 and
2 subsequent fiscal years, the Secretary shall, in
3 addition to adjustments under paragraphs (1),
4 (2), and (3), further increase the fee revenue
5 and fees if such an adjustment is necessary to
6 provide for at least 10 weeks of operating re-
7 serves of carryover user fees for the process for
8 the review of biosimilar biological product appli-
9 cations.

10 “(B) DECREASE.—

11 “(i) FISCAL YEAR 2023.—For fiscal
12 year 2023, if the Secretary has carryover
13 balances for such process in excess of 33
14 weeks of such operating reserves, the Sec-
15 retary shall decrease such fee revenue and
16 fees to provide for not more than 33 weeks
17 of such operating reserves.

18 “(ii) FISCAL YEAR 2024.—For fiscal
19 year 2024, if the Secretary has carryover
20 balances for such process in excess of 27
21 weeks of such operating reserves, the Sec-
22 retary shall decrease such fee revenue and
23 fees to provide for not more than 27 weeks
24 of such operating reserves.

1 “(iii) FISCAL YEAR 2025 AND SUBSE-
2 QUENT FISCAL YEARS.—For fiscal year
3 2025 and subsequent fiscal years, if the
4 Secretary has carryover balances for such
5 process in excess of 21 weeks of such oper-
6 ating reserves, the Secretary shall decrease
7 such fee revenue and fees to provide for
8 not more than 21 weeks of such operating
9 reserves.

10 “(C) FEDERAL REGISTER NOTICE.—If an
11 adjustment under subparagraph (A) or (B) is
12 made, the rationale for the amount of the in-
13 crease or decrease in fee revenue and fees shall
14 be contained in the annual Federal Register no-
15 tice under paragraph (5)(B) establishing fee
16 revenue and fees for the fiscal year involved.”;
17 and

18 (3) in paragraph (5), in the matter preceding
19 subparagraph (A), by striking “2018” and inserting
20 “2023”.

21 (e) CREDITING AND AVAILABILITY OF FEES.—Sub-
22 section (f)(3) of section 744H of the Federal Food, Drug,
23 and Cosmetic Act (21 U.S.C. 379j–52(f)(3)) is amended
24 by striking “2018 through 2022” and inserting “2023
25 through 2027”.

1 (f) WRITTEN REQUESTS FOR WAIVERS AND RE-
2 TURNS; DISPUTES CONCERNING FEES.—Section 744H(h)
3 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C.
4 379j–52(h)) is amended to read as follows:

5 “(h) WRITTEN REQUESTS FOR WAIVERS AND RE-
6 TURNS; DISPUTES CONCERNING FEES.—To qualify for
7 consideration for a waiver under subsection (d), or for the
8 return of any fee paid under this section, including if the
9 fee is claimed to have been paid in error, a person shall
10 submit to the Secretary a written request justifying such
11 waiver or return and, except as otherwise specified in this
12 section, such written request shall be submitted to the Sec-
13 retary not later than 180 days after such fee is due. A
14 request submitted under this paragraph shall include any
15 legal authorities under which the request is made.”.

16 **SEC. 404. REAUTHORIZATION; REPORTING REQUIREMENTS.**

17 Section 744I of the Federal Food, Drug, and Cos-
18 metic Act (21 U.S.C. 379j–53) is amended—

19 (1) in subsection (a)(1), by striking “Beginning
20 with fiscal year 2018, not” and inserting “Not”;

21 (2) by striking “Biosimilar User Fee Amend-
22 ments of 2017” each place it appears and inserting
23 “Biosimilar User Fee Amendments of 2022”;

24 (3) in subsection (a)(2), by striking “Beginning
25 with fiscal year 2018, the” and inserting “The”;

1 (4) in subsection (a)(3)(A), by striking “Not
2 later than 30 calendar days after the end of the sec-
3 ond quarter of fiscal year 2018, and not later than
4 30 calendar days after the end of each quarter of
5 each fiscal year thereafter” and inserting “Not later
6 than 30 calendar days after the end of each quarter
7 of each fiscal year for which fees are collected under
8 this part”;

9 (5) in subsection (b), by striking “Not later
10 than 120 days after the end of fiscal year 2018 and
11 each subsequent fiscal year for which fees are col-
12 lected under this part” and inserting “Not later
13 than 120 days after the end of each fiscal year for
14 which fees are collected under this part”;

15 (6) in subsection (c), by striking “Beginning
16 with fiscal year 2018, and for” and inserting “For”;
17 and

18 (7) in subsection (f)—

19 (A) in paragraph (1), in the matter pre-
20 ceding subparagraph (A), by striking “fiscal
21 year 2022” and inserting “fiscal year 2027”;
22 and

23 (B) in paragraph (3), by striking “January
24 15, 2022” and inserting “January 15, 2027”.

1 **SEC. 405. SUNSET DATES.**

2 (a) AUTHORIZATION.—Sections 744G and 744H of
3 the Federal Food, Drug, and Cosmetic Act (21 U.S.C.
4 379j–51, 379j–52) shall cease to be effective October 1,
5 2027.

6 (b) REPORTING REQUIREMENTS.—Section 744I of
7 the Federal Food, Drug, and Cosmetic Act shall cease to
8 be effective January 31, 2028.

9 (c) PREVIOUS SUNSET PROVISION.—Effective Octo-
10 ber 1, 2022, subsections (a) and (b) of section 405 of the
11 FDA Reauthorization Act of 2017 (Public Law 115–52)
12 are repealed.

13 **SEC. 406. EFFECTIVE DATE.**

14 The amendments made by this title shall take effect
15 on October 1, 2022, or the date of the enactment of this
16 Act, whichever is later, except that fees under part 8 of
17 subchapter C of chapter VII of the Federal Food, Drug,
18 and Cosmetic Act (21 U.S.C. 379j–51 et seq.) shall be
19 assessed for all biosimilar biological product applications
20 received on or after October 1, 2022, regardless of the
21 date of the enactment of this Act.

22 **SEC. 407. SAVINGS CLAUSE.**

23 Notwithstanding the amendments made by this title,
24 part 8 of subchapter C of chapter VII of the Federal Food,
25 Drug, and Cosmetic Act (21 U.S.C. 379j–51 et seq.), as
26 in effect on the day before the date of the enactment of

1 this title, shall continue to be in effect with respect to bio-
2 similar biological product applications and supplements
3 (as defined in such part as of such day) that were accepted
4 by the Food and Drug Administration for filing on or after
5 October 1, 2017, but before October 1, 2022, with respect
6 to assessing and collecting any fee required by such part
7 for a fiscal year prior to fiscal year 2023.

8 **TITLE V—IMPROVING DIVERSITY**
9 **IN CLINICAL STUDIES**

10 **SEC. 501. DIVERSITY ACTION PLANS FOR CLINICAL STUD-**
11 **IES.**

12 (a) DRUGS.—Section 505(i) of the Federal Food,
13 Drug, and Cosmetic Act (21 U.S.C. 355(i)) is amended
14 by adding at the end the following:

15 “(5)(A) In order for a new drug that is being studied
16 in a phase 3 study, as defined in section 312.21(c) of title
17 21, Code of Federal Regulations (or successor regula-
18 tions), or other pivotal study (other than bioavailability
19 or bioequivalence studies), to be exempt pursuant to this
20 subsection, the sponsor of a clinical investigation of such
21 new drug shall submit to the Secretary a diversity action
22 plan.

23 “(B) Such diversity action plan shall include—

24 “(i) the sponsor’s goals for enrollment in such
25 clinical study;

1 “(ii) the sponsor’s rationale for such goals; and

2 “(iii) an explanation of how the sponsor intends

3 to meet such goals.

4 “(C) The sponsor shall submit such diversity action

5 plan in the form and manner specified in the guidance

6 required by section 524B as soon as practicable but no

7 later than when the sponsor seeks feedback regarding such

8 a phase 3 study or other pivotal study of the drug.

9 “(D) The Secretary may waive the requirement in

10 subparagraph (A) if the Secretary determines that a waiv-

11 er is necessary based on what is known about the preva-

12 lence of the disease in terms of the patient population that

13 may use the new drug.

14 “(E) No diversity action plan shall be required for

15 a submission described in section 561.”.

16 (b) DEVICES.—Section 520(g) of the Federal Food,

17 Drug, and Cosmetic Act (21 U.S.C. 360j(g)) is amended

18 by adding at the end the following:

19 “(9)(A)(i) In order for a device in a clinical study

20 for which submission of an application for an investiga-

21 tional device exemption is required to be exempt under this

22 subsection, the sponsor of such study shall submit to the

23 Secretary in such application a diversity action plan in the

24 form and manner specified in the guidance required by

25 section 524B.

1 “(ii) In order for a device in a clinical study for which
2 submission of an application for an investigational device
3 exemption is not required, except for a device being stud-
4 ied as described in section 812.2(c) of title 21, Code of
5 Federal Regulations (or successor regulations), to be ex-
6 empt under this subsection, the sponsor of such study
7 shall develop and implement a diversity action plan. Such
8 diversity action plan shall be submitted to the Secretary
9 in any premarket notification under section 510(k), re-
10 quest for classification under section 513(f)(2), or applica-
11 tion for premarket approval under section 515 for such
12 device.

13 “(B) A diversity action plan under clause (i) or (ii)
14 of subparagraph (A) shall include—

15 “(i) the sponsor’s goals for enrollment in the
16 clinical study;

17 “(ii) the sponsor’s rationale for such goals; and

18 “(iii) an explanation of how the sponsor intends
19 to meet such goals.

20 “(C) The Secretary may waive the requirement in
21 subparagraph (A) or (B) if the Secretary determines that
22 a waiver is necessary based on what is known about the
23 prevalence of the disease in terms of the patient popu-
24 lation that may use the device.

1 “(D) No diversity action plan shall be required for
2 a submission described in section 561.”.

3 (c) GUIDANCE.—Subchapter A of chapter V of the
4 Federal Food, Drug, and Cosmetic Act (21 U.S.C. 351
5 et seq.) is amended by adding at the end the following:

6 **“SEC. 524B. GUIDANCE ON DIVERSITY ACTION PLANS FOR**
7 **CLINICAL STUDIES.**

8 “(a) IN GENERAL.—The Secretary shall issue guid-
9 ance relating to—

10 “(1) the format and content of the diversity ac-
11 tion plans required by sections 505(i)(5) and
12 520(g)(9) pertaining to the sponsor’s goals for clin-
13 ical study enrollment, disaggregated by age group,
14 sex, race, geographic location, socioeconomic status,
15 and ethnicity, including with respect to—

16 “(A) the rationale for the sponsor’s enroll-
17 ment goals, which may include—

18 “(i) the estimated prevalence or inci-
19 dence in the United States of the disease
20 or condition for which the drug or device
21 is being developed or investigated, if such
22 estimated prevalence or incidence is known
23 or can be determined based on available
24 data;

1 “(ii) what is known about the disease
2 or condition for which the drug or device
3 is being developed or investigated;

4 “(iii) any relevant pharmacokinetic or
5 pharmacogenomic data;

6 “(iv) what is known about the patient
7 population for such disease or condition,
8 including, to the extent data is available—

9 “(I) demographic information, in-
10 cluding age group, sex, race, geo-
11 graphic location, socioeconomic status,
12 and ethnicity;

13 “(II) non-demographic factors,
14 including co-morbidities affecting the
15 patient population; and

16 “(III) potential barriers to enroll-
17 ing diverse participants, such as pa-
18 tient population size, geographic loca-
19 tion, and socioeconomic status; and

20 “(v) any other data or information
21 relevant to selecting appropriate enroll-
22 ment goals, disaggregated by demographic
23 subgroup, such as the inclusion of preg-
24 nant and lactating women;

1 “(B) an explanation for how the sponsor
2 intends to meet such goals, including demo-
3 graphic-specific outreach and enrollment strate-
4 gies, study-site selection, clinical study inclusion
5 and exclusion practices, and any diversity train-
6 ing for study personnel; and

7 “(C) procedures for the public posting of
8 key information from the diversity action plan
9 that would be useful to patients and providers
10 on the sponsor’s website, as appropriate; and

11 “(2) how sponsors should include in regular re-
12 ports to the Secretary—

13 “(A) the sponsor’s progress in meeting the
14 goals referred to in paragraph (1)(A); and

15 “(B) if the sponsor does not expect to meet
16 such goals—

17 “(i) any updates needed to be made to
18 a diversity action plan referred to in para-
19 graph (1) to help meet such goals; and

20 “(ii) the sponsor’s reasons for why the
21 sponsor does not expect to meet such
22 goals.

23 “(b) ISSUANCE.—The Secretary shall—

24 “(1) not later than 12 months after the date of
25 enactment of this section, issue new draft guidance

1 or update existing draft guidance described in sub-
2 section (a); and

3 “(2) not later than 9 months after closing the
4 comment period on such draft guidance, finalize
5 such guidance.”.

6 (d) APPLICABILITY.—Sections 505(i)(5) and
7 520(g)(9) of the Federal Food, Drug, and Cosmetic Act,
8 as added by subsections (a) and (b) of this section, apply
9 only with respect to clinical investigations with respect to
10 which enrollment commences after the date that is 180
11 days after the publication of final guidance under section
12 524B(b)(2) of the Federal Food, Drug, and Cosmetic Act,
13 as added by subsection (c).

14 **SEC. 502. EVALUATION OF THE NEED FOR FDA AUTHORITY**
15 **TO MANDATE POSTAPPROVAL STUDIES OR**
16 **POSTMARKET SURVEILLANCE DUE TO INSUF-**
17 **FICIENT DEMOGRAPHIC SUBGROUP DATA.**

18 (a) IN GENERAL.—Not later than 2 years after the
19 date of publication of final guidance pursuant to section
20 524B(b)(2) of the Federal Food, Drug, and Cosmetic Act,
21 as added by section 501(c) of this Act, the Secretary of
22 Health and Human Services shall commence an evaluation
23 to assess whether additions or changes to statutes or regu-
24 lations are warranted to ensure that sponsors conduct
25 post-approval studies or postmarket surveillance where—

1 (1) premarket studies collected insufficient data
2 for underrepresented subgroups according to the
3 goals specified in the diversity action plans of such
4 sponsors; and

5 (2) the Secretary has requested additional stud-
6 ies be conducted.

7 (b) DETERMINATION AND REPORTING.—Not later
8 than 180 days after the commencement of the evaluation
9 under subsection (a), the Secretary of Health and Human
10 Services shall submit a report to the Congress on the out-
11 come of such evaluation, including any recommendations
12 related to additional needed authorities.

13 **SEC. 503. PUBLIC WORKSHOPS TO ENHANCE CLINICAL**
14 **STUDY DIVERSITY.**

15 (a) IN GENERAL.—Not later than one year after the
16 date of enactment of this Act, the Secretary of Health and
17 Human Services, in consultation with drug sponsors, med-
18 ical device manufacturers, patients, and other stake-
19 holders, shall convene one or more public workshops to
20 solicit input from stakeholders on increasing the enroll-
21 ment of historically underrepresented populations in clin-
22 ical studies and encouraging clinical study participation
23 that reflects the prevalence of the disease or condition
24 among demographic subgroups, where appropriate, and
25 other topics, including—

1 (1) how and when to collect and present the
2 prevalence or incidence data on a disease or condi-
3 tion by demographic subgroup, including possible
4 sources for such data and methodologies for assess-
5 ing such data;

6 (2) considerations for the dissemination, after
7 approval, of information to the public on clinical
8 study enrollment demographic data;

9 (3) the establishment of goals for enrollment in
10 clinical trials, including the relevance of the esti-
11 mated prevalence or incidence, as applicable, in the
12 United States of the disease or condition for which
13 the drug or device is being developed; and

14 (4) approaches to support inclusion of under-
15 represented populations and to encourage clinical
16 study participation that reflects the population ex-
17 pected to use the drug or device under study, includ-
18 ing with respect to—

19 (A) the establishment of inclusion and ex-
20 clusion criteria for certain subgroups, such as
21 pregnant and lactating women and individuals
22 with disabilities, including intellectual or devel-
23 opmental disabilities or mental illness;

24 (B) considerations regarding informed con-
25 sent with respect to individuals with intellectual

1 or developmental disabilities or mental illness,
2 including ethical and scientific considerations;

3 (C) the appropriate use of decentralized
4 trials or digital health tools;

5 (D) clinical endpoints;

6 (E) biomarker selection; and

7 (F) studying analysis.

8 (b) PUBLIC DOCKET.—The Secretary of Health and
9 Human Services shall establish a public comment period
10 to receive written comments related to the topics ad-
11 dressed during each public workshop convened under this
12 section. The public comment period shall remain open for
13 60 days following the date on which each public workshop
14 is convened.

15 (c) REPORT.—Not later than 180 days after the close
16 of the public comment period for each public workshop
17 convened under this section, the Secretary of Health and
18 Human Services shall make available on the public website
19 of the Food and Drug Administration a report on the top-
20 ics discussed at such workshop. The report shall include
21 a summary of, and response to, recommendations raised
22 in such workshop.

1 **SEC. 504. ANNUAL SUMMARY REPORT ON PROGRESS TO IN-**
2 **CREASE DIVERSITY IN CLINICAL STUDIES.**

3 (a) IN GENERAL.—Beginning not later than 2 years
4 after the date of enactment of this Act, and each year
5 thereafter, the Secretary of Health and Human Services
6 shall submit to the Congress, and publish on the public
7 website of the Food and Drug Administration, a report
8 that—

9 (1) summarizes, in aggregate, the diversity ac-
10 tion plans received pursuant to section 505(i)(5) or
11 520(g)(9) of the Federal Food, Drug, and Cosmetic
12 Act, as added by subsection (a) or (b) of section 501
13 of this Act; and

14 (2) contains information on—

15 (A) for drugs, biological products, and de-
16 vices approved, licensed, cleared, or classified
17 under section 505, 515, 510(k), or 513(f)(2) of
18 the Federal Food, Drug, and Cosmetic Act (21
19 U.S.C. 355; 360e; 360(k); and 360(f)(2)), or
20 section 351(a) of the Public Health Service Act
21 (42 U.S.C. 262(a)), whether the clinical studies
22 conducted with respect to such applications met
23 the demographic subgroup enrollment goals
24 from the diversity action plan submitted for
25 such applications;

1 (B) the reasons provided for why enroll-
2 ment goals from submitted diversity action
3 plans were not met; and

4 (C) any postmarket studies of a drug or
5 device in a demographic subgroup or subgroups
6 required or recommended by the Secretary
7 based on inadequate premarket clinical study
8 diversity or based on other reasons where a pre-
9 market study lacked adequate diversity, includ-
10 ing the status and completion date of any such
11 study.

12 (b) CONFIDENTIALITY.—Nothing in this section shall
13 be construed as authorizing the Secretary of Health and
14 Human Services to disclose any information that is a
15 trade secret or confidential information subject to section
16 552(b)(4) of title 5, United States Code, or section 1905
17 of title 18, United States Code.

18 **SEC. 505. PUBLIC MEETING ON CLINICAL STUDY FLEXIBILI-**
19 **TIES INITIATED IN RESPONSE TO COVID-19**
20 **PANDEMIC.**

21 (a) IN GENERAL.—Not later than 180 days after the
22 date on which the COVID-19 emergency period ends, the
23 Secretary of Health and Human Services shall convene a
24 public meeting to discuss the recommendations provided
25 by the Food and Drug Administration during the COVID-

1 19 emergency period to mitigate disruption of clinical
2 studies, including recommendations detailed in the guid-
3 ance entitled “Conduct of Clinical Trials of Medical Prod-
4 ucts During the COVID–19 Public Health Emergency,
5 Guidance for Industry, Investigators, and Institutional
6 Review Boards”, as updated on August 8, 2021, and by
7 any subsequent updates to such guidance. The Secretary
8 of Health and Human Services shall invite to such meet-
9 ing representatives from the pharmaceutical and medical
10 device industries who sponsored clinical studies during the
11 COVID–19 emergency period and organizations rep-
12 resenting patients.

13 (b) TOPICS.—Not later than 90 days after the date
14 on which the public meeting under subsection (a) is con-
15 vened, the Secretary of Health and Human Services shall
16 make available on the public website of the Food and Drug
17 Administration a report on the topics discussed at such
18 meeting. Such topics shall include discussion of—

19 (1) the actions drug sponsors took to utilize
20 such recommendations and the frequency at which
21 such recommendations were employed;

22 (2) the characteristics of the sponsors, studies,
23 and patient populations impacted by such rec-
24 ommendations;

1 (3) a consideration of how recommendations in-
2 tended to mitigate disruption of clinical studies dur-
3 ing the COVID–19 emergency period, including any
4 recommendations to consider decentralized clinical
5 studies when appropriate, may have affected access
6 to clinical studies for certain patient populations, es-
7 pecially unrepresented or underrepresented racial
8 and ethnic minorities; and

9 (4) recommendations for incorporating certain
10 clinical study disruption mitigation recommendations
11 into current or additional guidance to improve clin-
12 ical study access and enrollment of diverse patient
13 populations.

14 (c) COVID–19 EMERGENCY PERIOD DEFINED.—In
15 this section, the term “COVID–19 emergency period” has
16 the meaning given the term “emergency period” in section
17 1135(g)(1)(B) of the Social Security Act (42 U.S.C.
18 1320b–5(g)(1)(B)).

19 **SEC. 506. DECENTRALIZED CLINICAL STUDIES.**

20 (a) GUIDANCE.—The Secretary of Health and
21 Human Services shall—

22 (1) not later than 12 months after the date of
23 enactment of this Act, issue draft guidance that ad-
24 dresses considerations for decentralized clinical stud-
25 ies, including considerations regarding the engage-

1 ment, enrollment, and retention of a meaningfully
2 diverse clinical population, with respect to race, eth-
3 nicity, age, sex, and geographic location, when ap-
4 propriate; and

5 (2) not later than 1 year after closing the com-
6 ment period on such draft guidance, finalize such
7 guidance.

8 (b) CONTENT OF GUIDANCE.—The guidance under
9 subsection (a) shall address the following:

10 (1) Recommendations for how digital health
11 technology or other remote assessment options, such
12 as telehealth, could support decentralized clinical
13 studies, including guidance on considerations for se-
14 lecting technological platforms and mediums, data
15 collection and use, data integrity and security, and
16 communication to study participants through digital
17 technology.

18 (2) Recommendations for subject recruitment
19 and retention, including considerations for sponsors
20 to minimize or reduce burdens for clinical study par-
21 ticipants through the use of digital health tech-
22 nology, telehealth, local health care providers and
23 laboratories, or other means.

1 (3) Recommendations with respect to the eval-
 2 uation of data collected within a decentralized clin-
 3 ical study setting.

4 (c) DEFINITION.—In this section, the term “decen-
 5 tralized clinical study” means a clinical study in which
 6 some or all of the study-related activities occur at a loca-
 7 tion separate from the investigator’s location.

8 **TITLE VI—GENERIC DRUG** 9 **COMPETITION**

10 **SEC. 601. INCREASING TRANSPARENCY IN GENERIC DRUG** 11 **APPLICATIONS.**

12 (a) IN GENERAL.—Section 505(j)(3) of the Federal
 13 Food, Drug, and Cosmetic Act (21 U.S.C. 355(j)(3)) is
 14 amended by adding at the end the following:

15 “(H)(i) Upon request (in controlled correspondence
 16 or otherwise) by a person that has submitted or intends
 17 to submit an abbreviated application for a new drug under
 18 this subsection for which the Secretary has specified in
 19 regulation, including in section 314.94(a)(9) of title 21,
 20 Code of Federal Regulations (or any successor regula-
 21 tions), or recommended in applicable guidance, certain
 22 qualitative or quantitative criteria with respect to an inac-
 23 tive ingredient, or on the Secretary’s own initiative during
 24 the review of such abbreviated application, the Secretary

1 shall inform the person whether such new drug is quali-
2 tatively and quantitatively the same as the listed drug.

3 “(ii) Notwithstanding section 301(j), if the Secretary
4 determines that such new drug is not qualitatively or
5 quantitatively the same as the listed drug, the Secretary
6 shall identify and disclose to the person—

7 “(I) the ingredient or ingredients that cause the
8 new drug not to be qualitatively or quantitatively the
9 same as the listed drug; and

10 “(II) for any ingredient for which there is an
11 identified quantitative deviation, the amount of such
12 deviation.

13 “(iii) If the Secretary determines that such new drug
14 is qualitatively and quantitatively the same as the listed
15 drug, the Secretary shall not change or rescind such deter-
16 mination after the submission of an abbreviated applica-
17 tion for such new drug under this subsection unless—

18 “(I) the formulation of the listed drug has been
19 changed and the Secretary has determined that the
20 prior listed drug formulation was withdrawn for rea-
21 sons of safety or effectiveness; or

22 “(II) the Secretary makes a written determina-
23 tion that the prior determination must be changed
24 because an error has been identified.

1 “(iv) If the Secretary makes a written determination
2 described in clause (iii)(II), the Secretary shall provide no-
3 tice and a copy of the written determination to the person
4 making the request under clause (i).

5 “(v) The disclosures required by this subparagraph
6 are disclosures authorized by law including for purposes
7 of section 1905 of title 18, United States Code.”.

8 (b) GUIDANCE.—

9 (1) IN GENERAL.—Not later than 1 year after
10 the date of enactment of this Act, the Secretary of
11 Health and Human Services shall issue draft guid-
12 ance, or update guidance, describing how the Sec-
13 retary will determine whether a new drug is quali-
14 tatively and quantitatively the same as the listed
15 drug (as such terms are used in section
16 505(j)(3)(H) of the Federal Food, Drug, and Cos-
17 metic Act, as added by subsection (a)), including
18 with respect to assessing pH adjusters.

19 (2) PROCESS.—In issuing guidance as required
20 by paragraph (1), the Secretary of Health and
21 Human Services shall—

22 (A) publish draft guidance;

23 (B) provide a period of at least 60 days for
24 comment on the draft guidance; and

1 (C) after considering any comments re-
2 ceived, and not later than one year after the
3 close of the comment period on the draft guid-
4 ance, publish final guidance.

5 (c) APPLICABILITY.—Section 505(j)(3)(H) of the
6 Federal Food, Drug, and Cosmetic Act, as added by sub-
7 section (a), applies beginning on the date of enactment
8 of this Act, irrespective of the date on which the guidance
9 required by subsection (b) is finalized.

10 **SEC. 602. ENHANCING ACCESS TO AFFORDABLE MEDI-**
11 **CINES.**

12 Section 505(j)(10)(A) of the Federal Food, Drug,
13 and Cosmetic Act (21 U.S.C. 355(j)(10)(A)) is amended
14 by striking clauses (i) through (iii) and inserting the fol-
15 lowing:

16 “(i) a revision to the labeling of the listed drug
17 has been approved by the Secretary within 90 days
18 of when the application is otherwise eligible for ap-
19 proval under this subsection;

20 “(ii) the sponsor of the application agrees to
21 submit revised labeling for the drug that is the sub-
22 ject of the application not later than 60 days after
23 approval under this subsection of the application;

1 “(iii) the labeling revision described under
 2 clause (i) does not include a change to the ‘Warn-
 3 ings’ section of the labeling; and”.

4 **TITLE VII—RESEARCH, DEVELOPMENT, AND SUPPLY CHAIN** 5 **IMPROVEMENTS**

7 **Subtitle A—In General**

8 **SEC. 701. ANIMAL TESTING ALTERNATIVES.**

9 Section 505 of the Federal Food, Drug, and Cosmetic
 10 Act (21 U.S.C. 355) is amended—

11 (1) in subsection (b)(5)(B)(i)(II), by striking
 12 “animal” and inserting “nonclinical tests”;

13 (2) in subsection (i)—

14 (A) in paragraph (1)(A), by striking “pre-
 15 clinical tests (including tests on animals)” and
 16 inserting “nonclinical tests”; and

17 (B) in paragraph (2)(B), by striking “ani-
 18 mal” and inserting “nonclinical tests”; and

19 (3) after subsection (y), by inserting the fol-
 20 lowing:

21 “(z) NONCLINICAL TEST DEFINED.—For purposes
 22 of this section, the term ‘nonclinical test’ means a test con-
 23 ducted in vitro, in silico, or in chemico, or a nonhuman
 24 in vivo test, that occurs before or during the clinical trial

1 phase of the investigation of the safety and effectiveness
2 of a drug. Such test may include the following:

3 “(1) Cell-based assays.

4 “(2) Organ chips and microphysiological sys-
5 tems.

6 “(3) Computer modeling.

7 “(4) Other nonhuman or human biology-based
8 test methods.

9 “(5) Animal tests.”.

10 **SEC. 702. EMERGING TECHNOLOGY PROGRAM.**

11 Chapter V of the Federal Food, Drug, and Cosmetic
12 Act (21 U.S.C. 201 et seq.) is amended by inserting after
13 section 566 of such Act (21 U.S.C. 360bbb–5) the fol-
14 lowing:

15 **“SEC. 566A. EMERGING TECHNOLOGY PROGRAM.**

16 “(a) PROGRAM ESTABLISHMENT.—

17 “(1) IN GENERAL.—The Secretary shall estab-
18 lish a program to support the adoption of, and im-
19 prove the development of, innovative approaches to
20 drug product design and manufacturing.

21 “(2) ACTIONS.—In carrying out the program
22 under paragraph (1), the Secretary may—

23 “(A) facilitate and increase communication
24 between public and private entities, consortia,

1 and individuals with respect to innovative drug
2 product design and manufacturing;

3 “(B) solicit information regarding, and
4 conduct or support research on, innovative ap-
5 proaches to drug product design and manufac-
6 turing;

7 “(C) convene meetings with representatives
8 of industry, academia, other Federal agencies,
9 international agencies, and other interested per-
10 sons, as appropriate;

11 “(D) convene working groups to support
12 drug product design and manufacturing re-
13 search and development;

14 “(E) support education and training for
15 regulatory staff and scientists related to innova-
16 tive approaches to drug product design and
17 manufacturing;

18 “(F) advance regulatory science related to
19 the development and review of innovative ap-
20 proaches to drug product design and manufac-
21 turing;

22 “(G) convene or participate in working
23 groups to support the harmonization of inter-
24 national regulatory requirements related to in-

1 novative approaches to drug product design and
2 manufacturing; and

3 “(H) award grants or contracts to carry
4 out or support the program under paragraph
5 (1).

6 “(3) GRANTS AND CONTRACTS.—To seek a
7 grant or contract under this section, an entity shall
8 submit an application—

9 “(A) in such form and manner as the Sec-
10 retary may require; and

11 “(B) containing such information as the
12 Secretary may require, including a description
13 of—

14 “(i) how the entity will conduct the
15 activities to be supported through the
16 grant or contract; and

17 “(ii) how such activities will further
18 research and development related to, or
19 adoption of, innovative approaches to drug
20 product design and manufacturing.

21 “(b) GUIDANCE.—The Secretary shall—

22 “(1) issue or update guidance to help facilitate
23 the adoption of, and advance the development of, in-
24 novative approaches to drug product design and
25 manufacturing; and

1 “(2) include in such guidance descriptions of—

2 “(A) any regulatory requirements related
3 to the development or review of technologies re-
4 lated to innovative approaches to drug product
5 design and manufacturing, including updates
6 and improvements to such technologies after
7 product approval; and

8 “(B) data that can be used to demonstrate
9 the identity, safety, purity, and potency of
10 drugs manufactured using such technologies.

11 “(c) REPORT TO CONGRESS.—Not later than 4 years
12 after the date of enactment of this section, the Secretary
13 shall submit to the Committee on Energy and Commerce
14 of the House of Representatives and the Committee on
15 Health, Education, Labor, and Pensions of the Senate a
16 report containing—

17 “(1) an annual accounting of the allocation of
18 funds made available to carry out this section;

19 “(2) a description of how Food and Drug Ad-
20 ministration staff were utilized to carry out this sec-
21 tion and, as applicable, any challenges or limitations
22 related to staffing;

23 “(3) the number of public meetings held or par-
24 ticipated in by the Food and Drug Administration
25 pursuant to this section, including meetings con-

1 vened as part of a working group described in sub-
2 paragraph (D) or (G) of subsection (a)(2), and the
3 topics of each such meeting; and

4 “(4) the number of drug products approved or
5 licensed, after the date of enactment of this section,
6 using an innovative approach to drug product design
7 and manufacturing.

8 “(d) AUTHORIZATION OF APPROPRIATIONS.—To
9 carry out this section, there is authorized to be appro-
10 priated \$20,000,000 for each fiscal year 2023 through
11 2027.”.

12 **SEC. 703. IMPROVING THE TREATMENT OF RARE DISEASES**
13 **AND CONDITIONS.**

14 (a) REPORT ON ORPHAN DRUG PROGRAM.—

15 (1) IN GENERAL.—Not later than September
16 30, 2026, the Secretary shall submit to the Com-
17 mittee on Energy and Commerce of the House of
18 Representatives and the Committee on Health, Edu-
19 cation, Labor, and Pensions of the Senate a report
20 summarizing the activities of the Food and Drug
21 Administration related to designating drugs under
22 section 526 of the Federal Food, Drug, and Cos-
23 metic Act (21 U.S.C. 360bb) for a rare disease or
24 condition and approving such drugs under section
25 505 of such Act (21 U.S.C. 355) or licensing such

1 drugs under section 351 of the Public Health Serv-
2 ice Act (42 U.S.C. 262), including—

3 (A) the number of applications for such
4 drugs under section 505 of the Federal Food,
5 Drug, and Cosmetic Act (21 U.S.C. 355) or
6 section 351 of the Public Health Service Act
7 (42 U.S.C. 262) received by the Food and Drug
8 Administration, the number of such applica-
9 tions accepted and rejected for filing, and the
10 number of such applications pending, approved,
11 and disapproved by the Food and Drug Admin-
12 istration;

13 (B) a description of trends in drug approv-
14 als for rare diseases and conditions across re-
15 view divisions at the Food and Drug Adminis-
16 tration;

17 (C) the extent to which the Food and Drug
18 Administration is consulting with external ex-
19 perts pursuant to section 569(a)(2) of the Fed-
20 eral Food, Drug, and Cosmetic Act (21 U.S.C.
21 360bbb–8(a)(2)) on topics pertaining to drugs
22 for a rare disease or condition, including how
23 and when any such consultation is occurring;
24 and

1 (D) the Food and Drug Administration’s
2 efforts to promote best practices in the develop-
3 ment of novel treatments for rare diseases, in-
4 cluding—

5 (i) reviewer training on rare disease-
6 related policies, methods, and tools; and

7 (ii) new regulatory science and coordi-
8 nated support for patient and stakeholder
9 engagement.

10 (2) PUBLIC AVAILABILITY.—The Secretary
11 shall make the report under paragraph (1) available
12 to the public, including by posting the report on the
13 website of the Food and Drug Administration.

14 (3) INFORMATION DISCLOSURE.—Nothing in
15 this subsection shall be construed to authorize the
16 disclosure of information that is prohibited from dis-
17 closure under section 1905 of title 18, United States
18 Code, or subject to withholding under paragraph (4)
19 of section 552(b) of title 5, United States Code
20 (commonly referred to as the “Freedom of Informa-
21 tion Act”).

22 (b) STUDY ON EUROPEAN UNION SAFETY AND EFFI-
23 CACY REVIEWS OF DRUGS FOR RARE DISEASES AND CON-
24 DITIONS.—

1 (1) IN GENERAL.—The Secretary of Health and
2 Human Services shall enter into a contract with an
3 appropriate entity to conduct a study on processes
4 for evaluating the safety and efficacy of drugs for
5 rare diseases or conditions in the United States and
6 the European Union, including—

7 (A) flexibilities, authorities, or mechanisms
8 available to regulators in the United States and
9 the European Union specific to rare diseases or
10 conditions;

11 (B) the consideration and use of supple-
12 mental data submitted during review processes
13 in the United States and the European Union,
14 including data associated with open label exten-
15 sion studies and expanded access programs spe-
16 cific to rare diseases or conditions;

17 (C) an assessment of collaborative efforts
18 between United States and European Union
19 regulators related to—

20 (i) product development programs
21 under review;

22 (ii) policies under development re-
23 cently issued; and

24 (iii) scientific information related to
25 product development or regulation; and

1 (D) recommendations for how Congress
2 can support collaborative efforts described in
3 subparagraph (C).

4 (2) CONSULTATION.—The contract under para-
5 graph (1) shall provide for consultation with relevant
6 stakeholders, including—

7 (A) representatives from the Food and
8 Drug Administration and the European Medi-
9 cines Agency;

10 (B) rare disease or condition patients; and

11 (C) patient groups that—

12 (i) represent rare disease or condition
13 patients; and

14 (ii) have international patient out-
15 reach.

16 (3) REPORT.—The contract under paragraph
17 (1) shall provide for, not later than 2 years after the
18 date of entering into such contract—

19 (A) the completion of the study under
20 paragraph (1); and

21 (B) the submission of a report on the re-
22 sults of such study to the Committee on Energy
23 and Commerce of the House of Representatives
24 and the Committee on Health, Education,
25 Labor, and Pensions of the Senate.

1 (4) PUBLIC AVAILABILITY.—The contract under
2 paragraph (1) shall provide for the appropriate enti-
3 ty referred to in paragraph (1) to make the report
4 under paragraph (3) available to the public, includ-
5 ing by posting the report on the website of the ap-
6 propriate entity.

7 (c) PUBLIC MEETING.—

8 (1) IN GENERAL.—Not later than December 31,
9 2023, the Secretary of Health and Human Services,
10 acting through the Commissioner of Food and
11 Drugs, shall convene one or more public meetings to
12 solicit input from stakeholders regarding the ap-
13 proaches described in paragraph (2).

14 (2) APPROACHES.—The public meeting or
15 meetings under paragraph (1) shall address ap-
16 proaches to increasing and improving engagement
17 with rare disease or condition patients, groups rep-
18 resenting such patients, rare disease or condition ex-
19 perts, and experts on small population studies, in
20 order to improve the understanding with respect to
21 rare diseases or conditions of—

22 (A) patient burden;

23 (B) treatment options; and

24 (C) side effects of treatments, including—

1 (i) comparing the side effects of treat-
2 ments; and

3 (ii) understanding the risks of side ef-
4 fects relative to the health status of the pa-
5 tient and the progression of the disease or
6 condition.

7 (3) PUBLIC DOCKET.—The Secretary of Health
8 and Human Services shall establish a public docket
9 to receive written comments related to the ap-
10 proaches addressed during each public meeting
11 under paragraph (1). Such public docket shall re-
12 main open for 60 days following the date of each
13 such public meeting.

14 (4) REPORTS.—Not later than 180 days after
15 each public meeting under paragraph (1), the Com-
16 missioner of Food and Drugs shall develop and pub-
17 lish on the website of the Food and Drug Adminis-
18 tration a report on—

19 (A) the approaches discussed at the public
20 meeting; and

21 (B) any related recommendations.

22 (d) CONSULTATION ON THE SCIENCE OF SMALL
23 POPULATION STUDIES.—Section 569(a)(2) of the Federal
24 Food, Drug, and Cosmetic Act (21 U.S.C. 360bbb–
25 8(a)(2)) is amended by adding at the end the following:

1 “(C) SMALL POPULATION STUDIES.—The
2 external experts on the list maintained pursuant
3 to subparagraph (A) may include experts on the
4 science of small population studies.”.

5 (e) STUDY ON SUFFICIENCY AND USE OF FDA
6 MECHANISMS FOR INCORPORATING THE PATIENT AND
7 CLINICIAN PERSPECTIVE IN FDA PROCESSES RELATED
8 TO APPLICATIONS CONCERNING DRUGS FOR RARE DIS-
9 EASES OR CONDITIONS.—

10 (1) IN GENERAL.—The Comptroller General of
11 the United States shall conduct a study on the use
12 of Food and Drug Administration mechanisms and
13 tools to ensure that patient and physician perspec-
14 tives are considered and incorporated throughout the
15 processes of the Food and Drug Administration—

16 (A) for approving or licensing under sec-
17 tion 505 of the Federal Food, Drug, or Cos-
18 metic Act (21 U.S.C. 355) or section 351 of the
19 Public Health Service Act (42 U.S.C. 262) a
20 drug designated as a drug for a rare disease or
21 condition under section 526 of the Federal
22 Food, Drug, and Cosmetic Act (21 U.S.C.
23 360bb); and

1 (B) in making any determination related
2 to such a drug's approval, including assessment
3 of the drug's—

4 (i) safety or effectiveness; or

5 (ii) postapproval safety monitoring.

6 (2) TOPICS.—The study under paragraph (1)
7 shall—

8 (A) identify and compare the processes
9 that the Food and Drug Administration has
10 formally put in place and utilized to gather ex-
11 ternal expertise (including patients, patient
12 groups, and physicians) related to applications
13 for rare diseases or conditions;

14 (B) examine tools or mechanisms to im-
15 prove efforts and initiatives of the Food and
16 Drug Administration to collect and consider
17 such external expertise with respect to applica-
18 tions for rare diseases or conditions throughout
19 the application review and approval or licensure
20 processes, including within internal benefit-risk
21 assessments, advisory committee processes, and
22 postapproval safety monitoring; and

23 (C) examine processes or alternatives to
24 address or resolve conflicts of interest that im-
25 pede the Food and Drug Administration in

1 gaining external expert input on rare diseases
2 or conditions with a limited set of clinical and
3 research experts.

4 (3) REPORT.—Not later than 2 years after the
5 date of enactment of this Act, the Comptroller Gen-
6 eral of the United States shall—

7 (A) complete the study under paragraph
8 (1);

9 (B) submit a report on the results of such
10 study to the Congress; and

11 (C) include in such report recommenda-
12 tions, if appropriate, for changes to the proc-
13 esses and authorities of the Food and Drug Ad-
14 ministration to improve the collection and con-
15 sideration of external expert opinions of pa-
16 tients, patient groups, and physicians with ex-
17 pertise in rare diseases or conditions.

18 (f) DEFINITION.—In this section, the term “rare dis-
19 ease or condition” has the meaning given such term in
20 section 526(a)(2) of the Federal Food, Drug, and Cos-
21 metic Act (21 U.S.C. 360bb(a)(2)).

22 **SEC. 704. ANTIFUNGAL RESEARCH AND DEVELOPMENT.**

23 (a) DRAFT GUIDANCE.—Not later than 3 years after
24 the date of the enactment of this Act, the Secretary of
25 Health and Human Services, acting through the Commis-

1 sioner of Food and Drugs, shall issue draft guidance for
2 industry for the purposes of assisting entities seeking ap-
3 proval under section 505 of the Federal Food, Drug, and
4 Cosmetic Act (21 U.S.C. 355) or licensure under section
5 351 of the Public Health Service Act (42 U.S.C. 262) of
6 antifungal therapies designed to treat coccidioidomycosis
7 (commonly known as Valley Fever).

8 (b) FINAL GUIDANCE.—Not later than 18 months
9 after the close of the public comment period on the draft
10 guidance issued pursuant to subsection (a), the Secretary
11 of Health and Human Services, acting through the Com-
12 missioner of Food and Drugs, shall finalize the draft guid-
13 ance.

14 (c) WORKSHOP.—To assist entities developing pre-
15 ventive vaccines for fungal infections and coccidioidomy-
16 cosis, the Secretary of Health and Human Services shall
17 hold a public workshop.

18 **SEC. 705. ADVANCING QUALIFIED INFECTIOUS DISEASE**
19 **PRODUCT INNOVATION.**

20 (a) IN GENERAL.—Section 505E of the Federal
21 Food, Drug, and Cosmetic Act (21 U.S.C. 355f) is amend-
22 ed—

23 (1) in subsection (c)—

24 (A) in paragraph (2), by striking “or” at
25 the end;

1 (B) in paragraph (3), by striking the pe-
2 riod at the end and inserting “; or”; and

3 (C) by adding at the end the following:

4 “(4) an application pursuant to section 351(a)
5 of the Public Health Service Act.”;

6 (2) in subsection (d)(1), by inserting “of this
7 Act or section 351(a) of the Public Health Service
8 Act” after “section 505(b)”; and

9 (3) by amending subsection (g) to read as fol-
10 lows:

11 “(g) QUALIFIED INFECTIOUS DISEASE PRODUCT.—
12 The term ‘qualified infectious disease product’ means a
13 drug, including an antibacterial or antifungal drug or a
14 biological product, for human use that—

15 “(1) acts directly on bacteria or fungi or on
16 substances produced by such bacteria or fungi; and

17 “(2) is intended to treat a serious or life-threat-
18 ening infection, including such an infection caused
19 by—

20 “(A) an antibacterial or antifungal resist-
21 ant pathogen, including novel or emerging in-
22 fectionous pathogens; or

23 “(B) qualifying pathogens listed by the
24 Secretary under subsection (f).”.

1 (b) PRIORITY REVIEW.—Section 524A(a) of the Fed-
2 eral Food, Drug, and Cosmetic Act (21 U.S.C. 360n–1(a))
3 is amended by inserting “of this Act or section 351(a) of
4 the Public Health Service Act that requires clinical data
5 (other than bioavailability studies) to demonstrate safety
6 or effectiveness” before the period at the end.

7 **SEC. 706. NATIONAL CENTERS OF EXCELLENCE IN AD-**
8 **VANCED AND CONTINUOUS PHARMA-**
9 **CEUTICAL MANUFACTURING.**

10 (a) IN GENERAL.—Section 3016 of the 21st Century
11 Cures Act (21 U.S.C. 399h) is amended to read as follows:

12 **“SEC. 3016. NATIONAL CENTERS OF EXCELLENCE IN AD-**
13 **VANCED AND CONTINUOUS PHARMA-**
14 **CEUTICAL MANUFACTURING.**

15 “(a) IN GENERAL.—The Secretary of Health and
16 Human Services, acting through the Commissioner of
17 Food and Drugs—

18 “(1) shall solicit and, beginning not later than
19 one year after the date of enactment of the Prescrip-
20 tion Drug User Fee Amendments of 2022, receive
21 requests from institutions of higher education, or
22 consortia of institutions of higher education, to be
23 designated as a National Center of Excellence in Ad-
24 vanced and Continuous Pharmaceutical Manufac-
25 turing (in this section referred to as a ‘National

1 Center of Excellence’) to support the advancement,
2 development, and implementation of advanced and
3 continuous pharmaceutical manufacturing; and

4 “(2) shall so designate not more than 5 institu-
5 tions of higher education or consortia of such insti-
6 tutions that—

7 “(A) request such designation; and

8 “(B) meet the criteria specified in sub-
9 section (c).

10 “(b) REQUEST FOR DESIGNATION.—A request for
11 designation under subsection (a) shall be made to the Sec-
12 retary at such time, in such manner, and containing such
13 information as the Secretary may require. Any such re-
14 quest shall include a description of how the institution of
15 higher education, or consortium of institutions of higher
16 education, meets or plans to meet each of the criteria spec-
17 ified in subsection (c).

18 “(c) CRITERIA FOR DESIGNATION DESCRIBED.—The
19 criteria specified in this subsection with respect to an in-
20 stitution of higher education, or consortium of institutions
21 of higher education, are that the institution or consortium
22 has, as of the date of the submission of a request under
23 subsection (a) by such institution or consortium—

24 “(1) physical and technical capacity for re-
25 search, development, implementation, and dem-

1 onstration of advanced and continuous pharma-
2 ceutical manufacturing;

3 “(2) manufacturing knowledge-sharing net-
4 works with other institutions of higher education,
5 large and small pharmaceutical manufacturers, ge-
6 neric and nonprescription manufacturers, contract
7 manufacturers, and other relevant entities;

8 “(3) proven capacity to design, develop, imple-
9 ment, and demonstrate new, highly effective tech-
10 nologies for use in advanced and continuous phar-
11 maceutical manufacturing;

12 “(4) a track record for creating, preserving,
13 and transferring knowledge with respect to advanced
14 and continuous pharmaceutical manufacturing;

15 “(5) the proven ability to facilitate training of
16 an adequate future workforce for research on, and
17 implementation of, advanced and continuous phar-
18 maceutical manufacturing; and

19 “(6) experience in participating in and leading
20 advanced and continuous pharmaceutical manufac-
21 turing technology partnerships with other institu-
22 tions of higher education, large and small pharma-
23 ceutical manufacturers, generic and nonprescription
24 manufacturers, contract manufacturers, and other
25 relevant entities—

1 “(A) to support companies seeking to im-
2 plement advanced and continuous pharma-
3 ceutical manufacturing in the United States;

4 “(B) to support Federal agencies with
5 technical assistance and employee training,
6 which may include regulatory and quality met-
7 ric guidance as applicable, and hands-on train-
8 ing, for advanced and continuous pharma-
9 ceutical manufacturing;

10 “(C) with respect to advanced and contin-
11 uous pharmaceutical manufacturing, to orga-
12 nize and conduct research and development ac-
13 tivities needed to create new and more effective
14 technology, develop and share knowledge, create
15 intellectual property, and maintain technological
16 leadership;

17 “(D) to develop best practices for design-
18 ing and implementing advanced and continuous
19 pharmaceutical manufacturing processes; and

20 “(E) to assess and respond to the national
21 workforce needs for advanced and continuous
22 pharmaceutical manufacturing, including the
23 development and implementing of training pro-
24 grams.

1 “(d) TERMINATION OF DESIGNATION.—The Sec-
2 retary may terminate the designation of any National Cen-
3 ter of Excellence designated under this section if the Sec-
4 retary determines such National Center of Excellence no
5 longer meets the criteria specified in subsection (c). Not
6 later than 90 days before the effective date of such a ter-
7 mination, the Secretary shall provide written notice to the
8 National Center of Excellence, including the rationale for
9 such termination.

10 “(e) CONDITIONS FOR DESIGNATION.—As a condi-
11 tion of designation as a National Center of Excellence
12 under this section, the Secretary shall require that an in-
13 stitution of higher education or consortium of institutions
14 of higher education enter into an agreement with the Sec-
15 retary under which the institution or consortium agrees—

16 “(1) to collaborate directly with the Food and
17 Drug Administration to publish the reports required
18 by subsection (g);

19 “(2) to share data with the Food and Drug Ad-
20 ministration regarding best practices and research
21 generated through the funding under subsection (f);

22 “(3) to develop, along with industry partners
23 (which may include large and small biopharma-
24 ceutical manufacturers, generic and nonprescription
25 manufacturers, and contract research organizations

1 or contract manufacturers that carry out drug devel-
2 opment and manufacturing activities) and another
3 institution or consortium designated under this sec-
4 tion, if any, a roadmap for developing an advanced
5 and continuous pharmaceutical manufacturing work-
6 force;

7 “(4) to develop, along with industry partners
8 and other institutions or consortia of such institu-
9 tions designated under this section, a roadmap for
10 strengthening existing, and developing new, relation-
11 ships with other institutions of higher education or
12 consortia thereof; and

13 “(5) to provide an annual report to the Food
14 and Drug Administration regarding the institution’s
15 or consortium’s activities under this section, includ-
16 ing a description of how the institution or consor-
17 tium continues to meet and make progress on the
18 criteria specified in subsection (c).

19 “(f) FUNDING.—

20 “(1) IN GENERAL.—The Secretary shall award
21 funding, through grants, contracts, or cooperative
22 agreements, to the National Centers of Excellence
23 designated under this section for the purpose of
24 studying and recommending improvements to ad-
25 vanced and continuous pharmaceutical manufac-

1 turing, including such improvements as may enable
2 the Centers—

3 “(A) to continue to meet the conditions
4 specified in subsection (e);

5 “(B) to expand capacity for research on,
6 and development of, advanced and continuous
7 pharmaceutical manufacturing; and

8 “(C) to implement research infrastructure
9 in advanced and continuous pharmaceutical
10 manufacturing suitable for accelerating the de-
11 velopment of drug products needed to respond
12 to emerging medical threats, such as emerging
13 drug shortages, quality issues disrupting the
14 supply chain, epidemics and pandemics, and
15 other such situations requiring the rapid devel-
16 opment of new products or new manufacturing
17 processes.

18 “(2) CONSISTENCY WITH FDA MISSION.—As a
19 condition on receipt of funding under this sub-
20 section, a National Center of Excellence shall agree
21 to consider any input from the Secretary regarding
22 the use of funding that would—

23 “(A) help to further the advancement of
24 advanced and continuous pharmaceutical manu-

1 facturing through the National Center of Excel-
2 lence; and

3 “(B) be relevant to the mission of the
4 Food and Drug Administration.

5 “(3) RULE OF CONSTRUCTION.—Nothing in
6 this section shall be construed as precluding a Na-
7 tional Center for Excellence designated under this
8 section from receiving funds under any other provi-
9 sion of this Act or any other Federal law.

10 “(g) ANNUAL REVIEW AND REPORTS.—

11 “(1) ANNUAL REPORT.—Beginning not later
12 than one year after the date on which the first des-
13 ignation is made under subsection (a), and annually
14 thereafter, the Secretary shall—

15 “(A) submit to Congress a report describ-
16 ing the activities, partnerships and collabora-
17 tions, Federal policy recommendations, previous
18 and continuing funding, and findings of, and
19 any other applicable information from, the Na-
20 tional Centers of Excellence designated under
21 this section;

22 “(B) include in such report an accounting
23 of the Federal administrative expenses de-
24 scribed in subsection (i)(2) over the reporting
25 period; and

1 “(C) make such report available to the
2 public in an easily accessible electronic format
3 on the website of the Food and Drug Adminis-
4 tration.

5 “(2) REVIEW OF NATIONAL CENTERS OF EX-
6 CELLENCE AND POTENTIAL DESIGNEES.—The Sec-
7 retary shall periodically review the National Centers
8 of Excellence designated under this section to ensure
9 that such National Centers of Excellence continue to
10 meet the criteria for designation under this section.

11 “(3) REPORT ON LONG-TERM VISION OF FDA
12 ROLE.—Not later than 2 years after the date on
13 which the first designation is made under subsection
14 (a), the Secretary, in consultation with the National
15 Centers of Excellence designated under this section,
16 shall submit a report to the Congress on the long-
17 term vision of the Department of Health and
18 Human Services on the role of the Food and Drug
19 Administration in supporting advanced and contin-
20 uous pharmaceutical manufacturing, including—

21 “(A) a national framework of principles re-
22 lated to the implementation and regulation of
23 advanced and continuous pharmaceutical manu-
24 facturing;

1 “(B) a plan for the development of Federal
2 regulations and guidance for how advanced and
3 continuous pharmaceutical manufacturing can
4 be incorporated into the development of phar-
5 maceuticals and regulatory responsibilities of
6 the Food and Drug Administration;

7 “(C) a plan for development of Federal
8 regulations or guidance for how advanced and
9 continuous pharmaceutical manufacturing will
10 be reviewed by the Food and Drug Administra-
11 tion; and

12 “(D) appropriate feedback solicited from
13 the public, which may include other institutions
14 of higher education, large and small biopharma-
15 ceutical manufacturers, generic and non-
16 prescription manufacturers, and contract manu-
17 facturers.

18 “(h) DEFINITIONS.—In this section:

19 “(1) ADVANCED.—The term ‘advanced’, with
20 respect to pharmaceutical manufacturing, refers to
21 an approach that incorporates novel technology, or
22 uses an established technique or technology in a new
23 or innovative way, that enhances drug quality or im-
24 proves the performance of a manufacturing process.

1 “(2) CONTINUOUS.—The term ‘continuous’,
2 with respect to pharmaceutical manufacturing, re-
3 fers to a process—

4 “(A) where the input materials are con-
5 tinuously fed into and transformed within the
6 process, and the processed output materials are
7 continuously removed from the system; and

8 “(B) that consists of an integrated process
9 that consists of a series of two or more simulta-
10 neous unit operations.

11 “(3) INSTITUTION OF HIGHER EDUCATION.—
12 The term ‘institution of higher education’ has the
13 meaning given such term in section 101(a) of the
14 Higher Education Act of 1965 (20 U.S.C. 1001(a)).

15 “(4) SECRETARY.—The term ‘Secretary’ means
16 the Secretary of Health and Human Services, acting
17 through the Commissioner of Food and Drugs.

18 “(i) AUTHORIZATION OF APPROPRIATIONS.—

19 “(1) IN GENERAL.—There is authorized to be
20 appropriated to carry out this section \$100,000,000
21 for the period of fiscal years 2023 through 2027.

22 “(2) FEDERAL ADMINISTRATIVE EXPENSES.—
23 Of the amounts made available to carry out this sec-
24 tion for a fiscal year, the Secretary shall not use
25 more than eight percent for Federal administrative

1 expenses, including training, technical assistance, re-
 2 porting, and evaluation.”.

3 (b) **TRANSITION RULE.**—Section 3016 of the 21st
 4 Century Cures Act (21 U.S.C. 399h), as in effect on the
 5 day before the date of the enactment of this section, shall
 6 apply with respect to grants awarded under such section
 7 before such date of enactment.

8 (c) **CLERICAL AMENDMENT.**—The item relating to
 9 section 3016 in the table of contents in section 1(b) of
 10 the 21st Century Cures Act (Public Law 114–255) is
 11 amended to read as follows:

“Sec. 3016. National Centers of Excellence in Advanced and Continuous Phar-
 maceutical Manufacturing.”.

12 **SEC. 707. ADVANCED MANUFACTURING TECHNOLOGIES**
 13 **DESIGNATION PILOT PROGRAM.**

14 Subchapter A of chapter V of the Federal Food,
 15 Drug, and Cosmetic Act (21 U.S.C. 351 et seq.) is amend-
 16 ed by inserting after section 506J (21 U.S.C. 356j) the
 17 following:

18 **“SEC. 506K. ADVANCED MANUFACTURING TECHNOLOGIES**
 19 **DESIGNATION PILOT PROGRAM.**

20 “(a) **IN GENERAL.**—Not later than 1 year after the
 21 date of enactment of this section, the Secretary shall ini-
 22 tiate a pilot program under which persons may request
 23 designation of an advanced manufacturing technology as
 24 described in subsection (b).

1 “(b) DESIGNATION PROCESS.—The Secretary shall
2 establish a process for the designation under this section
3 of methods of manufacturing drugs, including biological
4 products, and active pharmaceutical ingredients of such
5 drugs, as advanced manufacturing technologies. A method
6 of manufacturing, or a combination of manufacturing
7 methods, is eligible for designation as an advanced manu-
8 facturing technology if such method or combination of
9 methods incorporates a novel technology, or uses an estab-
10 lished technique or technology in a novel way, that will
11 substantially improve the manufacturing process for a
12 drug and maintain equivalent or provide superior drug
13 quality, including by—

14 “(1) reducing development time for a drug
15 using the designated manufacturing method; or

16 “(2) increasing or maintaining the supply of—

17 “(A) a drug that is described in section
18 506C(a) and is intended to treat a serious or
19 life-threatening condition; or

20 “(B) a drug that is on the drug shortage
21 list under section 506E.

22 “(c) EVALUATION AND DESIGNATION OF AN AD-
23 VANCED MANUFACTURING TECHNOLOGY.—

24 “(1) SUBMISSION.—A person who requests des-
25 ignation of a method of manufacturing as an ad-

1 vanced manufacturing technology under this section
2 shall submit to the Secretary data or information
3 demonstrating that the method of manufacturing
4 meets the criteria described in subsection (b) in a
5 particular context of use. The Secretary may facili-
6 tate the development and review of such data or in-
7 formation by—

8 “(A) providing timely advice to, and inter-
9 active communication with, such person regard-
10 ing the development of the method of manufac-
11 turing; and

12 “(B) involving senior managers and experi-
13 enced staff of the Food and Drug Administra-
14 tion, as appropriate, in a collaborative, cross-
15 disciplinary review of the method of manufac-
16 turing, as applicable.

17 “(2) EVALUATION AND DESIGNATION.—Not
18 later than 180 calendar days after the receipt of a
19 request under paragraph (1), the Secretary shall de-
20 termine whether to designate such method of manu-
21 facturing as an advanced manufacturing technology,
22 in a particular context of use, based on the data and
23 information submitted under paragraph (1) and the
24 criteria described in subsection (b).

1 “(d) REVIEW OF ADVANCED MANUFACTURING
2 TECHNOLOGIES.—If the Secretary designates a method of
3 manufacturing as an advanced manufacturing technology,
4 the Secretary shall—

5 “(1) expedite the development and review of an
6 application submitted under section 505 of this Act
7 or section 351 of the Public Health Service Act, in-
8 cluding supplemental applications, for drugs that are
9 manufactured using a designated advanced manufac-
10 turing technology and could help mitigate or prevent
11 a shortage or substantially improve manufacturing
12 processes for a drug and maintain equivalent or pro-
13 vide superior drug quality, as described in subsection
14 (b); and

15 “(2) allow the holder of an advanced technology
16 designation, or a person authorized by the advanced
17 manufacturing technology designation holder, to ref-
18 erence or rely upon, in an application submitted
19 under section 505 of this Act or section 351 of the
20 Public Health Service Act, including a supplemental
21 application, data and information about the des-
22 ignated advanced manufacturing technology for use
23 in manufacturing drugs in the same context of use
24 for which the designation was granted.

1 “(e) IMPLEMENTATION AND EVALUATION OF AD-
2 VANCED MANUFACTURING TECHNOLOGIES PILOT.—

3 “(1) PUBLIC MEETING.—The Secretary shall
4 publish in the Federal Register a notice of a public
5 meeting, to be held not later than 180 days after the
6 date of enactment of this section, to discuss and ob-
7 tain input and recommendations from relevant
8 stakeholders regarding—

9 “(A) the goals and scope of the pilot pro-
10 gram, and a suitable framework, procedures,
11 and requirements for such program; and

12 “(B) ways in which the Food and Drug
13 Administration will support the use of advanced
14 manufacturing technologies and other innova-
15 tive manufacturing approaches for drugs.

16 “(2) PILOT PROGRAM GUIDANCE.—

17 “(A) IN GENERAL.—The Secretary shall—

18 “(i) not later than 180 days after the
19 public meeting under paragraph (1), issue
20 draft guidance regarding the goals and im-
21 plementation of the pilot program under
22 this section; and

23 “(ii) not later than 2 years after the
24 date of enactment of this section, issue

1 final guidance regarding the implementa-
2 tion of such program.

3 “(B) CONTENT.—The guidance described
4 in subparagraph (A) shall address—

5 “(i) the process by which a person
6 may request a designation under sub-
7 section (b);

8 “(ii) the data and information that a
9 person requesting such a designation is re-
10 quired to submit under subsection (c), and
11 how the Secretary intends to evaluate such
12 submissions;

13 “(iii) the process to expedite the de-
14 velopment and review of applications under
15 subsection (d); and

16 “(iv) the criteria described in sub-
17 section (b) for eligibility for such a des-
18 ignation.

19 “(3) REPORT.—Not later than 3 years after the
20 date of enactment of this section and annually there-
21 after, the Secretary shall publish on the website of
22 the Food and Drug Administration and submit to
23 the Committee on Health, Education, Labor, and
24 Pensions of the Senate and the Committee on En-
25 ergy and Commerce of the House of Representatives

1 a report containing a description and evaluation of
2 the pilot program being conducted under this sec-
3 tion, including the types of innovative manufacturing
4 approaches supported under the program. Such re-
5 port shall include the following:

6 “(A) The number of persons that have re-
7 quested designations and that have been grant-
8 ed designations.

9 “(B) The number of methods of manufac-
10 turing that have been the subject of designation
11 requests and that have been granted designa-
12 tions.

13 “(C) The average number of calendar days
14 for completion of evaluations under subsection
15 (c)(2).

16 “(D) An analysis of the factors in data
17 submissions that are relevant to determinations
18 to designate and not to designate after evalua-
19 tion under subsection (c)(2).

20 “(E) The number of applications received
21 under section 505 of this Act or section 351 of
22 the Public Health Service Act, including supple-
23 mental applications, that have included an ad-
24 vanced manufacturing technology designated

1 under this section, and the number of such ap-
2 plications approved.

3 “(f) SUNSET.—The Secretary—

4 “(1) may not consider any requests for designa-
5 tion submitted under subsection (c) after October 1,
6 2029; and

7 “(2) may continue all activities under this sec-
8 tion with respect to advanced manufacturing tech-
9 nologies that were designated pursuant to subsection
10 (d) prior to such date, if the Secretary determines
11 such activities are in the interest of the public
12 health.”.

13 **SEC. 708. PUBLIC WORKSHOP ON CELL THERAPIES.**

14 Not later than 3 years after the date of the enact-
15 ment of this Act, the Secretary of Health and Human
16 Services, acting through the Commissioner of Food and
17 Drugs, shall convene a public workshop with relevant
18 stakeholders to discuss best practices on generating sci-
19 entific data necessary to further facilitate the development
20 of certain human cell-, tissue-, and cellular-based medical
21 products (and the latest scientific information about such
22 products) that are regulated as drugs under the Federal
23 Food, Drug, and Cosmetic Act (21 U.S.C. 301 et seq.)
24 and biological products under section 351 of the Public

1 Health Service Act (42 U.S.C. 262), namely, stem-cell and
2 other cellular therapies.

3 **SEC. 709. REAUTHORIZATION OF BEST PHARMACEUTICALS**
4 **FOR CHILDREN.**

5 Section 409I(d)(1) of the Public Health Service Act
6 (42 U.S.C. 284m(d)(1)) is amended by striking “2018
7 through 2022” and inserting “2023 through 2027”.

8 **SEC. 710. REAUTHORIZATION FOR HUMANITARIAN DEVICE**
9 **EXEMPTION AND DEMONSTRATION GRANTS**
10 **FOR IMPROVING PEDIATRIC AVAILABILITY.**

11 (a) HUMANITARIAN DEVICE EXEMPTION.—Section
12 520(m)(6)(A)(iv) of the Federal Food, Drug, and Cos-
13 metic Act (21 U.S.C. 360j(m)(6)(A)(iv)) is amended by
14 striking “2022” and inserting “2027”.

15 (b) PEDIATRIC MEDICAL DEVICE SAFETY AND IM-
16 PROVEMENT ACT.—Section 305(e) of the Pediatric Med-
17 ical Device Safety and Improvement Act of 2007 (Public
18 Law 110–85) is amended by striking “2018 through
19 2022” and inserting “2023 through 2027”.

20 **SEC. 711. REAUTHORIZATION OF PROVISION RELATED TO**
21 **EXCLUSIVITY OF CERTAIN DRUGS CON-**
22 **TAINING SINGLE ENANTIOMERS.**

23 Section 505(u)(4) of the Federal Food, Drug, and
24 Cosmetic Act (21 U.S.C. 355(u)(4)) is amended by strik-
25 ing “2022” and inserting “2027”.

1 **SEC. 712. REAUTHORIZATION OF THE CRITICAL PATH PUB-**
 2 **LIC-PRIVATE PARTNERSHIP PROGRAM.**

3 Section 566(f) of the Federal Food, Drug, and Cos-
 4 metic Act (21 U.S.C. 360bbb–5(f)) is amended by striking
 5 “\$6,000,000 for each of fiscal years 2018 through 2022”
 6 and inserting “\$10,000,000 for each of fiscal years 2023
 7 through 2027”.

8 **SEC. 713. REAUTHORIZATION OF ORPHAN DRUG GRANTS.**

9 Section 5 of the Orphan Drug Act (21 U.S.C. 360ee)
 10 is amended—

11 (1) in subsection (a)—

12 (A) by striking “and (3)” and inserting
 13 “(3)”; and

14 (B) by inserting before the period at the
 15 end the following: “, and (4) developing regu-
 16 latory science pertaining to the chemistry, man-
 17 ufacturing, and controls of individualized med-
 18 ical products to treat individuals with rare dis-
 19 eases or conditions”; and

20 (2) in subsection (c), by striking “2018 through
 21 2022” and inserting “2023 through 2027”.

22 **SEC. 714. RESEARCH INTO PEDIATRIC USES OF DRUGS; AD-**
 23 **DITIONAL AUTHORITIES OF FOOD AND DRUG**
 24 **ADMINISTRATION REGARDING MOLECU-**
 25 **LARLY TARGETED CANCER DRUGS.**

26 (a) IN GENERAL.—

1 (1) ADDITIONAL ACTIVE INGREDIENT FOR AP-
2 PLICATION DRUG; LIMITATION REGARDING NOVEL-
3 COMBINATION APPLICATION DRUG.—Section
4 505B(a)(3) of the Federal Food, Drug, and Cos-
5 metic Act (21 U.S.C. 355c(a)(3)) is amended—

6 (A) by redesignating subparagraphs (B)
7 and (C) as subparagraphs (C) and (D), respec-
8 tively; and

9 (B) by striking subparagraph (A) and in-
10 serting the following:

11 “(A) IN GENERAL.—For purposes of para-
12 graph (1)(B), the investigation described in this
13 paragraph is (as determined by the Secretary)
14 a molecularly targeted pediatric cancer inves-
15 tigation of—

16 “(i) the drug or biological product for
17 which the application referred to in such
18 paragraph is submitted; or

19 “(ii) such drug or biological product
20 in combination with—

21 “(I) an active ingredient of a
22 drug or biological product—

23 “(aa) for which an approved
24 application under section 505(j)
25 under this Act or under section

1 351(k) of the Public Health
2 Service Act is in effect; and

3 “(bb) that is determined by
4 the Secretary to be the standard
5 of care for treating a pediatric
6 cancer; or

7 “(II) an active ingredient of a
8 drug or biological product—

9 “(aa) for which an approved
10 application under section 505(b)
11 of this Act or section 351(a) of
12 the Public Health Service Act to
13 treat an adult cancer is in effect
14 and is held by the same person
15 submitting the application under
16 paragraph (1)(B); and

17 “(bb) that is directed at a
18 molecular target that the Sec-
19 retary determines to be substan-
20 tially relevant to the growth or
21 progression of a pediatric cancer.

22 “(B) ADDITIONAL REQUIREMENTS.—

23 “(i) DESIGN OF INVESTIGATION.—A
24 molecularly targeted pediatric cancer inves-
25 tigation referred to in subparagraph (A)

1 shall be designed to yield clinically mean-
2 ingful pediatric study data that is gathered
3 using appropriate formulations for each
4 age group for which the study is required,
5 regarding dosing, safety, and preliminary
6 efficacy to inform potential pediatric label-
7 ing.

8 “(ii) LIMITATION.—An investigation
9 described in subparagraph (A)(ii) may be
10 required only if the drug or biological
11 product for which the application referred
12 to in paragraph (1)(B) contains either—

13 “(I) a single new active ingre-
14 dient; or

15 “(II) more than one active ingre-
16 dient, if an application for the com-
17 bination of active ingredients has not
18 previously been approved but each ac-
19 tive ingredient has been previously ap-
20 proved to treat an adult cancer.

21 “(iii) RESULTS OF ALREADY-COM-
22 PLETED PRECLINICAL STUDIES OF APPLI-
23 CATION DRUG.—The Secretary may re-
24 quire that reports on an investigation re-
25 quired pursuant to paragraph (1)(B) in-

1 clude the results of all preclinical studies
2 on which the decision to conduct such in-
3 vestigation was based.

4 “(iv) RULE OF CONSTRUCTION RE-
5 GARDING INACTIVE INGREDIENTS.—With
6 respect to a combination of active ingredi-
7 ents referred to in subparagraph (A)(ii),
8 such subparagraph shall not be construed
9 as addressing the use of inactive ingredi-
10 ents with such combination.”.

11 (2) DETERMINATION OF APPLICABLE REQUIRE-
12 MENTS.—Section 505B(e)(1) of the Federal Food,
13 Drug, and Cosmetic Act (21 U.S.C. 355c(e)(1)) is
14 amended by adding at the end the following: “The
15 Secretary shall determine whether subparagraph (A)
16 or (B) of subsection (a)(1) shall apply with respect
17 to an application before the date on which the appli-
18 cant is required to submit the initial pediatric study
19 plan under paragraph (2)(A).”.

20 (3) CLARIFYING APPLICABILITY.—Section
21 505B(a)(1) of the Federal Food, Drug, and Cos-
22 metic Act (21 U.S.C. 355c(a)(1)) is amended by
23 adding at the end the following:

24 “(C) RULE OF CONSTRUCTION.—No appli-
25 cation that is subject to the requirements of

1 subparagraph (B) shall be subject to the re-
2 quirements of subparagraph (A), and no appli-
3 cation (or supplement to an application) that is
4 subject to the requirements of subparagraph
5 (A) shall be subject to the requirements of sub-
6 paragraph (B).”.

7 (4) CONFORMING AMENDMENTS.—Section
8 505B(a) of the Federal Food, Drug, and Cosmetic
9 Act (21 U.S.C. 355c(a)) is amended—

10 (A) in paragraph (3)(C), as redesignated
11 by paragraph (1)(A) of this subsection, by
12 striking “investigations described in this para-
13 graph” and inserting “investigations referred to
14 in subparagraph (A)”;

15 (B) in paragraph (3)(D), as redesignated
16 by paragraph (1)(A) of this subsection, by
17 striking “the assessments under paragraph
18 (2)(B)” and inserting “the assessments re-
19 quired under paragraph (1)(A)”.

20 (b) GUIDANCE.—The Secretary shall—

21 (1) not later than 12 months after the date of
22 enactment of this Act, issue draft guidance on the
23 implementation of the requirements in subsection
24 (a); and

1 (2) not later than 12 months after closing the
2 comment period on such draft guidance, finalize
3 such guidance.

4 (c) APPLICABILITY.—The amendments made by this
5 section apply with respect to any application under section
6 505(b) of the Federal Food, Drug, and Cosmetic Act (21
7 U.S.C. 355(b)) and any application under section 351(a)
8 of the Public Health Service Act (42 U.S.C. 262), that
9 is submitted on or after the date that is 3 years after the
10 date of enactment of this Act.

11 (d) REPORTS TO CONGRESS.—

12 (1) SECRETARY OF HEALTH AND HUMAN SERV-
13 ICES.—Not later than 2 years after the date of en-
14 actment of this Act, the Secretary of Health and
15 Human Services shall submit to the Committee on
16 Energy and Commerce of the House of Representa-
17 tives and the Committee on Health, Education,
18 Labor, and Pensions of the Senate a report on the
19 Secretary's efforts, in coordination with industry, to
20 ensure implementation of the amendments made by
21 subsection (a).

22 (2) GAO STUDY AND REPORT.—

23 (A) STUDY.—Not later than 3 years after
24 the date of enactment of this Act, the Comp-
25 troller General of the United States shall con-

duct a study of the effectiveness of requiring assessments and investigations described in section 505B of the Federal Food, Drug, and Cosmetic Act (21 U.S.C.355c), as amended by subsection (a), in the development of drugs and biological products for pediatric cancer indications.

(B) FINDINGS.—Not later than 7 years after the date of enactment of this Act, the Comptroller General shall submit to the Committee on Energy and Commerce of the House of Representatives and the Committee on Health, Education, Labor, and Pensions of the Senate a report containing the findings of the study conducted under subparagraph (A).

Subtitle B—Inspections

SEC. 721. FACTORY INSPECTION.

(a) IN GENERAL.—Section 704(a)(1) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 374(a)(1)) is amended by striking “restricted devices” each place it appears and inserting “devices”.

(b) RECORDS OR OTHER INFORMATION.—

(1) ESTABLISHMENTS.—Section 704(a)(4)(A) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 374(a)(4)(A)) is amended—

1 (A) by striking “an establishment that is
2 engaged in the manufacture, preparation, prop-
3 agation, compounding, or processing of a drug”
4 and inserting “an establishment that is engaged
5 in the manufacture, preparation, propagation,
6 compounding, or processing of a drug or device,
7 or that is subject to inspection under paragraph
8 (5)(C),”; and

9 (B) by inserting after “a sufficient descrip-
10 tion of the records requested” the following:
11 “and a rationale for requesting such records or
12 other information in advance of, or in lieu of,
13 an inspection”.

14 (2) GUIDANCE.—

15 (A) IN GENERAL.—The Secretary of
16 Health and Human Services shall issue or up-
17 date guidance describing—

18 (i) circumstances in which the Sec-
19 retary intends to issue requests for records
20 or other information in advance of, or in
21 lieu of, an inspection under section
22 704(a)(4) of the Federal Food, Drug, and
23 Cosmetic Act, as amended by paragraph
24 (1);

1 (ii) processes for responding to such
2 requests electronically or in physical form;
3 and

4 (iii) factors the Secretary intends to
5 consider in evaluating whether such
6 records and other information are provided
7 within a reasonable timeframe, within rea-
8 sonable limits, and in a reasonable man-
9 ner, accounting for resource and other lim-
10 itations that may exist, including for small
11 businesses.

12 (B) TIMING.—The Secretary of Health
13 and Human Services shall—

14 (i) not later than 1 year after the date
15 of enactment of this Act, issue draft guid-
16 ance under subparagraph (A); and

17 (ii) not later than 1 year after the
18 close of the comment period for such draft
19 guidance, issue final guidance under sub-
20 paragraph (A).

21 (c) BIORESEARCH MONITORING INSPECTIONS.—

22 (1) IN GENERAL.—Section 704(a) of the Fed-
23 eral Food, Drug, and Cosmetic Act (21 U.S.C.
24 374(a)) is amended by adding at the end the fol-
25 lowing:

1 “(5) BIORESEARCH MONITORING INSPEC-
2 TIONS.—

3 “(A) IN GENERAL.—The Secretary may, to
4 ensure the accuracy and reliability of studies
5 and records or other information described in
6 subparagraph (B) and to assess compliance
7 with applicable requirements under this Act or
8 the Public Health Service Act, enter sites and
9 facilities specified in subparagraph (C) in order
10 to inspect such records or other information.

11 “(B) INFORMATION SUBJECT TO INSPEC-
12 TION.—An inspection under this paragraph
13 shall extend to all records and other informa-
14 tion related to the studies and submissions de-
15 scribed in subparagraph (E), including records
16 and information related to the conduct, results,
17 and analyses of, and the protection of human
18 and animal trial participants participating in,
19 such studies.

20 “(C) SITES AND FACILITIES SUBJECT TO
21 INSPECTION.—

22 “(i) SITES AND FACILITIES DE-
23 SCRIBED.—The sites and facilities subject
24 to inspection by the Secretary under this
25 paragraph are those owned or operated by

1 a person described in clause (ii) and which
2 are (or were) utilized by such person in
3 connection with—

4 “(I) developing an application or
5 other submission to the Secretary
6 under this Act or the Public Health
7 Service Act related to marketing au-
8 thorization for a product described in
9 paragraph (1);

10 “(II) preparing, conducting, or
11 analyzing the results of a study de-
12 scribed in subparagraph (E); or

13 “(III) holding any records or
14 other information described in sub-
15 paragraph (B).

16 “(ii) PERSONS DESCRIBED.—A person
17 described in this clause is—

18 “(I) the sponsor of an application
19 or submission specified in subpara-
20 graph (E);

21 “(II) a person engaged in any ac-
22 tivity described in clause (i) on behalf
23 of such a sponsor, through a contract,
24 grant, or other business arrangement
25 with such sponsor;

1 “(III) an institutional review
2 board, or other individual or entity,
3 engaged by contract, grant, or other
4 business arrangement with a non-
5 sponsor in preparing, collecting, or
6 analyzing records or other information
7 described in subparagraph (B); or

8 “(IV) any person not otherwise
9 described in this clause that conducts,
10 or has conducted, a study described in
11 subparagraph (E) yielding records or
12 other information described in sub-
13 paragraph (B).

14 “(D) CONDITIONS OF INSPECTION.—

15 “(i) ACCESS TO INFORMATION SUB-
16 JECT TO INSPECTION.—Subject to clause
17 (ii), an entity that owns or operates any
18 site or facility subject to inspection under
19 this paragraph shall provide the Secretary
20 with access to records and other informa-
21 tion described in subparagraph (B) that is
22 held by or under the control of such entity,
23 including—

1 “(I) permitting the Secretary to
2 record or copy such information for
3 purposes of this paragraph;

4 “(II) providing the Secretary
5 with access to any electronic informa-
6 tion system utilized by such entity to
7 hold, process, analyze, or transfer any
8 records or other information described
9 in subparagraph (B); and

10 “(III) permitting the Secretary
11 to inspect the facilities, equipment,
12 written procedures, processes, and
13 conditions through which records or
14 other information described in sub-
15 paragraph (B) is or was generated,
16 held, processed, analyzed, or trans-
17 ferred.

18 “(ii) NO EFFECT ON APPLICABILITY
19 OF PROVISIONS FOR PROTECTION OF PRO-
20 PRIETARY INFORMATION OR TRADE SE-
21 CRETS.—Nothing in clause (i) shall negate,
22 supersede, or otherwise affect the applica-
23 bility of provisions, under this or any other
24 Act, preventing or limiting the disclosure
25 of confidential commercial information or

1 other information considered proprietary or
2 trade secret.

3 “(iii) REASONABLENESS OF INSPEC-
4 TIONS.—An inspection under this para-
5 graph shall be conducted at reasonable
6 times and within reasonable limits and in
7 a reasonable manner.

8 “(E) STUDIES AND SUBMISSIONS DE-
9 SCRIBED.—The studies and submissions de-
10 scribed in this subparagraph are each of the fol-
11 lowing:

12 “(i) Clinical and nonclinical studies
13 submitted to the Secretary in support of,
14 or otherwise related to, applications and
15 other submissions to the Secretary under
16 this Act or the Public Health Service Act
17 for marketing authorization of a product
18 described in paragraph (1).

19 “(ii) Postmarket safety activities con-
20 ducted under this Act or the Public Health
21 Service Act.

22 “(iii) Any other clinical investigation
23 of—

1 “(I) a drug subject to section
2 505 or 512 of this Act or section 351
3 of the Public Health Service Act; or

4 “(II) a device subject to section
5 520(g).

6 “(iv) Any other submissions made
7 under this Act or the Public Health Serv-
8 ice Act with respect to which the Secretary
9 determines an inspection under this para-
10 graph is warranted in the interest of public
11 health.

12 “(F) CLARIFICATION.—This paragraph
13 clarifies the authority of the Secretary to con-
14 duct inspections of the type described in this
15 paragraph and shall not be construed as a basis
16 for inferring that, prior to the date of enact-
17 ment of this paragraph, the Secretary lacked
18 the authority to conduct such inspections, in-
19 cluding under this Act or the Public Health
20 Service Act.”.

21 (2) REVIEW OF PROCESSES AND PRACTICES;
22 GUIDANCE FOR INDUSTRY.—

23 (A) IN GENERAL.—The Secretary of
24 Health and Human Services shall—

1 (i) review processes and practices in
2 effect as of the date of enactment of this
3 Act applicable to inspections of foreign and
4 domestic sites and facilities described in
5 subparagraph (C)(i) of section 704(a)(5) of
6 the Federal Food, Drug, and Cosmetic
7 Act, as added by paragraph (1); and

8 (ii) evaluate whether any updates are
9 needed to facilitate the consistency of such
10 processes and practices.

11 (B) GUIDANCE.—

12 (i) IN GENERAL.—The Secretary of
13 Health and Human Services shall issue
14 guidance describing the processes and
15 practices applicable to inspections of sites
16 and facilities described in subparagraph
17 (C)(i) of section 704(a)(5) of the Federal
18 Food, Drug, and Cosmetic Act, as added
19 by paragraph (1), including with respect to
20 the types of records and information re-
21 quired to be provided, best practices for
22 communication between the Food and
23 Drug Administration and industry in ad-
24 vance of or during an inspection or request
25 for records or other information, and other

1 inspections-related conduct, to the extent
2 not specified in existing publicly available
3 Food and Drug Administration guides and
4 manuals for such inspections.

5 (ii) TIMING.—The Secretary of Health
6 and Human Services shall—

7 (I) not later than 18 months
8 after the date of enactment of this
9 Act, issue draft guidance under clause
10 (i); and

11 (II) not later than 1 year after
12 the close of the public comment period
13 for such draft guidance, issue final
14 guidance under clause (i).

15 **SEC. 722. USES OF CERTAIN EVIDENCE.**

16 Section 703 of the Federal Food, Drug, and Cosmetic
17 Act (21 U.S.C. 373) is amended by adding at the end the
18 following:

19 “(c) APPLICABILITY.—The limitations on the Sec-
20 retary’s use of evidence obtained under this section, or any
21 evidence which is directly or indirectly derived from such
22 evidence, in a criminal prosecution of the person from
23 whom such evidence was obtained shall not apply to evi-
24 dence, including records or other information, obtained
25 under authorities other than this section, unless such limi-

1 tations are specifically incorporated by reference in such
2 other authorities.”.

3 **SEC. 723. IMPROVING FDA INSPECTIONS.**

4 (a) RISK FACTORS FOR ESTABLISHMENTS.—Section
5 510(h)(4) of the Federal Food, Drug, and Cosmetic Act
6 (21 U.S.C. 360(h)(4)) is amended—

7 (1) by redesignating subparagraph (F) as sub-
8 paragraph (G); and

9 (2) by inserting after subparagraph (E) the fol-
10 lowing:

11 “(F) The compliance history of establish-
12 ments in the country or region in which the es-
13 tablishment is located that are subject to regu-
14 lation under this Act, including the history of
15 violations related to products exported from
16 such country or region that are subject to such
17 regulation.”.

18 (b) USE OF RECORDS.—Section 704(a)(4) of the
19 Federal Food, Drug, and Cosmetic Act (21 U.S.C.
20 374(a)(4)) is amended—

21 (1) by redesignating subparagraph (C) as sub-
22 paragraph (D); and

23 (2) by inserting after subparagraph (B) the fol-
24 lowing:

1 “(C) The Secretary may rely on any records or other
2 information that the Secretary may inspect under this sec-
3 tion to satisfy requirements that may pertain to a
4 preapproval or risk-based surveillance inspection, or to re-
5 solve deficiencies identified during such inspections, if ap-
6 plicable and appropriate.”.

7 (c) RECOGNITION OF FOREIGN GOVERNMENT IN-
8 SPECTIONS.—Section 809 of the Federal Food, Drug, and
9 Cosmetic Act (21 U.S.C. 384e) is amended—

10 (1) in subsection (a)(1), by inserting
11 “preapproval or” before “risk-based inspections”;
12 and

13 (2) by adding at the end the following:

14 “(c) PERIODIC REVIEW.—

15 “(1) IN GENERAL.—Beginning not later than 1
16 year after the date of the enactment of the Food
17 and Drug Amendments of 2022, the Secretary shall
18 periodically assess whether additional arrangements
19 and agreements with a foreign government or an
20 agency of a foreign government, as allowed under
21 this section, are appropriate.

22 “(2) REPORTS TO CONGRESS.—Beginning not
23 later than 4 years after the date of the enactment
24 of the Food and Drug Amendments of 2022, and
25 every 4 years thereafter, the Secretary shall submit

1 to the Committee on Energy and Commerce of the
 2 House of Representatives and the Committee on
 3 Health, Education, Labor, and Pensions of the Sen-
 4 ate a report describing the findings and conclusions
 5 of each review conducted under paragraph (1).”.

6 **SEC. 724. GAO REPORT ON INSPECTIONS OF FOREIGN ES-**
 7 **TABLISHMENTS MANUFACTURING DRUGS.**

8 (a) IN GENERAL.—Not later than 18 months after
 9 the date of the enactment of this Act, the Comptroller
 10 General of the United States shall submit to the Com-
 11 mittee on Energy and Commerce of the House of Rep-
 12 resentatives and the Committee on Health, Education,
 13 Labor, and Pensions of the Senate a report on inspections
 14 conducted by—

15 (1) the Secretary of Health and Human Serv-
 16 ices (in this section referred to as the “Secretary”)
 17 of foreign establishments pursuant to subsections (h)
 18 and (i) of section 510 and section 704 of the Fed-
 19 eral Food, Drug, and Cosmetic Act (21 U.S.C. 360;
 20 374); or

21 (2) a foreign government or an agency of a for-
 22 eign government pursuant to section 809 of such
 23 Act (21 U.S.C. 384e).

24 (b) CONTENTS.—The report conducted under sub-
 25 section (a) shall include—

1 (1) what alternative tools, including remote in-
2 spections or remote evaluations, other countries are
3 utilizing to facilitate inspections of foreign establish-
4 ments;

5 (2) how frequently trusted foreign regulators
6 conduct inspections of foreign facilities that could be
7 useful to the Food and Drug Administration to re-
8 view in lieu of its own inspections;

9 (3) how frequently and under what cir-
10 cumstances, including for what types of inspections,
11 the Secretary utilizes existing agreements or ar-
12 rangements under section 809 of the Federal Food,
13 Drug, and Cosmetic Act (21 U.S.C. 384e) and
14 whether the use of such agreements could be appro-
15 priately expanded;

16 (4) whether the Secretary has accepted reports
17 of inspections of facilities in China and India con-
18 ducted by entities with which they have entered into
19 such an agreement or arrangement;

20 (5) what additional foreign governments or
21 agencies of foreign governments the Secretary has
22 considered entering into a mutual recognition agree-
23 ment with and, if applicable, reasons why the Sec-
24 retary declined to enter into a mutual recognition

1 agreement with such foreign governments or agen-
2 cies;

3 (6) what tools, if any, the Secretary used to fa-
4 cilitate inspections of domestic facilities that could
5 also be effectively utilized to appropriately inspect
6 foreign facilities;

7 (7) what steps the Secretary has taken to iden-
8 tify and evaluate tools and strategies the Secretary
9 may use to continue oversight with respect to inspec-
10 tions when in-person inspections are disrupted;

11 (8) how the Secretary is considering incor-
12 porating alternative tools into the inspection activi-
13 ties conducted pursuant to the Federal Food, Drug,
14 and Cosmetic Act (21 U.S.C. 301 et seq.); and

15 (9) what steps the Secretary has taken to iden-
16 tify and evaluate how the Secretary may use alter-
17 native tools to address workforce shortages to carry
18 out such inspection activities.

19 **SEC. 725. UNANNOUNCED FOREIGN FACILITY INSPECTIONS**
20 **PILOT PROGRAM.**

21 (a) IN GENERAL.—The Secretary of Health and
22 Human Services (referred to in this section as the “Sec-
23 retary”) shall conduct a pilot program under which the
24 Secretary increases the conduct of unannounced surveil-
25 lance inspections of foreign human drug establishments

1 and evaluates the differences between such inspections of
2 domestic and foreign human drug establishments, includ-
3 ing the impact of announcing inspections to persons who
4 own or operate foreign human drug establishments in ad-
5 vance of an inspection. Such pilot program shall evalu-
6 ate—

7 (1) differences in the number and type of viola-
8 tions of section 501(a)(2)(B) of the Federal Food,
9 Drug, and Cosmetic Act (21 U.S.C. 351(a)(2)(B))
10 identified as a result of unannounced and announced
11 inspections of foreign human drug establishments
12 and any other significant differences between each
13 type of inspection;

14 (2) costs and benefits associated with con-
15 ducting announced and unannounced inspections of
16 foreign human drug establishments;

17 (3) barriers to conducting unannounced inspec-
18 tions of foreign human drug establishments and any
19 challenges to achieving parity between domestic and
20 foreign human drug establishment inspections; and

21 (4) approaches for mitigating any negative ef-
22 fects of conducting announced inspections of foreign
23 human drug establishments.

24 (b) PILOT PROGRAM SCOPE.—The inspections evalu-
25 ated under the pilot program under this section shall be

1 routine surveillance inspections and shall not include in-
2 spections conducted as part of the Secretary's evaluation
3 of a request for approval to market a drug submitted
4 under the Federal Food, Drug, and Cosmetic Act (21
5 U.S.C. 301 et seq.) or the Public Health Service Act (42
6 U.S.C. 201 et seq.).

7 (c) PILOT PROGRAM INITIATION.—The Secretary
8 shall initiate the pilot program under this section not later
9 than 180 days after the date of enactment of this Act.

10 (d) REPORT.—The Secretary shall, not later than
11 180 days following the completion of the pilot program
12 under this section, make available on the website of the
13 Food and Drug Administration a final report on the pilot
14 program under this section, including—

15 (1) findings and any associated recommenda-
16 tions with respect to the evaluation under subsection
17 (a), including any recommendations to address iden-
18 tified barriers to conducting unannounced inspec-
19 tions of foreign human drug establishments;

20 (2) findings and any associated recommenda-
21 tions regarding how the Secretary may achieve par-
22 ity between domestic and foreign human drug in-
23 spections; and

1 (3) the number of unannounced inspections
2 during the pilot program that would not be unan-
3 nounced under existing practices.

4 **SEC. 726. REAUTHORIZATION OF INSPECTION PROGRAM.**

5 Section 704(g)(11) of the Federal Food, Drug, and
6 Cosmetic Act (21 U.S.C. 374(g)(11)) is amended by strik-
7 ing “2022” and inserting “2027”.

8 **SEC. 727. ENHANCING INTRA-AGENCY COORDINATION AND**
9 **PUBLIC HEALTH ASSESSMENT WITH REGARD**
10 **TO COMPLIANCE ACTIVITIES.**

11 (a) COORDINATION.—Section 506D of the Federal
12 Food, Drug, and Cosmetic Act (21 U.S.C. 356d) is
13 amended by adding at the end the following:

14 “(g) COORDINATION.—The Secretary shall ensure
15 timely and effective internal coordination and alignment
16 among the field investigators of the Food and Drug Ad-
17 ministration and the staff of the Center for Drug Evalua-
18 tion and Research’s Office of Compliance and Drug Short-
19 age Program regarding—

20 “(1) the reviews of reports shared pursuant to
21 section 704(b)(2); and

22 “(2) any feedback or corrective or preventive
23 actions in response to such reports.”.

24 (b) REPORTING.—

1 (1) IN GENERAL.—Section 506C–1(a)(2) of the
2 Federal Food, Drug, and Cosmetic Act (21 U.S.C.
3 356c–1(a)(2)) is amended to read as follows:

4 “(2)(A) describes the communication between
5 the field investigators of the Food and Drug Admin-
6 istration and the staff of the Center for Drug Eval-
7 uation and Research’s Office of Compliance and
8 Drug Shortage Program, including the Food and
9 Drug Administration’s procedures for enabling and
10 ensuring such communication;

11 “(B) provides the number of reports described
12 in section 704(b)(2) that were required to be sent to
13 the appropriate offices of the Food and Drug Ad-
14 ministration and the number of such reports that
15 were sent; and

16 “(C) describes the coordination and alignment
17 activities undertaken pursuant to section 506D(g);”.

18 (2) APPLICABILITY.—The amendment made by
19 paragraph (1) shall apply with respect to reports
20 submitted on or after March 31, 2023.

21 **SEC. 728. REPORTING OF MUTUAL RECOGNITION AGREE-**
22 **MENTS FOR INSPECTIONS AND REVIEW AC-**
23 **TIVITIES.**

24 (a) IN GENERAL.—Not later than December 31,
25 2022, and annually thereafter, the Secretary of Health

1 and Human Services (referred to in this section as the
2 “Secretary”) shall publish a report on the public website
3 of the Food and Drug Administration on the utilization
4 of agreements entered into pursuant to section 809 of the
5 Federal Food, Drug, and Cosmetic Act (21 U.S.C. 384e)
6 or otherwise entered into by the Secretary in the previous
7 fiscal year to recognize inspections between drug regu-
8 latory authorities across countries and international re-
9 gions with analogous review criteria to the Food and Drug
10 Administration, such as the Pharmaceutical Inspection
11 Co-Operation Scheme, the Mutual Recognition Agreement
12 with the European Union, and the Australia-Canada-
13 Singapore-Switzerland-United Kingdom Consortium.

14 (b) CONTENT.—The report under subsection (a) shall
15 include each of the following:

16 (1) The total number of establishments that are
17 registered under section 510(i) of the Federal Food,
18 Drug, and Cosmetic Act (21 U.S.C. 360(i)), and the
19 number of such establishments in each region of in-
20 terest.

21 (2) The total number of inspections conducted
22 at establishments described in paragraph (1),
23 disaggregated by inspections conducted—

24 (A) pursuant to an agreement or other rec-
25 ognition described in subsection (a); and

1 (B) by employees or contractors of the
2 Food and Drug Administration.

3 (3) Of the inspections described in paragraph
4 (2), the total number of inspections in each region
5 of interest.

6 (4) Of the inspections in each region of interest
7 reported pursuant to paragraph (3), the number of
8 inspections in each FDA inspection category.

9 (5) Of the number of inspections reported
10 under each of paragraphs (3) and (4)—

11 (A) the number of inspections which have
12 been conducted pursuant to an agreement or
13 other recognition described in subsection (a);
14 and

15 (B) the number of inspections which have
16 been conducted by employees or contractors of
17 the Food and Drug Administration.

18 (c) DEFINITIONS.—In this section:

19 (1) FDA INSPECTION CATEGORY.—The term
20 “FDA inspection category” means the following in-
21 spection categories:

22 (A) Inspections to support approvals of
23 changes to the manufacturing process of drugs
24 approved under section 505 of the Federal
25 Food, Drug, and Cosmetic Act (21 U.S.C. 355)

1 or section 351 of the Public Health Service Act
2 (42 U.S.C. 262).

3 (B) Surveillance inspections.

4 (C) For-cause inspections.

5 (2) REGION OF INTEREST.—The term “region
6 of interest” means China, India, the European
7 Union, and any other geographic region as the Sec-
8 retary determines appropriate.

9 **SEC. 729. ENHANCING TRANSPARENCY OF DRUG FACILITY**
10 **INSPECTION TIMELINES.**

11 Section 902 of the FDA Reauthorization Act of 2017
12 (21 U.S.C. 355 note) is amended to read as follows:

13 **“SEC. 902. ANNUAL REPORT ON INSPECTIONS.**

14 “Not later than 120 days after the end of each fiscal
15 year, the Secretary of Health and Human Services shall
16 post on the public website of the Food and Drug Adminis-
17 tration information related to inspections of facilities nec-
18 essary for approval of a drug under subsection (c) or (j)
19 of section 505 of the Federal Food, Drug, and Cosmetic
20 Act (21 U.S.C. 355), approval of a device under section
21 515 of such Act (21 U.S.C. 360e), or clearance of a device
22 under section 510(k) of such Act (21 U.S.C. 360(k)) that
23 were conducted during the previous fiscal year. Such infor-
24 mation shall include the following:

1 “(1) The median time following a request from
2 staff of the Food and Drug Administration review-
3 ing an application or report to the beginning of the
4 inspection, including—

5 “(A) the median time for drugs described
6 in section 505(j)(11)(A)(i) of the Federal Food,
7 Drug, and Cosmetic Act (21 U.S.C.
8 355(j)(11)(A)(i));

9 “(B) the median time for drugs described
10 in section 506C(a) of such Act (21 U.S.C.
11 356c(a)) only; and

12 “(C) the median time for drugs on the
13 drug shortage list in effect under section 506E
14 of such Act (21 U.S.C. 356e).

15 “(2) The median time from the issuance of a
16 report pursuant to section 704(b) of such Act (21
17 U.S.C. 374(b)) to the sending of a warning letter,
18 issuance of an import alert, or holding of a regu-
19 latory meeting for inspections for which the Sec-
20 retary concluded that regulatory or enforcement ac-
21 tion was indicated, including the median time for
22 each category of drugs listed in subparagraphs (A)
23 through (C) of paragraph (1).

24 “(3) The median time from the sending of a
25 warning letter, issuance of an import alert, or hold-

ing of a regulatory meeting to resolution of the actions indicated to address the conditions or practices observed during an inspection.

“(4) The number of facilities that failed to implement adequate corrective or preventive actions following a report pursuant to such section 704(b), resulting in a withhold recommendation, including the number of such times for each category of drugs listed in subparagraphs (A) through (C) of paragraph (1).”.

TITLE VIII—TRANSPARENCY, PROGRAM INTEGRITY, AND REGULATORY IMPROVE- MENTS

SEC. 801. PROMPT REPORTS OF MARKETING STATUS BY HOLDERS OF APPROVED APPLICATIONS FOR BIOLOGICAL PRODUCTS.

(a) IN GENERAL.—Section 506I of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 356i) is amended—

(1) in subsection (a)—

(A) in the matter preceding paragraph (1), by striking “The holder of an application approved under subsection (c) or (j) of section 505” and inserting “The holder of an application approved under subsection (c) or (j) of sec-

tion 505 of this Act or subsection (a) or (k) of section 351 of the Public Health Service Act”;

(B) in paragraph (2), by striking “established name” and inserting “established name (for biological products, by proper name)”; and

(C) in paragraph (3), by striking “or abbreviated application number” and inserting “, abbreviated application number, or biologics license application number”; and

(2) in subsection (b)—

(A) in the matter preceding paragraph (1), by striking “The holder of an application approved under subsection (c) or (j)” and inserting “The holder of an application approved under subsection (c) or (j) of section 505 of this Act or subsection (a) or (k) of section 351 of the Public Health Service Act”;

(B) in paragraph (1), by striking “established name” and inserting “established name (for biological products, by proper name)”; and

(C) in paragraph (2), by striking “or abbreviated application number” and inserting “, abbreviated application number, or biologics license application number”.

1 (b) ADDITIONAL ONE-TIME REPORT.—Subsection
2 (c) of section 506I of the Federal Food, Drug, and Cos-
3 metic Act (21 U.S.C. 356i) is amended to read as follows:

4 “(c) ADDITIONAL ONE-TIME REPORT.—Within 180
5 days of the date of enactment of the Food and Drug
6 Amendments of 2022, all holders of applications approved
7 under subsection (a) or (k) of section 351 of the Public
8 Health Service Act shall review the information in the list
9 published under section 351(k)(9)(A) and shall submit a
10 written notice to the Secretary—

11 “(1) stating that all of the application holder’s
12 biological products in the list published under sec-
13 tion 351(k)(9)(A) that are not listed as discontinued
14 are available for sale; or

15 “(2) including the information required pursu-
16 ant to subsection (a) or (b), as applicable, for each
17 of the application holder’s biological products that
18 are in the list published under section 351(k)(9)(A)
19 and not listed as discontinued, but have been discon-
20 tinued from sale or never have been available for
21 sale.”.

22 (c) PURPLE BOOK.—Section 506I of the Federal
23 Food, Drug, and Cosmetic Act (21 U.S.C. 356i) is amend-
24 ed—

1 (1) by striking subsection (d) and inserting the
2 following:

3 “(d) FAILURE TO MEET REQUIREMENTS.—If a hold-
4 er of an approved application fails to submit the informa-
5 tion required under subsection (a), (b), or (c), the Sec-
6 retary may—

7 “(1) move the application holder’s drugs from
8 the active section of the list published under section
9 505(j)(7)(A) to the discontinued section of the list,
10 except that the Secretary shall remove from the list
11 in accordance with section 505(j)(7)(C) drugs the
12 Secretary determines have been withdrawn from sale
13 for reasons of safety or effectiveness; and

14 “(2) identify the application holder’s biological
15 products as discontinued in the list published under
16 section 351(k)(9)(A) of the Public Health Service
17 Act, except that the Secretary shall remove from the
18 list in accordance with section 351(k)(9)(B) of such
19 Act biological products for which the license has
20 been revoked or suspended for reasons of safety, pu-
21 rity, or potency.”; and

22 (2) in subsection (e)—

23 (A) by inserting after the first sentence the
24 following: “The Secretary shall update the list
25 published under section 351(k)(9)(A) of the

1 Public Health Service Act based on information
2 provided under subsections (a), (b), and (c) by
3 identifying as discontinued biological products
4 that are not available for sale, except that bio-
5 logical products for which the license has been
6 revoked or suspended for safety, purity, or po-
7 tency reasons shall be removed from the list in
8 accordance with section 351(k)(9)(B) of the
9 Public Health Service Act.”;

10 (B) by striking “monthly updates to the
11 list” and inserting “monthly updates to the lists
12 referred to in the preceding sentences”; and

13 (C) by striking “and shall update the list
14 based on” and inserting “and shall update such
15 lists based on”.

16 (d) TECHNICAL CORRECTIONS.—Section 506I(e) of
17 the Federal Food, Drug, and Cosmetic Act (21 U.S.C.
18 356i(e)) is amended—

19 (1) by striking “subsection 505(j)(7)(A)” and
20 inserting “section 505(j)(7)(A)”; and

21 (2) by striking “subsection 505(j)(7)(C)” and
22 inserting “section 505(j)(7)(C)”.

1 **SEC. 802. ENCOURAGING BLOOD DONATION.**

2 (a) STREAMLINING PATIENT AND BLOOD DONOR
3 INPUT.—Section 3003 of the 21st Century Cures Act (21
4 U.S.C. 360bbb–8c note) is amended to read as follows:

5 **“SEC. 3003. STREAMLINING PATIENT AND BLOOD DONOR**
6 **INPUT.**

7 “Chapter 35 of title 44, United States Code, shall
8 not apply to the collection of information to which a re-
9 sponse is voluntary, to solicit—

10 “(1) the views and perspectives of patients
11 under section 569C of the Federal Food, Drug, and
12 Cosmetic Act (21 U.S.C. 360bbb–8c) (as amended
13 by section 3001) or section 3002; or

14 “(2) information from blood donors or potential
15 blood donors to support the development of rec-
16 ommendations by the Secretary of Health and
17 Human Services acting through the Commissioner of
18 Food and Drugs concerning blood donation.”.

19 (b) CLERICAL AMENDMENT.—The table of contents
20 in section 1(b) of the 21st Century Cures Act is amended
21 by striking the item relating to section 3003 and inserting
22 the following:

“Sec. 3003. Streamlining patient and blood donor input.”.

1 **SEC. 803. REGULATION OF CERTAIN PRODUCTS AS DRUGS.**

2 Section 503 of the Federal Food, Drug, and Cosmetic
3 Act (21 U.S.C. 353) is amended by adding at the end the
4 following:

5 “(h)(1) Any contrast agent, radioactive drug, or OTC
6 monograph drug shall be deemed to be a drug under sec-
7 tion 201(g) and not a device under section 201(h).

8 “(2) For purposes of this subsection:

9 “(A) The term ‘contrast agent’ means an arti-
10 cle that is intended for use in conjunction with a
11 medical imaging device, and—

12 “(i) is a diagnostic radiopharmaceutical, as
13 defined in sections 315.2 and 601.31 of title
14 21, Code of Federal Regulations (or any suc-
15 cessor regulations); or

16 “(ii) is a diagnostic agent that improves
17 the visualization of structure or function within
18 the body by increasing the relative difference in
19 signal intensity within the target tissue, struc-
20 ture, or fluid.

21 “(B) The term ‘radioactive drug’ has the mean-
22 ing given such term in section 310.3(n) of title 21,
23 Code of Federal Regulations (or any successor regu-
24 lations), except that such term does not include—

25 “(i) an implant or article similar to an im-
26 plant;

1 “(ii) an article that applies radiation from
2 outside of the body; or

3 “(iii) the radiation source of an article de-
4 scribed in clause (i) or (ii).

5 “(C) The term ‘OTC monograph drug’ has the
6 meaning given such term in section 744L.

7 “(3) Nothing in this subsection shall be construed as
8 allowing for the classification of a product as a drug (as
9 defined in section 201(g)) if such product—

10 “(A) is not described in paragraph (1); and

11 “(B) meets the definition of a device under sec-
12 tion 201(h),

13 unless another provision of this Act otherwise indicates a
14 different classification.”.

15 **SEC. 804. POSTAPPROVAL STUDIES AND PROGRAM INTEG-**
16 **RITY FOR ACCELERATED APPROVAL DRUGS.**

17 (a) IN GENERAL.—Section 506(c) of the Federal
18 Food, Drug, and Cosmetic Act (21 U.S.C. 356(c)) is
19 amended—

20 (1) by striking paragraph (2) and inserting the
21 following:

22 “(2) LIMITATION.—

23 “(A) IN GENERAL.—Approval of a product
24 under this subsection may be subject to 1 or
25 both of the following requirements:

1 “(i) That the sponsor conduct an ap-
2 propriate postapproval study or studies
3 (which may be augmented or supported by
4 real world evidence) to verify and describe
5 the predicted effect on irreversible mor-
6 bidity or mortality or other clinical benefit.

7 “(ii) That the sponsor submit copies
8 of all promotional materials related to the
9 product during the preapproval review pe-
10 riod and, following approval and for such
11 period thereafter as the Secretary deter-
12 mines to be appropriate, at least 30 days
13 prior to dissemination of the materials.

14 “(B) STUDIES NOT REQUIRED.—If the
15 Secretary does not require that the sponsor of
16 a product approved under accelerated approval
17 conduct a postapproval study under this para-
18 graph, the Secretary shall publish on the
19 website of the Food and Drug Administration
20 the rationale for why such study is not appro-
21 priate or necessary.

22 “(C) POSTAPPROVAL STUDY CONDI-
23 TIONS.—Not later than the time of approval of
24 a product under accelerated approval, the Sec-
25 retary shall specify the conditions for a post-

1 approval study or studies required to be con-
2 ducted under this paragraph with respect to
3 such product, which may include enrollment
4 targets, the study protocol, and milestones, in-
5 cluding the target date of study completion.

6 “(D) STUDIES BEGUN BEFORE AP-
7 PROVAL.—The Secretary may require such
8 study or studies to be underway prior to ap-
9 proval.”; and

10 (2) by striking paragraph (3) and inserting the
11 following:

12 “(3) EXPEDITED WITHDRAWAL OF AP-
13 PROVAL.—

14 “(A) IN GENERAL.—The Secretary may
15 withdraw approval of a product approved under
16 accelerated approval using expedited procedures
17 described in subparagraph (B), if—

18 “(i) the sponsor fails to conduct any
19 required postapproval study of the product
20 with due diligence, including with respect
21 to conditions specified by the Secretary
22 under paragraph (2)(C);

23 “(ii) a study required to verify and
24 describe the predicted effect on irreversible
25 morbidity or mortality or other clinical

1 benefit of the product fails to verify and
2 describe such effect or benefit;

3 “(iii) other evidence demonstrates
4 that the product is not shown to be safe or
5 effective under the conditions of use; or

6 “(iv) the sponsor disseminates false or
7 misleading promotional materials with re-
8 spect to the product.

9 “(B) EXPEDITED PROCEDURES DE-
10 SCRIBED.—Expedited procedures described in
11 this subparagraph shall consist of, prior to the
12 withdrawal of accelerated approval—

13 “(i) providing the sponsor with—

14 “(I) due notice;

15 “(II) an explanation for the pro-
16 posed withdrawal;

17 “(III) an opportunity for a meet-
18 ing with the Commissioner of Food
19 and Drugs or the Commissioner’s des-
20 ignee; and

21 “(IV) an opportunity for written
22 appeal to—

23 “(aa) the Commissioner of
24 Food and Drugs; or

1 “(bb) a designee of the
2 Commissioner who has not par-
3 ticipated in the proposed with-
4 drawal of approval (other than a
5 meeting pursuant to subclause
6 (III)) and is not a subordinate of
7 an individual (other than the
8 Commissioner) who participated
9 in such proposed withdrawal;

10 “(ii) providing an opportunity for
11 public comment on the notice proposing to
12 withdraw approval;

13 “(iii) the publication of a summary of
14 the public comments received, and the Sec-
15 retary’s response to such comments, on the
16 website of the Food and Drug Administra-
17 tion; and

18 “(iv) convening and consulting an ad-
19 visory committee on issues related to the
20 proposed withdrawal, if requested by the
21 sponsor and if no such advisory committee
22 has previously advised the Secretary on
23 such issues with respect to the withdrawal
24 of the product prior to the sponsor’s re-
25 quest.

1 “(4) LABELING.—

2 “(A) IN GENERAL.—Subject to subpara-
3 graph (B), the labeling for a product approved
4 under accelerated approval shall include—

5 “(i) a statement indicating that the
6 product was approved under accelerated
7 approval;

8 “(ii) a statement indicating that con-
9 tinued approval of the product is subject to
10 postmarketing studies to verify clinical
11 benefit;

12 “(iii) identification of the surrogate or
13 intermediate endpoint or endpoints that
14 supported approval and any known limita-
15 tions of such surrogate or intermediate
16 endpoint or endpoints in determining clin-
17 ical benefit; and

18 “(iv) a succinct description of the
19 product and any uncertainty about antici-
20 pated clinical benefit and a discussion of
21 available evidence with respect to such clin-
22 ical benefit.

23 “(B) APPLICABILITY.—The labeling re-
24 quirements of subparagraph (A) shall apply
25 only to products approved under accelerated ap-

1 proval for which the predicted effect on irre-
2 versible morbidity or mortality or other clinical
3 benefit has not been verified.

4 “(C) RULE OF CONSTRUCTION.—With re-
5 spect to any application pending before the Sec-
6 retary on the date of enactment of the Food
7 and Drug Amendments of 2022, the Secretary
8 shall allow any applicable changes to the prod-
9 uct labeling required to comply with subpara-
10 graph (A) to be made by supplement after the
11 approval of such application.

12 “(5) REPORTING.—Not later than September
13 30, 2025, the Secretary shall submit to the Com-
14 mittee on Energy and Commerce of the House of
15 Representatives and the Committee on Health, Edu-
16 cation, Labor, and Pensions of the Senate a report
17 describing circumstances in which the Secretary con-
18 sidered real world evidence submitted to support
19 postapproval studies required under this subsection
20 that were completed after the date of enactment of
21 the Food and Drug Amendments of 2022.”.

22 (b) REPORTS OF POSTMARKETING STUDIES.—Sec-
23 tion 506B(a) of the Federal Food, Drug, and Cosmetic
24 Act (21 U.S.C. 356b(a)) is amended—

1 (1) by redesignating paragraph (2) as para-
2 graph (3); and

3 (2) by inserting after paragraph (1) the fol-
4 lowing:

5 “(2) ACCELERATED APPROVAL.—Notwith-
6 standing paragraph (1), a sponsor of a drug ap-
7 proved under accelerated approval shall submit to
8 the Secretary a report of the progress of any study
9 required under section 506(c), including progress to-
10 ward enrollment targets, milestones, and other infor-
11 mation as required by the Secretary, not later than
12 180 days after the approval of such drug and not
13 less frequently than every 180 days thereafter, until
14 the study is completed or terminated.”.

15 (c) GUIDANCE.—

16 (1) IN GENERAL.—The Secretary of Health and
17 Human Services shall issue guidance describing—

18 (A) how sponsor questions related to the
19 identification of novel surrogate or intermediate
20 clinical endpoints may be addressed in early-
21 stage development meetings with the Food and
22 Drug Administration;

23 (B) the use of novel clinical trial designs
24 that may be used to conduct appropriate post-
25 approval studies as may be required under sec-

1 tion 506(c)(2)(A) of the Federal Food, Drug,
2 and Cosmetic Act (21 U.S.C. 356(c)(2)(A)), as
3 amended by subsection (a); and

4 (C) the expedited procedures described in
5 section 506(c)(3)(B) of the Federal Food,
6 Drug, and Cosmetic Act (21 U.S.C.
7 356(c)(3)(B)).

8 (2) FINAL GUIDANCE.—The Secretary shall
9 issue—

10 (A) draft guidance under paragraph (1)
11 not later than 18 months after the date of en-
12 actment of this Act; and

13 (B) final guidance not later than 1 year
14 after the close of the public comment period on
15 such draft guidance.

16 (d) RARE DISEASE ENDPOINT ADVANCEMENT
17 PILOT.—

18 (1) IN GENERAL.—The Secretary of Health and
19 Human Services shall establish a pilot program
20 under which the Secretary will establish procedures
21 to provide increased interaction with sponsors of
22 rare disease drug development programs for pur-
23 poses of advancing the development of efficacy
24 endpoints, including surrogate and intermediate

1 endpoints, for drugs intended to treat rare diseases,
2 including through—

3 (A) determining eligibility of participants
4 for such a program; and

5 (B) developing and implementing a process
6 for applying to, and participating in, such a
7 program.

8 (2) PUBLIC WORKSHOPS.—The Secretary shall
9 conduct up to 3 public workshops, which shall be
10 completed not later than September 30, 2026, to
11 discuss topics relevant to the development of
12 endpoints for rare diseases, which may include dis-
13 cussions about—

14 (A) novel endpoints developed through the
15 pilot program established under this subsection;
16 and

17 (B) as appropriate, the use of real world
18 evidence and real world data to support the val-
19 idation of efficacy endpoints, including surro-
20 gate and intermediate endpoints, for rare dis-
21 eases.

22 (3) REPORT.—Not later than September 30,
23 2027, the Secretary shall submit to the Committee
24 on Energy and Commerce of the House of Rep-
25 resentatives and the Committee on Health, Edu-

1 cation, Labor, and Pensions of the Senate a report
2 describing the outcomes of the pilot program estab-
3 lished under this subsection.

4 (4) GUIDANCE.—Not later than September 30,
5 2027, the Secretary shall issue guidance describing
6 best practices and strategies for development of effi-
7 cacy endpoints, including surrogate and intermediate
8 endpoints, for rare diseases.

9 (5) SUNSET.—The Secretary may not accept
10 any new application or request to participate in the
11 program established by this subsection on or after
12 October 1, 2027.

13 **SEC. 805. FACILITATING THE USE OF REAL WORLD EVI-**
14 **DENCE.**

15 (a) GUIDANCE.—Not later than 1 year after the date
16 of the enactment of this Act, the Secretary of Health and
17 Human Services shall issue, or revise existing, guidance
18 on considerations for the use of real world data and real
19 world evidence to support regulatory decisionmaking, as
20 follows:

21 (1) With respect to drugs, such guidance shall
22 address—

23 (A) the use of such data and evidence to
24 support the approval of a drug application
25 under section 505 of the Federal Food, Drug,

1 and Cosmetic Act (21 U.S.C. 355) or a biological
2 product application under section 351 of the
3 Public Health Service Act (42 U.S.C. 262), or
4 to support an investigational use exemption
5 under section 505(i) of the Federal Food, Drug,
6 and Cosmetic Act or section 351(a)(3) of the
7 Public Health Service Act; and

8 (B) the use of such data and evidence ob-
9 tained as a result of the use of drugs author-
10 ized for emergency use under section 564 of the
11 Federal Food, Drug, and Cosmetic Act (21
12 U.S.C. 360bbb-3) in such applications, submis-
13 sions, or requests; and

14 (C) standards and methodologies which
15 may be used for collection and analysis of real
16 world evidence included in such applications,
17 submissions, or requests, as appropriate.

18 (2) With respect to devices, such guidance shall
19 address—

20 (A) the use of such data and evidence to
21 support the approval, clearance, or classification
22 of a device pursuant to an application or sub-
23 mission submitted under section 510(k),
24 513(f)(2), or 515 of the Federal Food, Drug,
25 and Cosmetic Act (21 U.S.C. 360(k),

1 360c(f)(2), 360e), or to support an investiga-
2 tional use exemption under section 520(g) of
3 such Act (21 U.S.C. 360j(g));

4 (B) the use of such data and evidence ob-
5 tained as a result of the use of devices author-
6 ized for emergency use under section 564 of the
7 Federal Food, Drug, and Cosmetic Act (21
8 U.S.C. 360bbb-3), in such applications, submis-
9 sions, or requests; and

10 (C) standards and methodologies which
11 may be used for collection and analysis of real
12 world evidence included in such applications,
13 submissions, or requests, as appropriate.

14 (b) REPORT TO CONGRESS.—Not later than 2 years
15 after the termination of the public health emergency deter-
16 mination by the Secretary of Health and Human Services
17 under section 564 of the Federal Food, Drug, and Cos-
18 metic Act (21 U.S.C. 360bbb-3) on February 4, 2020,
19 with respect to the Coronavirus Disease 2019 (COVID-
20 19), the Secretary shall submit a report to the Committee
21 on Energy and Commerce of the House of Representatives
22 and the Committee on Health, Education, Labor, and
23 Pensions of the Senate on—

24 (1) the number of applications, submissions, or
25 requests submitted for clearance or approval under

1 section 505, 510(k), 513(f)(2), or 515 of the Fed-
2 eral Food, Drug, and Cosmetic Act (21 U.S.C. 355,
3 360(k), 360c(f)(2), 360e) or section 351 of the Pub-
4 lic Health Service Act, for which an authorization
5 under section 564 of the Federal Food, Drug, and
6 Cosmetic Act (21 U.S.C. 360bbb-3) was previously
7 granted;

8 (2) of the number of applications so submitted,
9 the number of such applications—

10 (A) for which real world evidence was sub-
11 mitted and used to support a regulatory deci-
12 sion; and

13 (B) for which real world evidence was sub-
14 mitted and determined to be insufficient to sup-
15 port a regulatory decision; and

16 (3) a summary explanation of why, in the case
17 of applications described in paragraph (2)(B), real
18 world evidence could not be used to support regu-
19 latory decisions.

20 (c) INFORMATION DISCLOSURE.—Nothing in this
21 section shall be construed to authorize the disclosure of
22 information that is prohibited from disclosure under sec-
23 tion 1905 of title 18, United States Code, or subject to
24 withholding under subsection (b)(4) of section 552 of title

1 5, United States Code (commonly referred to as the
2 “Freedom of Information Act”).

3 **SEC. 806. DUAL SUBMISSION FOR CERTAIN DEVICES.**

4 Section 513 of the Federal Food, Drug, and Cosmetic
5 Act (21 U.S.C. 360c) is amended by adding at the end
6 the following:

7 “(k) For a device authorized for emergency use under
8 section 564 for which, in accordance with section 564(m),
9 the Secretary has deemed a laboratory examination or pro-
10 cedure associated with such device to be in the category
11 of examinations and procedures described in section
12 353(d)(3) of the Public Health Service Act, the sponsor
13 of such device may, when submitting a request for classi-
14 fication under section 513(f)(2), submit a single submis-
15 sion containing—

16 “(1) the information needed for such a request;
17 and

18 “(2) sufficient information to enable the Sec-
19 retary to determine whether such laboratory exam-
20 ination or procedure satisfies the criteria to be cat-
21 egorized under section 353(d)(3) of the Public
22 Health Service Act.”.

1 **SEC. 807. MEDICAL DEVICES ADVISORY COMMITTEE MEET-**
2 **INGS.**

3 (a) IN GENERAL.—The Secretary shall convene one
4 or more panels of the Medical Devices Advisory Committee
5 not less than once per year for the purpose of providing
6 advice to the Secretary on topics related to medical devices
7 used in pandemic preparedness and response, including
8 topics related to in vitro diagnostics.

9 (b) REQUIRED PANEL MEMBER.—A panel convened
10 under subsection (a) shall include at least 1 population
11 health-specific representative.

12 (c) SUNSET.—This section shall cease to be effective
13 on October 1, 2027.

14 **SEC. 808. ENSURING CYBERSECURITY OF MEDICAL DE-**
15 **VICES.**

16 (a) IN GENERAL.—Subchapter A of chapter V of the
17 Federal Food, Drug, and Cosmetic Act (21 U.S.C. 351
18 et seq.), as amended by section 501, is further amended
19 by adding at the end the following:

20 **“SEC. 524C. ENSURING CYBERSECURITY OF DEVICES.**

21 “(a) IN GENERAL.—For purposes of ensuring cyber-
22 security throughout the lifecycle of a cyber device, any per-
23 son who submits a premarket submission for the cyber de-
24 vice shall include such information as the Secretary may
25 require to ensure that the cyber device meets such cyberse-
26 curity requirements as the Secretary determines to be ap-

1 appropriate to demonstrate a reasonable assurance of safety
2 and effectiveness, including at a minimum the cybersecu-
3 rity requirements under subsection (b).

4 “(b) CYBERSECURITY REQUIREMENTS.—At a min-
5 imum, the manufacturer of a cyber device shall meet the
6 following cybersecurity requirements:

7 “(1) The manufacturer shall have a plan to ap-
8 propriately monitor, identify, and address in a rea-
9 sonable time postmarket cybersecurity vulnerabilities
10 and exploits, including coordinated vulnerability dis-
11 closure and procedures.

12 “(2) The manufacturer shall design, develop,
13 and maintain processes and procedures to ensure the
14 device and related systems are cybersecure, and shall
15 make available updates and patches to the cyber de-
16 vice and related systems throughout the lifecycle of
17 the cyber device to address—

18 “(A) on a reasonably justified regular
19 cycle, known unacceptable vulnerabilities; and

20 “(B) as soon as possible out of cycle, crit-
21 ical vulnerabilities that could cause uncontrolled
22 risks.

23 “(3) The manufacturer shall provide in the la-
24 beling of the cyber device a software bill of mate-

1 rials, including commercial, open-source, and off-the-
2 shelf software components.

3 “(4) The manufacturer shall comply with such
4 other requirements as the Secretary may require to
5 demonstrate reasonable assurance of the safety and
6 effectiveness of the device for purposes of cybersecu-
7 rity, which the Secretary may require by an order
8 published in the Federal Register.

9 “(c) SUBSTANTIAL EQUIVALENCE.—In making a de-
10 termination of substantial equivalence under section
11 513(i) for a cyber device, the Secretary may—

12 “(1) find that cybersecurity information for the
13 cyber device described in the relevant premarket
14 submission in the cyber device’s use environment is
15 inadequate; and

16 “(2) issue a nonsubstantial equivalence deter-
17 mination based on this finding.

18 “(d) DEFINITION.—In this section:

19 “(1) CYBER DEVICE.—The term ‘cyber device’
20 means a device that—

21 “(A) includes software, including software
22 as or in a device;

23 “(B) has the ability to connect to the
24 internet; or

1 “(C) contains any such technological char-
2 acteristics that could be vulnerable to cyberse-
3 curity threats.

4 “(2) LIFECYCLE OF THE CYBER DEVICE.—The
5 term ‘lifecycle of the cyber device’ includes the
6 postmarket lifecycle of the cyber device.

7 “(3) PREMARKET SUBMISSION.—The term ‘pre-
8 market submission’ means any submission under
9 section 510(k), 513, 515(c), 515(f), or 520(m).

10 “(e) EXEMPTION.—The Secretary may identify de-
11 vices or types of devices that are exempt from meeting
12 the cybersecurity requirements established by this section
13 and regulations promulgated pursuant to this section. The
14 Secretary shall publish in the Federal Register, and up-
15 date, as appropriate, a list of the devices and types of de-
16 vices so identified by the Secretary.”.

17 (b) PROHIBITED ACT.—Section 301(q) of the Fed-
18 eral Food, Drug, and Cosmetic Act (21 U.S.C. 331(q))
19 is amended by adding at the end the following:

20 “(3) The failure to comply with any requirement
21 under section 524C (relating to ensuring device cybersecu-
22 rity).”.

23 (c) ADULTERATION.—Section 501 of the Federal
24 Food, Drug, and Cosmetic Act (21 U.S.C. 351) is amend-
25 ed by inserting after paragraph (j) the following:

1 “(k) If it is a device subject to the requirements set
2 forth in section 524C (relating to ensuring device cyberse-
3 curity) and fails to comply with any requirement under
4 that section.”.

5 (d) MISBRANDING.—Section 502(t) of the Federal
6 Food, Drug, and Cosmetic Act (21 U.S.C. 352(t)) is
7 amended—

8 (1) by striking “or (3)” and inserting “(3)”;
9 and

10 (2) by inserting before the period at the end the
11 following: “, or (4) to furnish a software bill of ma-
12 terials as required under section 524C (relating to
13 ensuring device cybersecurity)”.

14 **SEC. 809. PUBLIC DOCKET ON PROPOSED CHANGES TO**
15 **THIRD-PARTY VENDORS.**

16 (a) IN GENERAL.—

17 (1) OPENING PUBLIC DOCKET.—Not later than
18 90 days after the date of enactment of this Act, the
19 Secretary of Health and Human Services shall open
20 a single public docket to solicit comments on factors
21 that generally should be considered by the Secretary
22 when reviewing requests from sponsors of drugs sub-
23 ject to risk evaluation and mitigation strategies to
24 change third-party vendors engaged by sponsors to

1 aid in implementation and management of the strat-
2 egies.

3 (2) FACTORS.—Such factors include the poten-
4 tial effects of changes in third-party vendors on—

5 (A) patient access; and

6 (B) prescribing and administration of the
7 drugs by health care providers.

8 (3) CLOSING PUBLIC DOCKET.—The Secretary
9 of Health and Human Services may close such pub-
10 lic docket not earlier than 90 days after such docket
11 is opened.

12 (4) NO DELAY.—Nothing in this section shall
13 delay agency action on any modification to a risk
14 evaluation and mitigation strategy.

15 (b) GAO REPORT.—Not later than December 31,
16 2026, the Comptroller General of the United States shall
17 submit to the Committee on Energy and Commerce of the
18 House of Representatives and the Committee on Health,
19 Education, Labor, and Pensions of the Senate a report
20 on—

21 (1) the number of changes in third-party ven-
22 dors (engaged by sponsors to aid implementation
23 and management of risk evaluation and mitigation
24 strategies) for an approved risk evaluation and miti-
25 gation strategy the Secretary of Health and Human

1 Services has approved under section 505–1(h) of the
 2 Federal Food, Drug, and Cosmetic Act (21 U.S.C.
 3 355–1(h));

4 (2) any issues affecting patient access to the
 5 drug that is subject to the strategy or considerations
 6 with respect to the administration or prescribing of
 7 such drug by health care providers that arose as a
 8 result of such modifications; and

9 (3) how such issues were resolved, as applica-
 10 ble.

11 **SEC. 810. FACILITATING EXCHANGE OF PRODUCT INFOR-**
 12 **MATION PRIOR TO APPROVAL.**

13 (a) IN GENERAL.—Section 502 of the Federal Food,
 14 Drug, and Cosmetic Act (21 U.S.C. 352) is amended—

15 (1) in paragraph (a)—

16 (A) by striking “drugs for coverage” and
 17 inserting “drugs or devices for coverage”; and

18 (B) by striking “drug” each place it ap-
 19 pears and inserting “drug or device”, respec-
 20 tively;

21 (2) in paragraphs (a)(1) and (a)(2)(B), by
 22 striking “under section 505 or under section 351 of
 23 the Public Health Service Act” and inserting “under
 24 section 505, 510(k), 513(f)(2), or 515 of this Act or
 25 section 351 of the Public Health Service Act”;

1 (3) in paragraph (a)(1)—

2 (A) by striking “under section 505 or
3 under section 351(a) of the Public Health Serv-
4 ice Act” and inserting “under section 505,
5 510(k), 513(f)(2), or 515 of this Act or section
6 351 of the Public Health Service Act”; and

7 (B) by striking “in section 505(a) or in
8 subsections (a) and (k) of section 351 of the
9 Public Health Service Act” and inserting “in
10 section 505, 510(k), 513(f)(2), or 515 of this
11 Act or section 351 of the Public Health Service
12 Act”; and

13 (4) by adding at the end the following:

14 “(gg)(1) Unless its labeling bears adequate directions
15 for use in accordance with paragraph (f), except that (in
16 addition to drugs or devices that conform with exemptions
17 pursuant to such paragraph) no drug or device shall be
18 deemed to be misbranded under such paragraph through
19 the provision of product information to a payor, formulary
20 committee, or other similar entity with knowledge and ex-
21 pertise in the area of health care economic analysis car-
22 rying out its responsibilities for the selection of drugs or
23 devices for coverage or reimbursement if the product infor-
24 mation relates to an investigational drug or device or in-
25 vestigational use of a drug or device that is approved,

1 cleared, granted marketing authorization, or licensed
2 under section 505, 510(k), 513(f)(2), or 515 of this Act
3 or section 351 of the Public Health Service Act (as appli-
4 cable), provided—

5 “(A) the product information includes—

6 “(i) a clear statement that the investiga-
7 tional drug or device or investigational use of a
8 drug or device has not been approved, cleared,
9 granted marketing authorization, or licensed
10 under section 505, 510(k), 513(f)(2), or 515 of
11 this Act or section 351 of the Public Health
12 Service Act (as applicable) and that the safety
13 and effectiveness of the drug or device or use
14 has not been established;

15 “(ii) information related to the stage of de-
16 velopment of the drug or device involved, such
17 as—

18 “(I) the status of any study or studies
19 in which the investigational drug or device
20 or investigational use is being investigated;

21 “(II) how the study or studies relate
22 to the overall plan for the development of
23 the drug or device; and

24 “(III) whether an application, pre-
25 market notification, or request for classi-

1 fication for the investigational drug or de-
2 vice or investigational use has been sub-
3 mitted to the Secretary and when such a
4 submission is planned;

5 “(iii) in the case of information that in-
6 cludes factual presentations of results from
7 studies, which shall not be selectively presented,
8 a description of—

9 “(I) all material aspects of study de-
10 sign, methodology, and results; and

11 “(II) all material limitations related
12 to the study design, methodology, and re-
13 sults;

14 “(iv) where applicable, a prominent state-
15 ment disclosing the indication or indications for
16 which the Secretary has approved, granted mar-
17 keting authorization, cleared, or licensed the
18 product pursuant to section 505, 510(k),
19 513(f)(2), or 515 of this Act or section 351 of
20 the Public Health Service Act, and a copy of
21 the most current required labeling; and

22 “(v) updated information, if previously
23 communicated information becomes materially
24 outdated as a result of significant changes or as

1 a result of new information regarding the prod-
2 uct or its review status; and

3 “(B) the product information does not in-
4 clude—

5 “(i) information that represents that an
6 unapproved product—

7 “(I) has been approved, cleared,
8 granted marketing authorization, or li-
9 censed under section 505, 510(k),
10 513(f)(2), or 515 of this Act or section
11 351 of the Public Health Service Act (as
12 applicable); or

13 “(II) has otherwise been determined
14 to be safe or effective for the purpose or
15 purposes for which the drug or device is
16 being studied; or

17 “(ii) information that represents that an
18 unapproved use of a drug or device that has
19 been so approved, granted marketing authoriza-
20 tion, cleared, or licensed—

21 “(I) is so approved, granted mar-
22 keting authorization, cleared, or licensed;
23 or

1 “(II) that the product is safe or effec-
2 tive for the use or uses for which the drug
3 or device is being studied.

4 “(2) For purposes of this paragraph, the term ‘prod-
5 uct information’ includes—

6 “(A) information describing the drug or device
7 (such as drug class, device description, and fea-
8 tures);

9 “(B) information about the indication or indica-
10 tions being investigated;

11 “(C) the anticipated timeline for a possible ap-
12 proval, clearance, marketing authorization, or licen-
13 sure pursuant to section 505, 510(k), 513, or 515
14 of this Act or section 351 of the Public Health Serv-
15 ice Act;

16 “(D) drug or device pricing information;

17 “(E) patient utilization projections;

18 “(F) product-related programs or services; and

19 “(G) factual presentations of results from stud-
20 ies that do not characterize or make conclusions re-
21 garding safety or efficacy.”.

22 (b) GAO STUDY AND REPORT.—Beginning on the
23 date that is 5 years and 6 months after the date of enact-
24 ment of this Act, the Comptroller General of the United
25 States shall conduct a study on the provision and use of

1 information pursuant to section 502(gg) of the Federal
2 Food, Drug, and Cosmetic Act, as added by this sub-
3 section (a), between manufacturers of drugs and devices
4 (as defined in section 201 of the Federal Food, Drug, and
5 Cosmetic Act (21 U.S.C. 321)) and entities described in
6 such section 502(gg). Such study shall include an analysis
7 of the following:

8 (1) The types of information communicated be-
9 tween such manufacturers and payors.

10 (2) The manner of communication between
11 such manufacturers and payors.

12 (3)(A) Whether such manufacturers file an ap-
13 plication for approval, marketing authorization,
14 clearance, or licensing of a new drug or device or the
15 new use of a drug or device that is the subject of
16 communication between such manufacturers and
17 payors under section 502(gg) of the Federal Food,
18 Drug, and Cosmetic Act, as added by subsection (a).

19 (B) How frequently the Food and Drug Admin-
20 istration approves, grants marketing authorization,
21 clears, or licenses the new drug or device or new use.

22 (C) The timeframe between the initial commu-
23 nications permitted under section 502(gg) of the
24 Federal Food, Drug, and Cosmetic Act, as added by
25 subsection (a), regarding an investigational drug or

1 device or investigational use, and the initial mar-
2 keting of such drug or device.

3 **SEC. 811. BANS OF DEVICES FOR ONE OR MORE INTENDED**
4 **USES.**

5 (a) IN GENERAL.—Section 516(a) of the Federal
6 Food, Drug, and Cosmetic Act (21 U.S.C. 360f(a)) is
7 amended—

8 (1) in paragraph (1), by inserting “for one or
9 more intended use” before the semicolon at the end;
10 and

11 (2) in the matter following paragraph (2), by
12 inserting “for any such intended use or uses. A de-
13 vice that is banned for one or more intended uses is
14 not a legally marketed device under section 1006
15 when intended for such use or uses” after “banned
16 device”.

17 (b) SPECIFIC DEVICES DEEMED BANNED.—Section
18 516 of the Federal Food, Drug, and Cosmetic Act (21
19 U.S.C. 360f) is further amended by adding at the end the
20 following:

21 “(c) SPECIFIC DEVICE BANNED.—Electrical stimula-
22 tion devices that apply a noxious electrical stimulus to a
23 person’s skin intended to reduce or cease self-injurious be-
24 havior or aggressive behavior are deemed to be banned de-
25 vices, as described in subsection (a).

1 “(d) REVERSAL BY REGULATION.—Devices banned
 2 under this section are banned devices unless or until the
 3 Secretary promulgates a regulation to make such devices
 4 or use of such devices no longer banned based on a finding
 5 that such devices or use of such devices does not present
 6 substantial deception or an unreasonable and substantial
 7 risk of illness or injury, or that such risk can be corrected
 8 or eliminated by labeling.”.

9 **SEC. 812. CLARIFYING APPLICATION OF EXCLUSIVE AP-**
 10 **PROVAL, CERTIFICATION, OR LICENSURE**
 11 **FOR DRUGS DESIGNATED FOR RARE DIS-**
 12 **EASES OR CONDITIONS.**

13 (a) APPLICATION OF EXCLUSIVE APPROVAL, CER-
 14 TIFICATION, OR LICENSURE FOR DRUGS DESIGNATED
 15 FOR RARE DISEASES OR CONDITIONS.—Section 527 of
 16 the Federal Food, Drug, and Cosmetic Act (21 U.S.C.
 17 360cc) is amended—

18 (1) in subsection (a), in the matter following
 19 paragraph (2), by striking “same disease or condi-
 20 tion” and inserting “same approved indication or
 21 use within such rare disease or condition”;

22 (2) in subsection (b)—

23 (A) in the matter preceding paragraph (1),
 24 by striking “same rare disease or condition”
 25 and inserting “same indication or use for which

1 the Secretary has approved or licensed such
2 drug”; and

3 (B) in paragraph (1), by striking “with the
4 disease or condition for which the drug was des-
5 ignated” and inserting “for whom the drug is
6 indicated”; and

7 (3) in subsection (c), by striking “same rare
8 disease or condition” and inserting “same indication
9 or use”.

10 (b) APPLICATION OF AMENDMENTS.—The amend-
11 ments made by subsection (a) shall apply with respect to
12 any drug designated under section 526 of the Federal
13 Food, Drug, and Cosmetic Act (21 U.S.C. 360bb), regard-
14 less of the date on which the drug was so designated, and
15 regardless of the date on which the drug was approved
16 under section 505 of such Act (21 U.S.C. 355) or licensed
17 under section 351 of the Public Health Service Act (42
18 U.S.C. 262).

19 **SEC. 813. GAO REPORT ON THIRD-PARTY REVIEW.**

20 Not later than September 30, 2026, the Comptroller
21 General of the United States shall submit to the Com-
22 mittee on Energy and Commerce of the House of Rep-
23 resentatives and the Committee on Health, Education,
24 Labor, and Pensions of the Senate a report on the third-
25 party review program described in section 523 of the Fed-

1 eral Food, Drug, and Cosmetic Act (21 U.S.C. 360m).

2 Such report shall include—

3 (1) a description of the financial and staffing
4 resources used to carry out such program;

5 (2) a description of actions taken by the Sec-
6 retary pursuant section 523(b)(2)(C) of the Federal
7 Food, Drug, and Cosmetic Act (21 U.S.C.
8 360m(b)(2)(C)); and

9 (3) the results of an audit of the performance
10 of select persons accredited under such program.

11 **SEC. 814. REPORTING ON PENDING GENERIC DRUG APPLI-**
12 **CATIONS AND PRIORITY REVIEW APPLICA-**
13 **TIONS.**

14 Section 807 of the FDA Reauthorization Act of 2017
15 (Public Law 115–52) is amended, in the matter preceding
16 paragraph (1), by striking “2022” and inserting “2027”.

17 **SEC. 815. FDA WORKFORCE IMPROVEMENTS.**

18 Section 714A of the Federal Food, Drug, and Cos-
19 metic Act (21 U.S.C. 379d–3a) is amended—

20 (1) in subsection (a), by striking “medical prod-
21 ucts” and inserting “products regulated by the Food
22 and Drug Administration”; and

23 (2) by striking subsection (d) and inserting the
24 following:

1 “(d) AGENCY-WIDE STRATEGIC WORKFORCE
2 PLAN.—

3 “(1) IN GENERAL.—Not later than 1 year after
4 the date of enactment of the Food and Drug
5 Amendments of 2022, the Commissioner of Food
6 and Drugs shall develop and begin implementation
7 of an agency-wide strategic workforce plan at the
8 Food and Drug Administration, which shall in-
9 clude—

10 “(A) agency-wide human capital goals and
11 strategies;

12 “(B) performance measures, benchmarks,
13 or other elements to facilitate the monitoring
14 and evaluation of the progress made toward
15 such goals and the effectiveness of such strate-
16 gies; and

17 “(C) a process for updating such plan
18 based on timely and relevant information on an
19 ongoing basis.

20 “(2) REPORT TO CONGRESS.—Not later than
21 18 months after the date of enactment of the Food
22 and Drug Amendments of 2022, the Secretary shall
23 submit to the Committee on Energy and Commerce
24 of the House of Representatives and the Committee
25 on Health, Education, Labor, and Pensions of the

1 Senate a report describing the plan under paragraph
2 (1) and the status of its implementation.”.

3 **TITLE IX—MISCELLANEOUS**

4 **SEC. 901. DETERMINATION OF BUDGETARY EFFECTS.**

5 The budgetary effects of this Act, for the purpose of
6 complying with the Statutory Pay-As-You-Go Act of 2010,
7 shall be determined by reference to the latest statement
8 titled “Budgetary Effects of PAYGO Legislation” for this
9 Act, submitted for printing in the Congressional Record
10 by the Chairman of the House Budget Committee, pro-
11 vided that such statement has been submitted prior to the
12 vote on passage.

13 **SEC. 902. MEDICAID IMPROVEMENT FUND.**

14 Section 1941(b)(3)(A) of the Social Security Act (42
15 U.S.C. 1396w–1(b)(3)(A)) is amended by striking “\$0”
16 and inserting “\$450,000,000”.

Passed the House of Representatives June 8, 2022.

Attest:

Clerk.

117TH CONGRESS
2^D SESSION

H. R. 7667

AN ACT

To amend the Federal Food, Drug, and Cosmetic Act to revise and extend the user-fee programs for prescription drugs, medical devices, generic drugs, and biosimilar biological products, and for other purposes.